

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS	17	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS	18	JUN 18	DWPI: New coverage - French Granted Patents
NEWS	19	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS	20	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS	21	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAPLUS, CASREACT, and MARPAT
NEWS	22	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS	23	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS	24	JUN 29	Enhanced Batch Search Options in DGENE, USGENE,

and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:59:27 ON 13 JUL 2010

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 09:59:43 ON 13 JUL 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2010 HIGHEST RN 1231299-84-5

DICTIONARY FILE UPDATES: 12 JUL 2010 HIGHEST RN 1231299-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10569873 formula II.str



```

chain nodes :
1  2  3  4 11 12 13 14 18 19 21 22
ring nodes :
5  6  7  8  9 10
chain bonds :
1-2 1-3 1-18 3-4 11-12 11-13 11-14 18-19 19-21 21-22
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-3 1-18 18-19 19-21 21-22
exact bonds :
3-4 11-12 11-13 11-14
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

```

G1:C,O,S,N

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 18:CLASS 19:CLASS
21:Atom 22:Atom

```

```

Generic attributes :
21:
Saturation           : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System  : Monocyclic
22:
Saturation           : Unsaturated


```

L1 STRUCTURE UPLOADED

```

=> d L1
L1 HAS NO ANSWERS
L1 STR

```



G1 C, O, S, N

Structure attributes must be viewed using STN Express query preparation.

=> s L1 SSS SAM

SAMPLE SEARCH INITIATED 10:01:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 97126 TO ITERATE

2.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1923977 TO 1961063
PROJECTED ANSWERS: 553 TO 1389

L2 1 SEA SSS SAM L1

=> s L1 SSS full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:01:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1943605 TO ITERATE

81.5% PROCESSED 1584971 ITERATIONS 1981 ANSWERS
91.8% PROCESSED 1783819 ITERATIONS 1982 ANSWERS
97.0% PROCESSED 1885875 ITERATIONS 1982 ANSWERS
100.0% PROCESSED 1943605 ITERATIONS 1982 ANSWERS
SEARCH TIME: 00.01.10

L3 1982 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	193.50	193.72

FILE 'CAPLUS' ENTERED AT 10:02:47 ON 13 JUL 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2010 VOL 153 ISS 3
FILE LAST UPDATED: 12 Jul 2010 (20100712/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3 SSS full
L4 54 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 54 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:273629 CAPLUS Full-text
DOCUMENT NUMBER: 152:311595
TITLE: Preparation of oxazole, oxadiazole and thiazole compounds as diacylglycerol acyltransferase inhibitors
INVENTOR(S): Gangopadhyay, Ashok Kumar; Kadam, Kishorkumar Shivajirao; Jadhav, Ravindra Dnyandev; Mistry, Hitesh; Sharma, Rajiv
PATENT ASSIGNEE(S): Piramal Life Sciences Limited, India
SOURCE: PCT Int. Appl., 265pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2010023609	A1	20100304	WO 2009-IB53708	20090824
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			



AB The present invention relates to isoxazole compds. of general formula I (wherein R1 = cycloalkyl, alkylaryl, aryl, etc.; L1 = O, SO2NH, SO2NHCONH, etc.; Rx and Ry independently = H, halogen, CN, etc.; p = 1-4; L2 = CO, CONH, CSNH, etc.; R2 = CH2, NHCH2, CH2CH2, etc.; R3 = H, alkyl, alkenyl, etc.), processes for their preparation, pharmaceutical compns. containing them and their use as medicaments, in particular to the use of these compds. in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. Example compound II was prepared by a multi-step synthesis involving the preparation of intermediate 3-(4-nitrophenyl)isoxazole-5-carboxylic acid Et ester which is reduced and subsequently reacted with 2-chloro-6-fluorobenzothiazole to give II. II demonstrated an inhibition range of 50 - 75% against hDGAT1 at a concentration of 10 μ M.

IT 1210761-38-8P 1210761-41-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of oxazole, oxadiazole and thiazole compds. as diacylglycerol acyltransferase inhibitors)

RN 1210761-38-8 CAPLUS

CN L-Valine, N-[[3-[4-[[2-oxo-2-[[3-(trifluoromethyl)phenyl]amino]acetyl]amino]phenyl]-5-isoxazolyl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1210761-41-3 CAPLUS

CN L-Valine, N-[[3-[4-[[2-oxo-2-[[3-(trifluoromethyl)phenyl]amino]acetyl]amino]phenyl]-5-isoxazolyl]carbonyl]-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:115411 CAPLUS Full-text

DOCUMENT NUMBER: 152:215278

TITLE: Preparation of 3,4-diarylpiperazines as protein kinase inhibitors

INVENTOR(S): Pulici, Maurizio; Zuccotto, Fabio; Badari, Alessandra;
Nuvoloni, Stefano; Cervi, Giovanni; Traquandi,
Gabriella; Biondaro, Sonia; Trifiro', Paolo;
Marchionni, Chiara; Modugno, Michele

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy

SOURCE: PCT Int. Appl., 166pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND	DATE
1	1950
2	1951
3	1952
4	1953
5	1954
6	1955
7	1956
8	1957
9	1958
10	1959
11	1960
12	1961
13	1962
14	1963
15	1964
16	1965
17	1966
18	1967
19	1968
20	1969
21	1970
22	1971
23	1972
24	1973
25	1974
26	1975
27	1976
28	1977
29	1978
30	1979
31	1980
32	1981
33	1982
34	1983
35	1984
36	1985
37	1986
38	1987
39	1988
40	1989
41	1990
42	1991
43	1992
44	1993
45	1994
46	1995
47	1996
48	1997
49	1998
50	1999
51	2000
52	2001
53	2002
54	2003
55	2004
56	2005
57	2006
58	2007
59	2008
60	2009
61	2010
62	2011
63	2012
64	2013
65	2014
66	2015
67	2016
68	2017
69	2018
70	2019
71	2020
72	2021
73	2022
74	2023
75	2024
76	2025
77	2026
78	2027
79	2028
80	2029
81	2030
82	2031
83	2032
84	2033
85	2034
86	2035
87	2036
88	2037
89	2038
90	2039
91	2040
92	2041
93	2042
94	2043
95	2044
96	2045
97	2046
98	2047
99	2048
100	2049

APPLICATION NO.

DATE _____

-----	-----	-----	-----	-----
WO 2010010154	A1	20100128	WO 2009-EP59506	20090723
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:


EP 2008-161076

A 20080724

OTHER SOURCE(S):

MARPAT 152:215278

GI



I

AB The invention relates to 3,4-diarylpyrazole derivs. I [$m = 0-6$; $R_1 = H, CCl_3, CF_3, \text{halo, etc.}$; $R_2 = H, \text{halo, (un)substituted } NH_2, \text{etc.}$; $R_3-R_6 = H, \text{halo, } CF_3, \text{etc.}$; $R_7 = H, \text{alkyl, cycloalkyl, etc.}$; $A = CON(Y), CON(Y)O, CON(Y)N(Y), \text{etc.}$; $Y = H \text{ or alkyl}$], and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compns. comprising them. The compds. I may be useful, in therapy, in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. Over two-hundred compds. I were prepared E.g., a multi-step synthesis of 1-(2,4-difluorophenyl)-3-{3-[4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenyl}-urea, starting from 3-nitrobenzaldehyde, was given. Compds. I were found to possess a remarkable activity in inhibiting cell proliferation, with IC_{50} values lower than $10 \mu M$ on the cell line with mutated B-Raf (A375), and higher on the cell line with wild-type B-Raf (Mewo).


IT 1206834-69-6P 1206834-70-9P 1206834-71-0P
1206834-81-2P 1206834-83-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3,4-diarylpyrazole derivs. as protein kinase modulators useful in treatment of diseases associated with dysregulated protein kinase activity, like cancer)


RN 1206834-69-6 CAPLUS

CN Urea, N-[[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1206834-70-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]- (CA INDEX NAME)




RN 1206834-71-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]- (CA INDEX NAME)




RN 1206834-81-2 CAPLUS

CN Urea, N-[2-fluoro-4-(trifluoromethyl)phenyl]-N'-[[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]- (CA INDEX NAME)



RN 1206834-83-4 CAPLUS

CN Urea, N-[[3-[4-(4-pyridinyl)-1H-pyrazol-3-yl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1412582 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 152:110790

TITLE: Imidazo[1,2-a]pyrazine diaryl ureas: Inhibitors of the receptor tyrosine kinase EphB4

AUTHOR(S): Mitchell, Scott A.; Danca, Mihaela Diana; Blomgren, Peter A.; Darrow, James W.; Currie, Kevin S.; Kropf, Jeffrey E.; Lee, Seung H.; Gallion, Steven L.; Xiong, Jin-Ming; Pippin, Douglas A.; DeSimone, Robert W.; Brittelli, David R.; Eustice, David C.; Bourret, Aaron; Hill-Drzewi, Melissa; Maciejewski, Patricia M.; Elkin, Lisa L.

CORPORATE SOURCE: Department of Medicinal Chemistry, CGI Pharmaceuticals, Inc., Branford, CT, 06405, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(24), 6991-6995
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 152:110790

AB Inhibition of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) has been validated by recently launched small mols. Sutent and Nexavar, both of which display activities against several angiogenesis-related RTKs. EphB4, a receptor tyrosine kinase (RTK) involved in the processes of embryogenesis and angiogenesis, has been shown to be aberrantly up regulated in many cancer types such as breast, lung, bladder and prostate. We propose that inhibition of EphB4 in addition to other validated RTKs would enhance the

anti-angiogenic effect and ultimately result in more pronounced anti-cancer efficacy. Herein we report the discovery and SAR of a novel series of imidazo[1,2-a]pyrazine diarylureas that show nanomolar potency for the EphB4 receptor, in addition to potent activity against several other RTKs.


IT 1202810-94-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazopyrazine diaryl ureas as inhibitors of receptor tyrosine kinase EphB4)

RN 1202810-94-3 CAPLUS

CN Urea, N-[[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:772006 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 151:77758

TITLE: Preparation of glycolic amides as nonsteroidal progesterone receptor modulators

INVENTOR(S): Kirkland, Thomas; Schwede, Wolfgang; Moeller, Carsten; Baeuerle, Stefan; Wyrwa, Ralf; Rotgeri, Andrea

PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 308pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009077186	A1	20090625	WO 2008-EP10828	20081212
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			

TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 EP 2070909 A1 20090617 EP 2007-76093 20071215
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
 AL, BA, HR, MK, RS
 US 20090270381 A1 20091029 US 2008-333789 20081212
 PRIORITY APPLN. INFO.: US 2007-6015P P 20071214
 EP 2007-76093 A 20071215
 DE 2007-102007032800T0 20070710
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 151:77758
 GI



AB Title compds. I [A = H, alkyl, alkenyl, etc.; R1, R2 = alkyl, carbocycle with provisos, etc.; R3 = H, alkyl, alkenyl, etc.; X = O, CH2; Y = (CH2)m, CH=CH, etc.; m = 0-1; R4 = bicyclic aryl with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of phenylmagnesium chloride and diketone II afforded claimed glycolic amide III. In progesterone receptor inhibition assays, 11-examples of compds. I exhibited IC50 values ranging from 1.8-27 nM.

IT 1160964-58-8P 1160964-59-9P 1160964-60-2P
 1160964-62-4P 1160964-63-5P 1160964-64-6P
 1160964-65-7P 1160964-66-8P 1160964-67-9P
 1160964-68-0P 1160964-69-1P 1160964-70-4P
 1160964-72-6P 1160964-73-7P 1160964-74-8P
 1160964-75-9P 1160964-76-0P 1160964-77-1P
 1160964-79-3P 1160964-80-6P 1160964-81-7P
 1160964-82-8P 1160964-83-9P 1160964-84-0P
 1160964-85-1P 1160964-86-2P 1160964-87-3P
 1160964-88-4P 1160964-90-8P 1160964-92-0P
 1160965-69-4P 1160965-70-7P 1160965-71-8P
 1160965-72-9P 1160965-73-0P 1160965-74-1P
 1160965-75-2P 1160965-76-3P 1160965-77-4P
 1160965-79-6P 1160965-80-9P 1160965-81-0P
 1160965-82-1P 1160965-84-3P 1160965-85-4P
 1160965-86-5P 1160965-87-6P 1160965-88-7P
 1160965-89-8P 1160965-90-1P 1160965-92-3P
 1160965-93-4P 1160965-94-5P 1160965-95-6P
 1160965-96-7P 1160965-97-8P 1160965-99-0P
 1160966-00-6P 1160966-01-7P 1160966-02-8P
 1160966-70-0P 1160966-71-1P 1160966-72-2P
 1160966-73-3P 1160966-74-4P 1160966-75-5P

1160966-76-6P	1160966-77-7P	1160966-78-8P
1160966-79-9P	1160966-80-2P	1160966-81-3P
1160966-84-6P	1160966-85-7P	1160966-87-9P
1160966-88-0P	1160966-89-1P	1160966-90-4P
1160966-91-5P	1160966-93-7P	1160966-94-8P
1160966-95-9P	1160966-96-0P	1160966-97-1P
1160966-98-2P	1160966-99-3P	1160967-00-9P
1160967-01-0P	1160967-02-1P	1160967-03-2P
1160975-45-0P	1160975-46-1P	1160975-47-2P
1160975-48-3P	1160975-49-4P	1160975-50-7P
1160975-51-8P	1160975-52-9P	1160975-53-0P
1160975-54-1P	1160975-55-2P	1160975-56-3P
1160975-57-4P	1160975-58-5P	1160975-59-6P
1160975-61-0P	1160975-62-1P	1160975-63-2P
1160975-64-3P	1160975-65-4P	1160975-66-5P
1160975-67-6P	1160975-68-7P	1160975-69-8P
1160975-70-1P	1160975-71-2P	1160975-72-3P
1160975-73-4P	1160975-74-5P	1160975-75-6P
1160976-41-9P	1160976-42-0P	1160976-43-1P
1160976-44-2P	1160976-45-3P	1160976-46-4P
1160976-47-5P	1160976-48-6P	1160976-49-7P
1160976-51-1P	1160976-53-3P	1160976-55-5P
1160976-57-7P	1160976-59-9P	1160976-61-3P
1160976-63-5P	1160976-65-7P	1160976-67-9P
1160976-69-1P	1160976-71-5P	1160976-73-7P
1160976-75-9P	1160976-77-1P	1160976-79-3P
1160976-81-7P	1160976-83-9P	1160976-85-1P
1160976-87-3P	1160976-89-5P	1160976-91-9P
1160977-51-4P	1160977-52-5P	1160977-53-6P
1160977-54-7P	1160977-55-8P	1160977-56-9P
1160977-58-1P	1160977-59-2P	1160977-60-5P
1160977-61-6P	1160977-62-7P	1160977-63-8P
1160977-64-9P	1160977-65-0P	1160977-66-1P
1160977-68-3P	1160977-69-4P	1160977-70-7P
1160977-71-8P	1160977-72-9P	1160977-73-0P
1160977-74-1P	1160977-75-2P	1160977-76-3P
1160977-77-4P	1160977-78-5P	1160977-79-6P
1160977-80-9P	1160977-82-1P	1160977-83-2P
1160986-92-4P	1160986-93-5P	1160986-95-7P
1160986-96-8P	1160986-97-9P	1160986-98-0P
1160986-99-1P	1160987-00-7P	1160987-01-8P
1160987-02-9P	1160987-03-0P	1160987-04-1P
1160987-05-2P	1160987-07-4P	1160987-08-5P
1160987-10-9P	1160987-11-0P	1160987-12-1P
1160987-13-2P	1160987-14-3P	1160987-15-4P
1160987-17-6P	1160987-18-7P	1160987-19-8P
1160987-20-1P	1160987-21-2P	1160987-22-3P
1160987-23-4P	1160987-24-5P	1160987-25-6P
1160988-21-5P	1160988-22-6P	1160988-23-7P
1160988-24-8P	1160988-25-9P	1160988-26-0P
1160988-27-1P	1160988-28-2P	1160988-29-3P
1160988-30-6P	1160988-31-7P	1160988-32-8P
1160988-33-9P	1160988-34-0P	1160988-35-1P
1160988-36-2P	1160988-38-4P	1160988-39-5P
1160988-40-8P	1160988-41-9P	1160988-42-0P
1160988-43-1P	1160988-44-2P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor

modulators)


RN 1160964-58-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-60-2 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-62-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)- (CA INDEX NAME)




RN 1160964-63-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)




RN 1160964-64-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)- (CA INDEX NAME)



RN 1160964-65-7 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)- (CA INDEX NAME)



RN 1160964-66-8 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -

cyclohexyl- α -hydroxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 1160964-67-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)- (CA INDEX NAME)




RN 1160964-68-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-69-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-70-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1160964-72-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-73-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-74-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160964-75-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl]- (CA INDEX NAME)




RN 1160964-76-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
oxopropyl]- (CA INDEX NAME)




RN 1160964-77-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160964-79-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-80-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-81-7 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160964-82-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160964-83-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160964-84-0 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160964-85-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methysulfonyl)- (CA INDEX NAME)




RN 1160964-86-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methysulfonyl)- (CA INDEX NAME)




RN 1160964-87-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160964-88-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 1160964-90-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160964-92-0 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160965-69-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-70-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-71-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-72-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-73-0 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-74-1 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-75-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-76-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-77-4 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-79-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-80-9 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160965-81-0 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-82-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-84-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-85-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-86-5 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
 oxopropyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-87-6 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160965-88-7 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160965-89-8 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-90-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-92-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-93-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-94-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-95-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160965-96-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methanesulfonyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160965-97-8 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methanesulfonyl)-, (+)- (CA INDEX
 NAME)

Rotation (+).




RN 1160965-99-0 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160966-00-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160966-01-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1160966-02-8 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
 NAME)

Rotation (+).




RN 1160966-70-0 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA
 INDEX NAME)

Rotation (-).




RN 1160966-71-1 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-72-2 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-73-3 CAPLUS
 CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-74-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-75-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-76-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-77-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-78-8 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-79-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-80-2 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-81-3 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160966-84-6 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160966-85-7 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-87-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160966-88-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-
 oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-89-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-90-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-91-5 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-93-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160966-94-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160966-95-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-96-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-97-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160966-98-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methanesulfonyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160966-99-3 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methanesulfonyl)-, (-)- (CA INDEX
 NAME)

Rotation (-).




RN 1160967-00-9 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160967-01-0 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1160967-02-1 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160967-03-2 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160975-45-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclopentyl-α-hydroxy- (CA INDEX
NAME)




RN 1160975-46-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-47-2 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-48-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)- (CA INDEX NAME)




RN 1160975-49-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)




RN 1160975-50-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)- (CA INDEX NAME)




RN 1160975-51-8 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-52-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-53-0 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)- (CA INDEX NAME)




RN 1160975-54-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-55-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-56-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy- (CA INDEX NAME)




RN 1160975-57-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160975-58-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160975-59-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)- (CA INDEX NAME)




RN 1160975-61-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160975-62-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160975-63-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1160975-64-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-65-4 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-66-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)- (CA INDEX NAME)




RN 1160975-67-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-68-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-69-8 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy- (CA INDEX NAME)




RN 1160975-70-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160975-71-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)- (CA INDEX NAME)




RN 1160975-72-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methanesulfonyl)- (CA INDEX NAME)




RN 1160975-73-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 1160975-74-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160975-75-6 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1160976-41-9 CAPLUS


CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160976-42-0 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1160976-43-1 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-44-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-45-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-46-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-47-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-48-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-49-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-51-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160976-53-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-

(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1160976-55-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1160976-57-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-61-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-63-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-65-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-67-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-69-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclopentyl-α-hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-71-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-73-7 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-75-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-77-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-79-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160976-81-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-83-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1160976-85-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-87-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-89-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160976-91-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1160977-51-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-52-5 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-53-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-54-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-55-8 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(3-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-56-9 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(3-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-58-1 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -

cyclopentyl- α -hydroxy-4-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-59-2 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-3-(4-pyridinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-60-5 CAPLUS


CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-2-(4-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-61-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-62-7 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160977-63-8 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-64-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160977-65-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160977-66-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(2-hydroxyacetyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160977-68-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-
 oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-69-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-70-7 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclopentyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-71-8 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
 NAME)

Rotation (-).




RN 1160977-72-9 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(hydroxymethyl)-, (-)- (CA INDEX
 NAME)

Rotation (-).



RN	1160977-74-1	CAPLUS
CN	[1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclopentyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)	


Rotation (-).



RN 1160977-75-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160977-76-3 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-methoxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160977-77-4 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160977-78-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1160977-79-6 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(methylsulfonyl)-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160977-80-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160977-82-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1160977-83-2 CAPLUS


CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclopentyl- α -hydroxy-4'-(trifluoromethyl)-, (-)- (CA INDEX
 NAME)

Rotation (-).




RN 1160986-92-4 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-
 cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX
 NAME)




RN 1160986-93-5 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160986-95-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160986-96-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160986-97-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160986-98-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160986-99-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160987-00-7 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160987-01-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1160987-02-9 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-03-0 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-04-1 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1160987-05-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-07-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-08-5 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-10-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-11-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-12-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]- (CA INDEX NAME)




RN 1160987-13-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-14-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-15-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-17-6 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA
 INDEX NAME)




RN 1160987-18-7 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA
 INDEX NAME)




RN 1160987-19-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA
 INDEX NAME)




RN 1160987-20-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-21-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-22-3 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-23-4 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)



RN 1160987-24-5 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1160987-25-6 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)



RN 1160988-21-5 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-22-6 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-23-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-24-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-25-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-26-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-27-1 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-28-2 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
 NAME)

Rotation (+).




RN 1160988-29-3 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
 NAME)

Rotation (+).



RN 1160988-30-6 CAPLUS
 CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-
 cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA
 INDEX NAME)


Rotation (+).



RN 1160988-31-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-32-8 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-33-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-34-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-35-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-36-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
(tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-38-4 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
(tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-39-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
 tetrahydro-2H-pyran-4-yl)propyl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-40-8 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-,
 (+)- (CA INDEX NAME)

Rotation (+).



RN 1160988-41-9 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-,
 (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-42-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-,
 (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-43-1 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (+)-
 (CA INDEX NAME)

Rotation (+).



RN 1160988-44-2 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)-
 (CA INDEX NAME)

Rotation (+).



IT	1160988-45-3P	1160988-46-4P	1160988-47-5P
	1160988-48-6P	1160988-49-7P	1160988-50-0P
	1160988-51-1P	1160989-18-3P	1160989-19-4P
	1160989-20-7P	1160989-21-8P	1160989-22-9P
	1160989-23-0P	1160989-24-1P	1160989-25-2P
	1160989-26-3P	1160989-27-4P	1160989-28-5P
	1160989-29-6P	1160989-30-9P	1160989-31-0P
	1160989-32-1P	1160989-33-2P	1160989-34-3P
	1160989-35-4P	1160989-36-5P	1160989-37-6P
	1160989-38-7P	1160989-39-8P	1160989-40-1P
	1160989-41-2P	1160989-42-3P	1160989-43-4P
	1160989-44-5P	1160989-45-6P	1160989-46-7P
	1160989-47-8P	1161003-55-9P	1161003-56-0P
	1161003-57-1P	1161003-58-2P	1161003-59-3P
	1161003-60-6P	1161003-61-7P	1161003-62-8P
	1161003-63-9P	1161003-64-0P	1161003-65-1P
	1161003-66-2P	1161003-67-3P	1161003-68-4P
	1161003-69-5P	1161003-70-8P	1161003-71-9P
	1161003-72-0P	1161003-73-1P	1161003-74-2P
	1161003-75-3P	1161003-76-4P	1161003-77-5P
	1161003-79-7P	1161003-80-0P	1161003-81-1P
	1161003-82-2P	1161003-83-3P	1161003-84-4P
	1161003-85-5P	1161004-56-3P	1161004-58-5P
	1161004-60-9P	1161004-62-1P	1161004-63-2P
	1161004-65-4P	1161004-66-5P	1161004-67-6P
	1161004-69-8P	1161004-71-2P	1161004-73-4P
	1161004-76-7P	1161004-78-9P	1161004-80-3P
	1161004-82-5P	1161004-84-7P	1161004-85-8P
	1161004-88-1P	1161004-90-5P	1161004-92-7P
	1161004-94-9P	1161004-96-1P	1161004-98-3P
	1161005-01-1P	1161005-03-3P	1161005-05-5P
	1161005-07-7P	1161005-08-8P	1161005-10-2P
	1161005-12-4P	1161005-79-3P	1161005-80-6P
	1161005-81-7P	1161005-82-8P	1161005-84-0P

1161005-85-1P	1161005-86-2P	1161005-87-3P
1161005-88-4P	1161005-90-8P	1161005-91-9P
1161005-92-0P	1161005-93-1P	1161005-94-2P
1161005-95-3P	1161005-97-5P	1161005-98-6P
1161005-99-7P	1161006-00-3P	1161006-01-4P
1161006-03-6P	1161006-04-7P	1161006-05-8P
1161006-06-9P	1161006-07-0P	1161006-09-2P
1161006-10-5P	1161006-11-6P	1161006-12-7P
1161006-13-8P	1161019-68-6P	1161019-69-7P
1161019-70-0P	1161019-71-1P	1161019-72-2P
1161019-73-3P	1161019-74-4P	1161019-75-5P
1161019-76-6P	1161019-77-7P	1161019-78-8P
1161019-79-9P	1161019-80-2P	1161019-81-3P
1161019-82-4P	1161019-83-5P	1161019-84-6P
1161019-85-7P	1161019-86-8P	1161019-87-9P
1161019-88-0P	1161019-89-1P	1161019-90-4P
1161019-91-5P	1161019-92-6P	1161019-93-7P
1161019-94-8P	1161019-95-9P	1161019-96-0P
1161019-97-1P	1161020-55-8P	1161020-56-9P
1161020-57-0P	1161020-58-1P	1161020-59-2P
1161020-60-5P	1161020-61-6P	1161020-62-7P
1161020-63-8P	1161020-64-9P	1161020-65-0P
1161020-66-1P	1161020-67-2P	1161020-68-3P
1161020-69-4P	1161020-70-7P	1161020-71-8P
1161020-72-9P	1161020-73-0P	1161020-74-1P
1161020-75-2P	1161020-76-3P	1161020-77-4P
1161020-78-5P	1161020-79-6P	1161020-80-9P
1161020-81-0P	1161020-82-1P	1161020-83-2P
1161020-84-3P	1161021-42-6P	1161021-43-7P
1161021-44-8P	1161021-45-9P	1161021-46-0P
1161021-47-1P	1161021-48-2P	1161021-49-3P
1161021-50-6P	1161021-51-7P	1161021-52-8P
1161021-53-9P	1161021-54-0P	1161021-55-1P
1161021-56-2P	1161021-57-3P	1161021-58-4P
1161021-59-5P	1161021-60-8P	1161021-61-9P
1161021-62-0P	1161021-63-1P	1161021-64-2P
1161021-66-4P	1161021-68-6P	1161021-70-0P
1161021-72-2P	1161021-74-4P	1161021-76-6P
1161021-77-7P	1161062-79-8P	1161062-80-1P
1161062-81-2P	1161062-82-3P	1161062-83-4P
1161062-84-5P	1161062-85-6P	1161062-86-7P
1161062-87-8P	1161062-88-9P	1161062-89-0P
1161062-90-3P	1161062-91-4P	1161062-92-5P
1161062-93-6P	1161062-94-7P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor modulators)

RN 1160988-45-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1160988-46-4 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-
 , (+)- (CA INDEX NAME)


Rotation (+).



RN 1160988-47-5 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-
 , (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-48-6 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-49-7 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-50-0 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (+)- (CA INDEX NAME)

Rotation (+).




RN 1160988-51-1 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
 , (+)- (CA INDEX NAME)

Rotation (+).



RN 1160989-18-3 CAPLUS
 CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-
 cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA
 INDEX NAME)


Rotation (-).



RN 1160989-19-4 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-20-7 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-21-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-22-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-23-0 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-24-1 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1160989-25-2 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1160989-26-3 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1160989-27-4 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-28-5 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-29-6 CAPLUS

CN 2H-Pyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-30-9 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-31-0 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-32-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
 , (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-33-2 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
 tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-34-3 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-35-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-pyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1160989-36-5 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-,
 (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-37-6 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-,
 (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-38-7 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-,
 (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-39-8 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1160989-40-1 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1160989-41-2 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1160989-42-3 CAPLUS

CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-
 , (-)- (CA INDEX NAME)


Rotation (-).



RN 1160989-43-4 CAPLUS


CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-
 , (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-44-5 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-45-6 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-46-7 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (-)- (CA INDEX NAME)

Rotation (-).




RN 1160989-47-8 CAPLUS
 CN 2H-Pyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
 , (-)- (CA INDEX NAME)


Rotation (-).



RN 1161003-55-9 CAPLUS
 CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-
 cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-56-0 CAPLUS
 CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-
 cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-57-1 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-58-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-59-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-60-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-61-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-62-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-63-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161003-64-0 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-65-1 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-66-2 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161003-67-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-68-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-69-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-70-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-71-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-72-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]- (CA INDEX NAME)




RN 1161003-73-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-74-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-75-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-76-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161003-77-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161003-79-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 1161003-80-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methoxysulfonyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-81-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161003-82-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 1161003-83-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161003-84-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161003-85-5 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)



RN 1161004-56-3 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-58-5 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-60-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-62-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-63-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-65-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-66-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-67-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-69-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-71-2 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-73-4 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-76-7 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-78-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-80-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-82-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-84-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-85-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-
piperidinyl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-88-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-
piperidinyl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-90-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-92-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161004-94-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-96-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161004-98-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-01-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161005-03-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-05-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-07-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-08-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-10-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-12-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1161005-79-3 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-80-6 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-81-7 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-82-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-84-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-85-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-86-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-87-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-88-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-90-8 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-91-9 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-92-0 CAPLUS

CN 4-Piperidineacetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-93-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-94-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-95-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-97-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-piperidinyl)propyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161005-98-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-
piperidinyl)propyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161005-99-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(4-
piperidinyl)propyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-00-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-01-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-03-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-04-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-05-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-06-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-07-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161006-09-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161006-10-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-11-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161006-12-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)-(CA INDEX NAME)


Rotation (-).



RN 1161006-13-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)-(CA INDEX NAME)

Rotation (-).




RN 1161019-68-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-69-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-70-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA INDEX NAME)




RN 1161019-71-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-72-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-73-3 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-74-4 CAPLUS
 CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-75-5 CAPLUS
 CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 1161019-76-6 CAPLUS
 CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161019-77-7 CAPLUS
 CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-
 N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA
 INDEX NAME)




RN 1161019-78-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA
INDEX NAME)




RN 1161019-79-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- (CA
INDEX NAME)




RN 1161019-80-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-
(CA INDEX NAME)




RN 1161019-81-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1161019-82-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)




RN 1161019-83-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
 tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-84-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-85-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]- (CA INDEX NAME)




RN 1161019-86-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1161019-87-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-
(CA INDEX NAME)




RN 1161019-88-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-
(CA INDEX NAME)




RN 1161019-89-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (CA
INDEX NAME)




RN 1161019-90-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161019-91-5 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 1161019-92-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 1161019-93-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]methyl]-
 (CA INDEX NAME)




RN 1161019-94-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
 (CA INDEX NAME)




RN 1161019-95-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)




RN 1161019-96-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
(CA INDEX NAME)



RN 1161019-97-1 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-
(CA INDEX NAME)



RN 1161020-55-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-56-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-57-0 CAPLUS


CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161020-58-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).




RN 1161020-59-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)

Rotation (+).



RN 1161020-60-5 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
NAME)


Rotation (+).



RN 1161020-61-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1161020-62-7 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
 NAME)

Rotation (+).




RN 1161020-63-8 CAPLUS
 CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX
 NAME)

Rotation (+).




RN 1161020-64-9 CAPLUS
 CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-
 N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)-
 (CA INDEX NAME)

Rotation (+).



RN 1161020-65-0 CAPLUS
 CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-
 N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)-
 (CA INDEX NAME)


Rotation (+).



RN 1161020-66-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-67-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-68-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-
 , (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-69-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-
 , (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-70-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-71-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(
(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-72-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-73-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-74-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-75-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-,
 (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-76-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (+)-
 (CA INDEX NAME)


Rotation (+).



RN 1161020-77-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161020-78-5 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161020-79-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-80-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-81-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-82-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
 , (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-83-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
 , (+)- (CA INDEX NAME)


Rotation (+).



RN 1161020-84-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161021-42-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-43-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-44-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-cyano[1,1'-biphenyl]-2-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-45-9 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-46-0 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1161021-47-1 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[2-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1161021-48-2 CAPLUS
CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX
NAME)


Rotation (-).



RN 1161021-49-3 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-50-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[2-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-51-7 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-52-8 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-3-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-53-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, α -[(4'-acetyl[1,1'-biphenyl]-2-yl)methyl]-
N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-54-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-55-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-56-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(2-hydroxyacetyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-57-3 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-58-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161021-59-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid,
 2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxo-2-(tetrahydro-2H-thiopyran-4-yl)propyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161021-60-8 CAPLUS
 CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]-,
 (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-61-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-62-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(hydroxymethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-63-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-64-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-66-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161021-68-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-70-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(methanesulfonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-72-2 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl]methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-74-4 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-76-6 CAPLUS

CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-
 α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161021-77-7 CAPLUS


CN 2H-Thiopyran-4-acetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro- α -hydroxy- α -[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161062-79-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-fluoro- α -hydroxy- (CA INDEX NAME)




RN 1161062-80-1 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1161062-81-2 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX NAME)




RN 1161062-82-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX NAME)




RN 1161062-83-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)





RN 1161062-84-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-phenyl)- (CA INDEX NAME)




RN 1161062-85-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)- (CA INDEX NAME)




RN 1161062-86-7 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)- (CA INDEX NAME)




RN 1161062-87-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-[(methylamino)carbonyl]- (CA INDEX
NAME)




RN 1161062-88-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-4'-[[(methylsulfonyl) amino]methyl]-
(CA INDEX NAME)




RN 1161062-89-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetylamino)-N-[4-cyano-3-
(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX
NAME)




RN 1161062-90-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-[(methylamino)sulfonyl]- (CA INDEX
 NAME)




RN 1161062-91-4 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(dimethylamino)sulfonyl]- α -hydroxy- (CA
 INDEX NAME)




RN 1161062-92-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]- (CA INDEX
 NAME)




RN 1161062-93-6 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-3'-[[[2-(dimethylamino)ethyl]amino]carbonyl]-α-
hydroxy- (CA INDEX NAME)



RN 1161062-94-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-
(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX
NAME)



IT	1161062-95-8P	1161062-96-9P	1161062-97-0P
	1161062-98-1P	1161062-99-2P	1161063-00-8P
	1161063-01-9P	1161063-02-0P	1161063-03-1P
	1161063-04-2P	1161063-86-0P	1161063-87-1P
	1161063-88-2P	1161063-89-3P	1161063-90-6P
	1161063-91-7P	1161063-92-8P	1161063-93-9P
	1161063-94-0P	1161063-95-1P	1161063-96-2P
	1161063-97-3P	1161063-98-4P	1161063-99-5P
	1161064-00-1P	1161064-01-2P	1161064-02-3P

1161064-03-4P	1161064-04-5P	1161064-05-6P
1161064-06-7P	1161064-07-8P	1161064-08-9P
1161064-09-0P	1161064-10-3P	1161064-11-4P
1161064-12-5P	1161064-13-6P	1161064-14-7P
1161064-15-8P	1161064-16-9P	1161064-17-0P
1161064-18-1P	1161064-19-2P	1161064-20-5P
1161064-21-6P	1161064-22-7P	1161064-23-8P
1161064-24-9P	1161064-25-0P	1161064-26-1P
1161064-27-2P	1161064-28-3P	1161064-29-4P
1161064-30-7P	1161064-31-8P	1161064-32-9P
1161064-33-0P	1161064-34-1P	1161064-35-2P
1161064-36-3P	1161064-37-4P	1161064-38-5P
1161064-39-6P	1161064-40-9P	1161064-41-0P
1161064-42-1P	1161064-43-2P	1161064-44-3P
1161064-45-4P	1161064-48-7P	1161064-49-8P
1161064-50-1P	1161064-51-2P	1161064-52-3P
1161064-53-4P	1161064-54-5P	1161064-55-6P
1161064-56-7P	1161064-57-8P	1161064-58-9P
1161064-59-0P	1161064-60-3P	1161064-61-4P
1161064-62-5P	1161064-63-6P	1161064-64-7P
1161064-65-8P	1161064-66-9P	1161064-67-0P
1161064-68-1P	1161064-69-2P	1161064-70-5P
1161064-71-6P	1161064-72-7P	1161064-73-8P
1161065-55-9P	1161065-56-0P	1161065-57-1P
1161065-58-2P	1161065-59-3P	1161065-60-6P
1161065-61-7P	1161065-62-8P	1161065-63-9P
1161065-64-0P	1161065-65-1P	1161065-66-2P
1161065-67-3P	1161065-68-4P	1161065-69-5P
1161065-70-8P	1161065-71-9P	1161065-72-0P
1161065-73-1P	1161065-74-2P	1161065-75-3P
1161065-76-4P	1161065-77-5P	1161065-78-6P
1161065-79-7P	1161065-80-0P	1161065-81-1P
1161065-82-2P	1161065-83-3P	1161065-84-4P
1161065-85-5P	1161065-86-6P	1161065-87-7P
1161065-88-8P	1161065-89-9P	1161065-90-2P
1161065-91-3P	1161065-92-4P	1161065-93-5P
1161065-94-6P	1161065-95-7P	1161065-96-8P
1161065-97-9P	1161065-98-0P	1161065-99-1P
1161066-00-7P	1161066-01-8P	1161066-02-9P
1161066-03-0P	1161066-04-1P	1161066-05-2P
1161066-06-3P	1161066-07-4P	1161066-08-5P
1161066-09-6P	1161066-10-9P	1161066-11-0P
1161066-12-1P	1161066-13-2P	1161066-14-3P
1161066-17-6P	1161066-18-7P	1161066-19-8P
1161066-20-1P	1161066-21-2P	1161066-22-3P
1161066-23-4P	1161066-24-5P	1161066-25-6P
1161066-26-7P	1161066-27-8P	1161066-28-9P
1161066-29-0P	1161066-30-3P	1161066-31-4P
1161066-32-5P	1161066-33-6P	1161066-34-7P
1161066-35-8P	1161066-36-9P	1161066-37-0P
1161066-38-1P	1161066-39-2P	1161066-40-5P
1161066-41-6P	1161066-42-7P	1161067-27-1P
1161067-28-2P	1161067-29-3P	1161067-30-6P
1161067-31-7P	1161067-32-8P	1161067-33-9P
1161067-34-0P	1161067-35-1P	1161067-36-2P
1161067-37-3P	1161067-38-4P	1161067-39-5P
1161067-40-8P	1161067-41-9P	1161067-42-0P
1161067-43-1P	1161067-44-2P	1161067-45-3P
1161067-46-4P	1161067-47-5P	1161067-48-6P
1161067-49-7P	1161067-50-0P	1161067-51-1P


1161067-52-2P	1161067-53-3P	1161067-54-4P
1161067-55-5P	1161067-56-6P	1161067-57-7P
1161067-58-8P	1161067-59-9P	1161067-60-2P
1161067-61-3P	1161067-62-4P	1161067-63-5P
1161067-64-6P	1161067-65-7P	1161067-66-8P
1161067-67-9P	1161067-68-0P	1161067-69-1P
1161067-70-4P	1161067-71-5P	1161067-72-6P
1161067-73-7P	1161067-74-8P	1161067-75-9P
1161067-76-0P	1161067-77-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycolic amides as nonsteroidal progesterone receptor modulators)


RN 1161062-95-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]- (CA INDEX NAME)




RN 1161062-96-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy- (CA INDEX NAME)




RN 1161062-97-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1161062-98-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-3'--[[2-(dimethylamino)ethyl]amino]carbonyl]-α-
hydroxy- (CA INDEX NAME)




RN 1161062-99-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX NAME)




RN 1161063-00-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy- (CA INDEX NAME)




RN 1161063-01-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-3'-[[4-(methanesulfonylamino)methyl]-
(CA INDEX NAME)




RN 1161063-02-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-4'-[(dimethylamino)carbonyl]-α-hydroxy- (CA
INDEX NAME)




RN 1161063-03-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-α-hydroxy-3'-(methanesulfonyl)- (CA INDEX NAME)




RN 1161063-04-2 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(cyclopropylamino)carbonyl]- α -hydroxy- (CA
INDEX NAME)




RN 1161063-86-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-87-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-88-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-89-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-90-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161063-91-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)



RN 1161063-92-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-α-hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)



RN 1161063-93-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-

[[(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-yl)methyl]-2-oxoethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161063-94-0 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161063-95-1 CAPLUS


CN 4-Piperidineacetamide, α -[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- (CA INDEX NAME)




RN 1161063-96-2 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-
 yl)methyl]- (CA INDEX NAME)



RN 1161063-97-3 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-
 yl)methyl]- (CA INDEX NAME)




RN 1161063-98-4 CAPLUS
 CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-
 yl)methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
 (CA INDEX NAME)




RN 1161063-99-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
(CA INDEX NAME)



RN 1161064-00-1 CAPLUS


CN 4-Piperidineacetamide, α -[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
(CA INDEX NAME)



RN 1161064-01-2 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylsulfonyl)amino]methyl][1,1'-

biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-02-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-hydroxy-α-[[4'-(methylsulfonyl)amino][1,1'-biphenyl]-3-
yl)methyl]- (CA INDEX NAME)




RN 1161064-03-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-[[3'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl)methyl]-α-
hydroxy- (CA INDEX NAME)




RN 1161064-04-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-
 yl)methyl]- (CA INDEX NAME)




RN 1161064-05-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl)methyl]- α -
 hydroxy- (CA INDEX NAME)




RN 1161064-06-7 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[[(methylsulfonyl)amino]methyl][1,1'-
 biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-07-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-
yl)methyl]- (CA INDEX NAME)




RN 1161064-08-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161064-09-0 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -
hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]-
(CA INDEX NAME)




RN 1161064-10-3 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161064-11-4 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)- (CA INDEX NAME)




RN 1161064-12-5 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)- (CA INDEX NAME)




RN 1161064-13-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-α-hydroxy-α-[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl- (CA INDEX NAME)



RN 1161064-14-7 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)-α-hydroxy-α-[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl- (CA INDEX NAME)



RN 1161064-15-8 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-[(3'-(methylamino)carbonyl)[1,1'-biphenyl]-3-yl]methyl-1-

(4-pyridinylcarbonyl)- (CA INDEX NAME)




RN 1161064-16-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-17-0 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-18-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid,
 3'-[2-(1-benzoyl-4-piperidinyl)-3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1161064-19-2 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-20-5 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)



RN 1161064-21-6 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]- (CA INDEX NAME)




RN 1161064-22-7 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
 yl]methyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-23-8 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]- (CA INDEX NAME)

yl)methyl]- (CA INDEX NAME)




RN 1161064-24-9 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-25-0 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-26-1 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-27-2 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-28-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-29-4 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-30-7 CAPLUS


CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-31-8 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-[1-[(4-

fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]- (CA INDEX NAME)




RN 1161064-32-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy- (CA INDEX NAME)




RN 1161064-33-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy-α-[[3'-[[[2-(methoxyethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-34-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-35-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-36-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-37-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-38-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(4-methyl-1-piperazinyl)methyl][1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 1161064-39-6 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-isoxazolylcarbonyl)- (CA INDEX NAME)




RN 1161064-40-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-41-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 1161064-42-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 1161064-43-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)




RN 1161064-44-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 1161064-45-4 CAPLUS


CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- (CA INDEX NAME)



RN 1161064-48-7 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-fluoro- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-49-8 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-50-1 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161064-51-2 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-52-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-53-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-54-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-55-6 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-56-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-[(methylamino)carbonyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-57-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-[(methylsulfonyl)amino]methyl-,
 (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-58-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetylamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-59-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-[(methylamino)sulfonyl]-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-60-3 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(dimethylamino)sulfonyl]- α -hydroxy-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1161064-61-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-62-5 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-3'-[[[2-(dimethylamino)ethyl]amino]carbonyl]- α -
hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-63-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-64-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-65-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-66-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylamino)carbonyl]-, (+)- (CA
INDEX NAME)


Rotation (+).



RN 1161064-67-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-3'-[[[2-(dimethylamino)ethyl]amino]carbonyl]-α-
hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-68-1 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-
(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (+)- (CA
INDEX NAME)

Rotation (+).




RN 1161064-69-2 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161064-70-5 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-[[(methylsulfonyl) amino]methyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161064-71-6 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-[(dimethylamino)carbonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161064-72-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1161064-73-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(cyclopropylamino)carbonyl]- α -hydroxy-, (+)-
 (CA INDEX NAME)


Rotation (+).



RN 1161065-55-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-56-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-57-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)

Rotation (+).




RN 1161065-58-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 1161065-59-3 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-60-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-61-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-62-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-63-9 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-64-0 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-65-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-66-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-67-3 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-68-4 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-69-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-70-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylsulfonyl)amino]methyl][1,1'-
 biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-71-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-
 yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-72-0 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -
 hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-73-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl]methyl]-, (+)-
 (CA INDEX NAME)


Rotation (+).



RN 1161065-74-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -
 hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-75-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[[(methylsulfonyl)amino]methyl][1,1'-
 biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-76-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-77-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-78-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-79-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-80-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-81-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-82-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-83-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-84-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(4-pyridinylcarbonyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-85-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-86-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-87-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-(1-benzoyl-4-piperidiny)-3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-88-8 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
 yl]methyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-89-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-90-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-91-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
 yl]methyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-92-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-93-5 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-94-6 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-95-7 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-96-8 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-97-9 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-98-0 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161065-99-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-00-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-01-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



—F

RN 1161066-02-9 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-03-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl)methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-04-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-05-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-06-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-07-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(4-methyl-1-piperazinyl)methyl][1,1'-biphenyl]-3-yl)methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-08-5 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-fluorophenyl)sulfonyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-09-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-10-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-11-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-12-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-13-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-14-3 CAPLUS

CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1161066-17-6 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-fluoro- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-18-7 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 3'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-19-8 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161066-20-1 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 2'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-21-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
2'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-cyclohexyl-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-22-3 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-23-4 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-2-(2-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-24-5 CAPLUS

CN Benzenepropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3-(3-thienyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-25-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-4'-[(methylamino)carbonyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-26-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-[(methanesulfonyl)amino]methyl-,
 (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-27-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, 4'-(acetamido)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-28-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-4'-[(methylamino)sulfonyl]-, (-)- (CA
INDEX NAME)


Rotation (-).



RN 1161066-29-0 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(dimethylamino)sulfonyl]- α -hydroxy-, (-)-
(CA INDEX NAME)


Rotation (-).



RN 1161066-30-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]-, (-)- (CA
INDEX NAME)


Rotation (-).



RN 1161066-31-4 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-3'-[[[2-(dimethylamino)ethyl]amino]carbonyl]- α -
hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-32-5 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 3'-cyano-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-33-6 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylsulfonyl)amino]-, (-)- (CA
 INDEX NAME)

Rotation (-).




RN 1161066-34-7 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 3'-(aminocarbonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA
 INDEX NAME)

Rotation (-).



RN 1161066-35-8 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-[(methylamino)carbonyl]-, (-)- (CA
 INDEX NAME)


Rotation (-).



RN 1161066-36-9 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
α-cyclohexyl-3'-[[[2-(dimethylamino)ethyl]amino]carbonyl]-α-
hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-37-0 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, 4'-(aminocarbonyl)-N-[4-cyano-3-
(trifluoromethyl)phenyl]-α-cyclohexyl-α-hydroxy-, (-)- (CA
INDEX NAME)

Rotation (-).




RN 1161066-38-1 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, 3'-(acetamino)-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161066-39-2 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl- α -hydroxy-3'-[[(methylsulfonyl) amino]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161066-40-5 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-[(dimethylamino)carbonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161066-41-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl- α -hydroxy-3'-(methylsulfonyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1161066-42-7 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(cyclopropylamino)carbonyl]- α -hydroxy-, (-)-
 (CA INDEX NAME)


Rotation (-).



RN 1161067-27-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-28-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-29-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161067-30-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161067-31-7 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-32-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-1-(methylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-33-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-α-hydroxy-1-(methylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-34-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[4'-[(methylsulfonyl)amino]methyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-35-1 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(methylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-36-2 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-37-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-38-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-(methylamino)carbonyl][1,1'-biphenyl]-3-
 yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-39-5 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-
 , (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-40-8 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-41-9 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]-1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-42-0 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylsulfonyl)amino]methyl][1,1'-
 biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-43-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-
 yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-44-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -
 hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-45-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-
 yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-46-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]- α -
 hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-47-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[4'-[[methylsulfonyl]amino]methyl][1,1'-
 biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-48-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-49-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-hydroxy-1-[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-50-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-51-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-52-2 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(2-phenylacetyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-53-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(phenylsulfonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-54-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-55-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(cyclopropylcarbonyl)- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-56-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-(4-pyridinylcarbonyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-57-7 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-58-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-59-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-(1-benzoyl-4-piperidiny)-3-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-60-2 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-
 yl]methyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-61-3 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-
 yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-62-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[3'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-63-5 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-64-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(1-piperazinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-65-7 CAPLUS

CN 4-Piperidineacetamide, α -[[4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-66-8 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-67-9 CAPLUS

CN 4-Piperidineacetamide, α -[[3'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-68-0 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-cyano[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-69-1 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -[[4'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-70-4 CAPLUS

CN 4-Piperidineacetamide, α -[(3'-acetyl[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-71-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -[(3'-formyl[1,1'-biphenyl]-3-yl)methyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-72-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
3'-[3-[4-cyano-3-(trifluoromethyl)phenyl]amino]-2-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-2-hydroxy-3-oxopropyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-73-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[[[2-(dimethylamino)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



—F

RN 1161067-74-8 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-75-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-76-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-77-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylcarbonyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




```
(preparation of glycolic amides as nonsteroidal progesterone receptor
modulators)
```

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)

COc1ccc(cc1)C(=O)Nc2cc(C#N)c(C(F)(F)F)cc2C(O)(Cc3ccc(cc3)-c4ccc(cc4)CN5CCOCC5)Cc6ccccc6S(=O)(=O)c7ccc(F)cc7


RN 1161067-79-3 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(4-methyl-1-piperazinyl)methyl][1,1'-biphenyl]-3-yl)methyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1161067-80-6 CAPLUS
 CN 4-Piperidineacetamide, α -[[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)methyl]-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy-1-(5-isoxazolylcarbonyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161067-81-7 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)sulfonyl][1,1'-biphenyl]-3-yl)methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-82-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3'-[(methylamino)sulfonyl][1,1'-biphenyl]-3-yl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-83-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(3-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-84-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-85-1 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy- α -[[3-(4-pyridinyl)phenyl]methyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1161067-86-2 CAPLUS


CN 4-Piperidineacetamide, α -([1,1'-biphenyl]-3-ylmethyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1161067-89-5 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -cyclohexyl-4'-(1,2-dihydroxyethyl)- α -hydroxy- (CA INDEX NAME)



RN 1161067-92-0 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-

α -cyclohexyl-4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]- α -hydroxy- (CA INDEX NAME)




RN 1161067-95-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1161067-98-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy- (CA INDEX NAME)




RN 1161068-01-4 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy- (CA INDEX NAME)




RN 1161068-04-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[4'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-α-hydroxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 1161068-07-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[3'-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]-α-hydroxy- (CA INDEX NAME)




RN 1161068-16-1 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -hydroxy-3'-[(methylamino)carbonyl]- α -[4-(trifluoromethyl)cyclohexyl]- (CA INDEX NAME)




RN 1161404-02-9 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(1R)-1,2-dihydroxyethyl]- α -hydroxy-,
 (α R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1161404-03-0 CAPLUS
 CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(1S)-1,2-dihydroxyethyl]- α -hydroxy-,
 (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-04-1 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(1S)-1,2-dihydroxyethyl]- α -hydroxy-,
 (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-05-2 CAPLUS


CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(1R)-1,2-dihydroxyethyl]- α -hydroxy-,
 (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-06-3 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-07-4 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1161404-08-5 CAPLUS
CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
isoxazolyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-09-6 CAPLUS

CN [1,1'-Biphenyl]-3-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -cyclohexyl-4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
 isoxazolyl]- α -hydroxy-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-10-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[(1R)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-11-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1S)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1161404-12-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-13-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1S)-2-[[4-cyano-3-(trifluoromethyl)phenyl]amino]-1-[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-hydroxy-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-14-3 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-α-[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-α-hydroxy-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-15-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-16-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-17-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-18-7 CAPLUS


CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1161404-19-8 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
 isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 1161404-20-1 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
 isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α R)- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 1161404-21-2 CAPLUS
 CN 4-Piperidineacetamide, 1-benzoyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-
 α -[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-
 isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-, (α S)- (CA
 INDEX NAME)

Absolute stereochemistry.



RN 1161404-22-3 CAPLUS
 CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-
 [(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-
 biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α R)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-23-4 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-24-5 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-25-6 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[4'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]- α -hydroxy-1-(methylsulfonyl)-, (α S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-26-7 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-27-8 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-28-9 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(5S)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1161404-29-0 CAPLUS

CN 4-Piperidineacetamide, N-[4-cyano-3-(trifluoromethyl)phenyl]- α -[[3'-[(5R)-4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl][1,1'-biphenyl]-3-yl]methyl]-1-[(4-fluorophenyl)sulfonyl]- α -hydroxy-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:740002 CAPLUS Full-text
 DOCUMENT NUMBER: 151:50538
 TITLE: Substituted isoxazoline pesticides
 INVENTOR(S): Mita, Takeshi; Maeda, Kazushige; Komoda, Mitsuaki; Ikeda, Eitatsu; Toyama, Ken-Ichi; Iwasa, Motoyoshi
 PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
 SOURCE: U.S. Pat. Appl. Publ., 217pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 20090156643	A1	20090618	US 2008-230780	20080904
WO 2007105814	A1	20070920	WO 2007-JP55325	20070312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

WO 2010027051	A1	20100311	WO 2009-JP65510	20090904
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.:

JP 2006-65097	A	20060310
WO 2007-JP55325	A2	20070312
US 2008-230780	A	20080904
JP 2008-308692	A	20081203
JP 2009-66167	A	20090318
JP 2009-154984	A	20090630

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:50538


GI




I

AB Provided are pesticidal isoxazolines (I), or salts thereof, wherein A1, A2 and A3 independently = C, N; G = benzene ring, etc.; L = CH₂, C(CH₃), CH(CN), etc.; X = halo, C1-6 haloalkyl, etc.; Y = halo, C1-6 alkyl, etc.; R1 = COR1a, etc.; R1a = (halo)alkyl, etc.; R2 = H, C1-6 haloalkyl, alkenyl, etc.; R3 = haloalkyl, etc.; m = 0-5 integer, n = 0-4 integer. These compds. have excellent insecticidal and acaricidal activities and may be used as endo- or ectoparasiticides for mammals or birds. Thus, 1-[4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]phenylmethyl]-3-(2,2,2-trifluoroethyl)urea (prepared) showed an insecticidal rate of ≥80% against cabbage moth (*Plutella xylostella*) when tested at 10 ppm.

IT 1160869-00-0P 1160869-01-1P
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and use as pesticide)
 RN 1160869-00-0 CAPLUS
 CN Urea, N-[[2-chloro-4-[4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)





RN 1160869-01-1 CAPLUS
 CN Urea, N-[[2-chloro-4-[4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L4 ANSWER 6 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:564854 CAPLUS Full-text
 DOCUMENT NUMBER: 150:563825
 TITLE: Preparation of imidazole derivatives as cytokine inhibitors
 INVENTOR(S): Su, Weiguo; Deng, Wei; Cai, Yu; Duan, Jifeng
 PATENT ASSIGNEE(S): Hutchison Medipharma Limited, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 59pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 101423518	A	20090506	CN 2008-10175305	20081103
PRIORITY APPLN. INFO.:			CN 2007-10047763	A 20071102
OTHER SOURCE(S):	CASREACT 150:563825; MARPAT 150:563825			
GI				




AB The title compds. with general formula I [wherein A = a bond, (CRaRb)_n, or heteroaryl; n = 1 - 5; Ra and Rb = independently H or alkyl; B = 5- to 6-membered heteroaryl; X = a bond, SO, SO₂, C(=O), C(=O)O, etc.; R1 and R2 = independently H, halo, alkyl, haloalkyl, etc.; R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.] or pharmaceutically acceptable salts or solvates thereof were prepared as cytokine inhibitors. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.

IT 1149382-58-0P, 1-[[3-(1H-Imidazo[1,2-a]pyridin-2-yl)phenyl]methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of imidazole derivs. as cytokine inhibitors)

RN 1149382-58-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl]methyl]- (CA INDEX NAME)





L4 ANSWER 7 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:552776 CAPLUS Full-text
 DOCUMENT NUMBER: 150:515170
 TITLE: Preparation of imidazole derivatives as cytokine inhibitors
 INVENTOR(S): Deng, Wei; Su, Wei-Guo; Cai, Yu; Duan, Jeff
 PATENT ASSIGNEE(S): Hutchison Medipharma Enterprises Limited, Peop. Rep. China
 SOURCE: U.S. Pat. Appl. Publ., 41pp.; Chemical Indexing Equivalent to 150:515169 (WO)
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20090118292	A1	20090507	US 2007-934154	20071102
AU 2008318491	A1	20090507	AU 2008-318491	20081031
CA 2704431	A1	20090507	CA 2008-2704431	20081031
WO 2009059162	A1	20090507	WO 2008-US82027	20081031


W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-934154 A 20071102
 WO 2008-US82027 W 20081031

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI



- AB Title compds. I [A = bond, (CRA_{Rb})_n, or heteroaryl; n = 1-5; Ra and Rb independently = H or alkyl; B = 5- to 6-membered heteroaryl; X = bond, SO, SO₂, CO, COO, etc.; R1 and R2 independently = H, halo, alkyl, haloalkyl, etc.; R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by an over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.
- IT 1149382-58-0P, 1-[[3-(1H-Imidazo[1,2-a]pyridin-2-yl)phenyl]methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole derivs. as cytokine inhibitors)
- RN 1149382-58-0 CAPLUS
- CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl]methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:549738 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 150:515169
 TITLE: Preparation of imidazole derivatives as cytokine inhibitors



INVENTOR(S): Deng, Wei; Su, Wei-Guo; Cai, Yu; Duan, Jeff
 PATENT ASSIGNEE(S): Hutchison Medipharma Enterprises Limited, Bahamas
 SOURCE: PCT Int. Appl., 81pp.; Chemical Indexing Equivalent to
 150:515170 (US)
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009059162	A1	20090507	WO 2008-US82027	20081031
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090118292	A1	20090507	US 2007-934154	20071102
AU 2008318491	A1	20090507	AU 2008-318491	20081031
CA 2704431	A1	20090507	CA 2008-2704431	20081031
PRIORITY APPLN. INFO.:			US 2007-934154	A 20071102
			WO 2008-US82027	W 20081031

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:515169


GI



AB Title compds. I [A = bond, (CRaRb)_n, or heteroaryl; n = 1-5; Ra and Rb independently = H or alkyl; B = 5- to 6-membered heteroaryl; X = bond, SO, SO₂, CO, COO, etc.; R1 and R2 independently = H, halo, alkyl, haloalkyl, etc.;

R3 = H, halo, (un)substituted alkyl, haloalkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed. Also disclosed are methods of using these compds. to decrease the level of a cytokine (e.g., TNF α or IL-1 β) in a subject and to treat a disorder mediated by an over production of a cytokine. E.g., cyclization of 3-(2-bromoacetyl)benzonitrile with 6-chloropyridazin-3-amine to give 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)benzonitrile which was treated with Pd-C/H₂ and NH₂OH followed by cyclization reaction gave II. Selected invention compds. demonstrated significant inhibition of TNF α and IL-1 β production at a dose ranging 1 to 1000 mg/kg in vivo assays.

IT 1149382-58-0P, 1-[[3-(1H-Imidazo[1,2-a]pyridin-2-yl)phenyl]methyl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole derivs. as cytokine inhibitors)
 RN 1149382-58-0 CAPLUS
 CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1,5-dihydroimidazo[1,2-a]pyridin-2-yl)phenyl]methyl]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:336276 CAPLUS Full-text
 DOCUMENT NUMBER: 150:306681
 TITLE: Preparation of 1-benzoxazones and related compounds as nonsteroidal progesterone receptor modulators
 INVENTOR(S): Schwede, Wolfgang; Moeller, Carsten; Schmidt, Anja; Fuhrmann, Ulrike; Rotgeri, Andrea; Kirkland, Thomas Andrew; Wyrwa, Ralf
 PATENT ASSIGNEE(S): Bayer Schering Pharma AG, Germany
 SOURCE: U.S. Pat. Appl. Publ., 145 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090075989	A1	20090319	US 2007-961314	20071220
PRIORITY APPLN. INFO.:			DE 2006-102006061912A	20061221
			US 2007-880707P	P 20070117
			US 2007-979208P	P 20071011

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 150:306681
 GI




AB The invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compns. which comprise these compds. The compds. according to the invention are suitable for the therapy and prophylaxis of gynecol. disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, and for the therapy and prophylaxis of hormone-dependent tumors and for use for female fertility control and for hormone replacement therapy. Compds. of formula I wherein q is 0, and 1; X is O, and H₂; Y = (CH₂)₀₋₁, CH=CH, and C.tplbond.C; R₁ = (un)substituted (mono/bi)cyclic C₆₋₁₂ aryl, (un)substituted 5- to 12-membered heteroaryl, (un)substituted C₃₋₁₀ cycloalkyl, etc.; R₂ = (un)substituted (mono/bi)cyclic C₆₋₁₂ aryl and (un)substituted 5- to 12-membered heteroaryl; R₃ is benzoxazones, isoquinolinones, indanones, benzotriazoles, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by acylation of 6-amino-4-methyl-2,3-benzoxazin-1-one with phenylglyoxylic acid; the resulting 6-[2-phenyl-2-oxoacetyl-amino]-4-methyl-2,3-benzoxazin-1-one underwent addition with phenylacetylene to give compound II. All the invention compds. were evaluated for their progestrone receptor modulatory activity. In progesterone receptor assays, example compound II exhibited IC₅₀ values ranging from 30 nM.

IT 1036306-76-9P 1036306-78-1P 1036306-80-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazones and related compds. as nonsteroidal progesterone receptor modulators)


RN 1036306-76-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-phenyl- (CA INDEX NAME)




RN 1036306-78-1 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1036306-80-5 CAPLUS
CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



L4 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1339943 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 149:534229
TITLE: Preparation of
2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine
derivatives and related compounds for treatment of
Alzheimer's disease
INVENTOR(S): Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro;
Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira;
Yukimasa, Akira; Hori, Akihiro; Kooriyama, Yuji;
Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 354pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133273	A1	20081106	WO 2008-JP57842	20080423
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2151435	A1	20100210	EP 2008-751980	20080423
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
US 20100160290	A1	20100624	US 2009-597470	20091124
PRIORITY APPLN. INFO.:			JP 2007-114764	A 20070424
			WO 2008-JP57842	W 20080423

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:534229

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = each (un)substituted carbocyclic or heterocyclic ring group; E = a bond, Alk1, O-Alk1, S-Alk1, N(R0)-Alk1; Alk1 = lower alkylene or alkenylene; R0 = H, lower alkyl, acyl; X = S, O, NR1; R1 = H, lower alkyl; R2a, R2b = H, HO, each (un)substituted lower alkyl, lower alkenyl, NH2, amidino, acyl, CONH2, carbamoylcarbonyl, lower alkylsulfonyl, arylsulfonyl, or heterocyclyl; R3a, R3b, R4a, R4b = H, halo, HO, each (un)substituted lower alkyl, lower alkenyl, acyl, lower alkoxycarbonyl, NH2, CONH2, carbocyclyl, or heterocyclyl, CO2H; n, m = an integer of 0-3, provided that n+m = 1-3; R5 = H, each lower alkyl, lower alkenyl, lower alkynyl, carbocyclyl, or heterocyclyl], pharmaceutically acceptable salts thereof, or hydrates thereof were prepared These compds. inhibit proteinase BACE-1 and the production of amyloid β protein and are useful for treatment of diseases induced by the production, secretion, or deposition of amyloid β protein, in particular Alzheimer's disease. Thus, addition reaction of N-(3-acetyl-5-bromophenyl)-2,2,2-trifluoroacetamide with vinylmagnesium chloride in THF/Et2O in a dry ice-acetone bath for 20 min, under ice cooling for 30 min, and at room temperature for 35 min gave an allyl alc. (II) which under went condensation reaction with thiourea in 1 M HCl/EtOAc solution at room temperature for 69 h and at 40° for 45 h to give an isothiurea (III). Cyclization of III in the presence of CF3SO3 in CF3CO2H at room temperature for 3.5 h gave a 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine (IV; R = H, R1 = CF3CO) which underwent N-protection with di(tert-butyl) dicarbonate in the presence of Et3N in THF under ice-cooling for 2 h and at room temperature for 3 h to give IV (R = Boc, R1 = CF3CO). IV (R = Boc, R1 = CF3CO) was treated

with a mixture of 1 M NaOH aqueous solution and THF at 50° for 4 h and then with 4 M HCl/1,4-dioxane solution to give IV.2HCl (R = R1 = H). The compound (V) at 10 mg/kg p.o. in vivo lowered amyloid β protein by 50.1% in rat brain after 3 h. [This abstract record is one of 4 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 935986-15-5P 935996-49-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivs. and related compds. as inhibitors of proteinase BACE-1 and production of amyloid β protein for treatment of Alzheimer's disease)


RN 935986-15-5 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 935996-49-9 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:881451 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 149:176348

TITLE: Preparation of novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators

INVENTOR(S): Nardi, Antonio; Demnitz, Joachim; Grunnet, Morten; Christophersen, Palle; Jones, David Spencer; Nielsen, Elsebet Oestergaard; Stroebaek, Dorte; Madsen, Lars Siim

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008087177	A1	20080724	WO 2008-EP50487	20080117
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2121640	A1	20091125	EP 2008-701548	20080117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
US 20100137327	A1	20100603	US 2009-522273	20090903
PRIORITY APPLN. INFO.:			DK 2007-82	A 20070118
			US 2007-880962P	P 20070118
			WO 2008-EP50487	W 20080117

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:176348; MARPAT 149:176348

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [X = absent, NH; R1 = tetrazolyl; R2 = halo, OH or Ph (optionally substituted with one or more halo and/or CF3); R3, R4 = halo, CF3, OH and/or Ph] that are found to be potent modulators of potassium channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of potassium channels, were prepared. Thus, a 2-step synthesis of II, starting from III, was given. II was tested for the BK channel opening activity (data given). Pharmaceutical compns. comprising compound I are disclosed.


IT 1040405-77-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel semicarbazide and carbonylhydrazide derivs. as potent modulators of potassium channels useful in treatment and prevention of diseases)

RN 1040405-77-3 CAPLUS

CN Hydrazinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:806303 CAPLUS Full-text
 DOCUMENT NUMBER: 149:128881
 TITLE: Preparation of 1-benzoxazones and related compounds as nonsteroidal progesterone receptor modulators
 INVENTOR(S): Schwede, Wolfgang; Kirkland, Thomas Andrew; Schmidt, Anja; Fuhrmann, Ulrike; Moeller, Carsten; Rotgeri, Andrea; Wyrwa, Ralf
 PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 214pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008077646	A1	20080703	WO 2007-EP11486	20071220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

DE 102007049630 A1 20091029 DE 2007-102007049630 20071011
 PRIORITY APPLN. INFO.: DE 2006-102006061912A 20061221

DE 2007-102007049630A 20071011

OTHER SOURCE(S): MARPAT 149:128881

GI



AB Title compds. I [Z = (CH₂)_q; q = 0, 1; A = alkyl, alkenyl, alkynyl, etc.; X = O, H₂; Y = (CH₂)_m, CH=CH, etc.; m = 0, 1; R₁ = aromatic, heteroarom. with provisos; R₂ = mono or bicyclic aryl with provisos; R₃ = benzoxazones with provisos; X = O, H₂; Y = (CH₂)_m, CH=CH, etc.; m = 0, 1] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of ketone II and Ph magnesium bromide afforded claimed 1-benzoxazone III. In progesterone receptor assays, 13-examples of compds. I exhibited IC₅₀ values ranging from 3-40 nM.


IT 1036306-76-9P 1036306-78-1P 1036306-80-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazones and related compds. as nonsteroidal progesterone receptor modulators)


RN 1036306-76-9 CAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]-α-hydroxy-α-phenyl- (CA INDEX NAME)




RN 1036306-78-1 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1036306-80-5 CAPLUS
 CN [1,1'-Biphenyl]-2-propanamide, 4'-acetyl-N-[4-cyano-3-(trifluoromethyl)phenyl]- α -hydroxy- α -phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:462774 CAPLUS Full-text
 DOCUMENT NUMBER: 149:454
 TITLE: Synthesis and characterization of
 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives:
 Part 3. New potent non-competitive metabotropic
 glutamate receptor 2/3 antagonists
 AUTHOR(S): Woltering, Thomas J.; Wichmann, Juergen; Goetschi,
 Erwin; Adam, Geo; Kew, James N. C.; Knoflach,
 Frederic; Ballard, Theresa M.; Huwyler, Joerg; Mutel,
 Vincent; Gatti, Silvia
 CORPORATE SOURCE: Pharma Discovery Chemistry CNS, F. Hoffmann-La Roche
 Ltd., Basel, CH-4070, Switz.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),
 18(8), 2725-2729
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:454

AB A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivs. was evaluated as
 non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-
 moiety in 8-position with smaller less lipophilic substituents produced
 compds. inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low
 nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3.
 These compds. were able to reverse LY354740-mediated inhibition of field
 excitatory postsynaptic potentials in the rat dentate gyrus and in vivo
 activity could be demonstrated by reversal of the LY354740-induced
 hypoactivity in mice after oral administration.


IT 473538-74-8P 473538-75-9P 473538-86-2P
 473538-87-3P 473538-89-5P 473538-90-8P
 473549-45-0P 473549-62-1P 473550-12-8P
 473550-13-9P 473550-16-2P 1029958-22-2P
 1029958-28-8P 1029958-39-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of 1,3-dihydro-benzo [b][1,4]diazepin-2-one derivs. as
 metabotropic receptor 2/3 antagonists)


RN 473538-74-8 CAPLUS

CN Carbamic acid, N-[2-[[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-
 yl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-75-9 CAPLUS

CN Carbamic acid, N-[2-[[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-
 yl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-86-2 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-87-3 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-89-5 CAPLUS

CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-90-8 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-45-0 CAPLUS

CN Carbamic acid, N-[5-(dimethylamino)-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-62-1 CAPLUS

CN Carbamic acid, N-[5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-12-8 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-13-9 CAPLUS

CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-16-2 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1029958-22-2 CAPLUS


CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1029958-28-8 CAPLUS
 CN Carbamic acid, N-[5-ethyl-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1029958-39-1 CAPLUS
 CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:71249 CAPLUS Full-text

DOCUMENT NUMBER: 148:168699

TITLE: Substituted isoxalines, pharmaceutical compositions containing same, methods of preparing same, and uses of same

INVENTOR(S): Brittain, Dominic; Bader, Benjamin; Huwe, Christoph; Lienau, Philip; Siemeister, Gerhard; Tatamiya, Takayuki; Weinmann, Hilmar

PATENT ASSIGNEE(S): Bayer Schering Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 150pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006561	A1	20080117	WO 2007-EP6147	20070706
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1878730	A1	20080116	EP 2006-90122	20060712
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
CA 2657336	A1	20080117	CA 2007-2657336	20070706
EP 2046764	A1	20090415	EP 2007-765167	20070706
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009542752	T	20091203	JP 2009-518787	20070706
US 20080027059	A1	20080131	US 2007-776232	20070711
PRIORITY APPLN. INFO.:			EP 2006-90122	A 20060712
			US 2006-831198P	P 20060717
			WO 2007-EP6147	W 20070706

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 148:168699; MARPAT 148:168699
GI



AB Title compds. I [R1 = H, sulfenyl, sulfinyl, alkyl, etc.; R2 and R3 = H, halo, CN, OH, etc.; R4 = H, halo, mercapto, amino, etc.; A = aryl or heteroaryl; X = H, F, Cl, Br, and I wherein at least one X = F and wherein [CX2]nCX3 group is optionally substituted; Z = (un)substituted alkenyl], and their pharmaceutically acceptable salts, are prepared and disclosed as HDAC inhibitors. Thus, e.g., II was prepared by reductive amination of benzaldehyde with 3-(3-aminomethylphenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-5-ol (preparation given). In HDAC6 assays, I demonstrated IC50 values of less than 100 mM.

IT 1002297-27-9P 1002297-30-4P 1002297-36-0P


1002298-21-6P 1002298-25-0P 1002298-32-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoxazlines as HDAC inhibitors)


RN 1002297-27-9 CAPLUS

CN Urea, N-[[4-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1002297-30-4 CAPLUS

CN Urea, N-[[4-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1002297-36-0 CAPLUS

CN Urea, N-[[4-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1002298-21-6 CAPLUS


CN Urea, N-[[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1002298-25-0 CAPLUS
 CN Urea, N-[[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1002298-32-9 CAPLUS
 CN Urea, N-[[3-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1364457 CAPLUS Full-text
 DOCUMENT NUMBER: 148:11215
 TITLE: Preparation of pyrazole acetamide derivatives as modulators of the 5-HT_{2A} serotonin receptor useful for the treatment of disorders related thereto
 INVENTOR(S): Teegarden, Bradley; Feichtinger, Konrad; Strah-Pleyne, Sonja; Ulmann, Brett; Xiong, Yifeng
 PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 207pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007136875	A2	20071129	WO 2007-US12230	20070517


WO 2007136875 A3 20080410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 2051978 A2 20090429 EP 2007-809149 20070517
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
JP 2009537556 T 20091029 JP 2009-511117 20070517
PRIORITY APPLN. INFO.: US 2006-801800P P 20060518
WO 2007-US12230 W 20070517
OTHER SOURCE(S): CASREACT 148:11215; MARPAT 148:11215
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention pertains to certain compds. of Formula I (wherein V is O or NH; W is C1-4 alkylene optionally substituted; Z is substituted amino, alkoxy, etc.; R1 is H, C1-6 alkyl, etc.; R2 is H, C1-6 acyl, etc.; R3 is H, C2-6 alkenyl, C1-6 alkoxy, etc.; R4 is H, amino, C1-6-alkylamino, etc.; R5, R6 and R7 are H, C1-6 acyl, etc.; R8 and R9 are H, C1-3-alkyl, etc.) pharmaceutical compns. thereof that modulate the activity of the 5-HT2A serotonin receptor. Compds. and pharmaceutical compns. thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered sep. or together. Preparation of I is exemplified. For example, II was prepared by reacting 3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenylamine with bromoacetyl bromide and 4-chloro-2-fluoroaniline. In a [¹²⁵I]DOI radioligand binding assay for human 5-HT2A receptors II had an IC₅₀ of 0.19 nM.

IT 958258-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazole acetamide derivs. as modulators of 5-HT2A serotonin receptor useful for treatment of disorders related thereto)

RN 958258-95-2 CAPLUS
CN Ethanediame, N1-[4-methoxy-3-(4-methoxy-1-methyl-1H-pyrazol-5-yl)phenyl]-N2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L4 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:485607 CAPLUS Full-text
 DOCUMENT NUMBER: 146:482079
 TITLE: Preparation of 2-aminodihydrothiazine derivatives as
 β -secretase inhibitors
 INVENTOR(S): Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro;
 Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira;
 Yukimasa, Akira; Hori, Akihiro; Koriyama, Yuji;
 Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko
 PATENT ASSIGNEE(S): Japan
 SOURCE: PCT Int. Appl., 330pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007049532	A1	20070503	WO 2006-JP321015	20061023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006307314	A1	20070503	AU 2006-307314	20061023
CA 2628074	A1	20070503	CA 2006-2628074	20061023
EP 1942105	A1	20080709	EP 2006-822035	20061023
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20090082560	A1	20090326	US 2008-89409	20080418
MX 2008005196	A	20080529	MX 2008-5196	20080421
IN 2008CN02017	A	20090206	IN 2008-CN2017	20080424
KR 2008059330	A	20080626	KR 2008-712436	20080523
CN 101346357	A	20090114	CN 2006-80048810	20080623
PRIORITY APPLN. INFO.:			JP 2005-309642	A 20051025

JP 2006-76636 A 20060320
 WO 2006-JP21015 W 20061023
 WO 2006-JP321015 W 20061023

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:482079

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = (un)substituted carbocyclyl or heterocyclyl; E = a single bond, Alk1, O-Alk1, S-Alk1, N(R0)-Alk1; Alk1 = lower alkylene or lower alkenylene; R0 = H, lower alkyl, acyl; X = S, O, NR1; R1 = H, lower alkyl; R2a, R2b = H, HO, (un)substituted lower alkyl, lower alkenyl, NH2, amidino, acyl, CONH2, carbamoylcarbonyl, lower alkylsulfonyl, arylsulfonyl, carbocyclyl, or heterocyclyl; R3a, R3b, R4a, R4b = H, halo, CO2H, (un)substituted lower alkyl, lower alkenyl, acyl, lower alkoxycarbonyl, NH2, CONH2, carbocyclyl, or heterocyclyl; n m = an integer of 0-3; n+m = 1-3; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, carbocyclyl, or heterocyclyl; when E = a single bond, the ring A and R5 together form a bicyclic fused ring] pharmaceutically acceptable salts thereof or solvates of either are prepared A β -site APP-cleaving enzyme 1 (BACE 1, β -secretase) inhibitor containing, as an active ingredient, any one of a compound represented by the formula I is claimed. These compds. inhibit the production of amyloid β -protein and are useful for the treatment of diseases induced by production, secretion, or deposition of amyloid β -protein, e.g. Alzheimer's disease. Thus, amidation of 4-methyl-4-(3-amino-5-bromophenyl)-2-(tert-butoxycarbonylamino)-5,6-dihydro-4H-1,3-thiazine with 4-bromobenzoyl chloride in the presence of Et3N in THF for 40 min under ice-cooling followed by treatment with 4 M HCl/1,4-dioxane for 24 h gave benzamide (II). The compound II and benzamide (III) showed IC50 of 0.140 and 0.027 μ g/mL against recombinant human β -secretase.

IT 935986-15-5P 935996-49-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-aminodihydrothiazine derivs. as β -secretase inhibitors)


RN 935986-15-5 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 935996-49-9 CAPLUS

CN Acetamide, 2-[3-(2-amino-5,6-dihydro-4-methyl-4H-1,3-thiazin-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1312481 CAPLUS Full-text
 DOCUMENT NUMBER: 146:68200
 TITLE: Use of oxyacetamide compounds for promoting, inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or bleaching
 INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel; Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: PCT Int. Appl., 86pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006131282	A1	20061214	WO 2006-EP5327	20060512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2886844	A1	20061215	FR 2005-51554	20050609
FR 2886844	B1	20070914		
EP 1888017	A1	20080220	EP 2006-761971	20060512
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008542413	T	20081127	JP 2008-515114	20060512
US 20080166310	A1	20080710	US 2007-180	20071210
PRIORITY APPLN. INFO.:			FR 2005-51554	A 20050609
			US 2005-689537P	P 20050613
			WO 2006-EP5327	W 20060512

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:68200; MARPAT 146:68200

AB The present invention relates to the cosmetic use of at least one 2-oxyacetamide compound below, or a salt and/or solvate thereof, as an agent for


promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or as an agent for preventing and/or limiting the depigmentation and/or bleaching of keratin materials, and more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the eyebrows. The present invention more particularly relates to the cosmetic use of at least one 2-oxyacetamide compound or a salt and/or solvate thereof, as an agent for preventing and/or limiting the canities of the said human keratin fibers. Thus, [2-(3-chlorophenoxy)-N-furan-2-yl]methylacetamide (Compound 23) was prepared by reacting a chloroacetamide derivative (prepared from furfurylamine and chloroacetyl chloride) with 3-chlorophenol in a yield of 73%. At concentration of 50 μ M, the Compound 23 demonstrated the inhibitory properties on 15-hydroxyprostaglandin dehydrogenase activity (inhibition of 80%). A hair lotion was prepared containing Compound 23 1.0 g, propylene glycol 30.0 g, Et alc. 40.0 g, and water to 100.0 g. The lotion makes it possible to prevent and/or reduce the canities of the hair.

IT 302551-11-7P 867257-98-5E 867258-00-2E

RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (oxyacetamide compds. for promoting, inducing and/or stimulating pigmentation of keratin fibers and for limiting their depigmentation and/or bleaching)


RN 302551-11-7 CAPLUS

CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 867257-98-5 CAPLUS


CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 867258-00-2 CAPLUS

CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-

(CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1061897 CAPLUS Full-text
DOCUMENT NUMBER: 145:419188
TITLE: Preparation of sulfoximine-pyrimidine macrocycles for treatment of diseases of dysregulated vascular growth.
INVENTOR(S): Luecking, Ulrich
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 51pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1710246	A1	20061011	EP 2005-90098	20050408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 20060252782	A1	20061109	US 2006-399619	20060407
CA 2604353	A1	20061019	CA 2006-2604353	20060410
WO 2006108695	A2	20061019	WO 2006-EP3535	20060410
WO 2006108695	A3	20070222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
 EP 1879900 A2 20080123 EP 2006-742601 20060410
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008546636 T 20081225 JP 2008-504710 20060410
 PRIORITY APPLN. INFO.: EP 2005-90098 A 20050408
 US 2005-670640P P 20050413
 WO 2006-EP3535 W 20060410
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 145:419188; MARPAT 145:419188
 GI




AB Title compds. [I; A = phenylene, heteroarylene; X = (substituted) C2-6
 alkylene; Y = NR4, O, S; R1, R2 = H, OH, halo, NO2, cyano, (substituted)
 alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl(alkyl),
 heteroaryl(alkyl), etc.; R3 = halo, NO2, cyano, alkylthio, amino,
 (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl,
 phenyl(alkyl), heteroaryl(alkyl), PhO, heteroaryloxy, etc.; R4 = H, alkyl],
 were prepared Thus, S-(3-aminophenyl)-S-[4-[(5-iodo-2- chloropyrimidin-4-
 yl)amino]butyl]sulfoximide (preparation given) in MeCN/H2O was added over 3 h
 to MeCN/H2O/4M HCl at 50° to give after 24 h 50% I [R1, R2 = H; R3 = iodo; A =
 1,3-phenylene; X = (CH2)4; Y = NH], which was coupled with N-phenyl-N'-[4-
 (4,4,5,5-tetramethyl-1,3,2-dixabaorolan-2- yl)phenyl]urea to give 13% I [R1,
 R2 = H; R3 = PhNHCONH; A = 1,3-phenylene; X = (CH2)4; Y = NH]. The latter
 inhibited Tie2 with IC50 ≤1 μM.

IT 1175150-33-0
 RL: PRPH (Prophetic)
 (Preparation of sulfoximine-pyrimidine macrocycles for treatment of
 diseases of dysregulated vascular growth.)

RN 1175150-33-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:884558 CAPLUS Full-text

DOCUMENT NUMBER: 145:293054

TITLE: Preparation of imidazo[1,2-a]pyridines as VEGFR-2
inhibitors for treating neoplasm

INVENTOR(S): Barda, David Anthony; Burkholder, Timothy Paul;
Clayton, Joshua Ryan; Hao, Yan; Heath, Perry Clark;
Henry, James Robert; Knobeloch, John Monte; Mendel,
David; Mclean, Johnathan Alexander; Remick, David
Michael; Rempala, Mark Edward; Wang, Zhao-Qing; Yip,
Yvonne Yee Mai; Zhong, Boyu

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 153pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091671	A1	20060831	WO 2006-US6283	20060223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006216710	A1	20060831	AU 2006-216710	20060223
CA 2599124	A1	20060831	CA 2006-2599124	20060223
EP 1904494	A1	20080402	EP 2006-735794	20060223
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008531574	T	20080814	JP 2007-557126	20060223
IN 2007KN02929	A	20070914	IN 2007-KN2929	20070810
KR 2007099029	A	20071008	KR 2007-719338	20070823
KR 904938	B1	20090629		
MX 2007010326	A	20071016	MX 2007-10326	20070823
ZA 2007007136	A	20081126	ZA 2007-7136	20070823
CN 101128461	A	20080220	CN 2006-80006004	20070824
NO 2007004666	A	20071109	NO 2007-4666	20070913
US 20090227622	A1	20090910	US 2008-816416	20080530
US 7666879	B2	20100223		


PRIORITY APPLN. INFO.: US 2005-655981P P 20050224
WO 2006-US6283 W 20060223

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:293054; MARPAT 145:293054

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention is related to imidazopyridines I [R1 = (un)substituted 2-pyridonyl, Ph, thiophenyl, pyrazolyl, etc.; R2, R3 = H, alkyl optionally substituted with OH; R4 = (un)substituted thiazolyl, pyridinyl, Ph; R5 = CONHR6, OC(:O)NHR6, NHCOCH2R6, NHCONHR6, C(:S)NHR6; ; X = (CH2)n; n = 0-4 for R5 = OC(:O)NHR6, NHCOCH2R6, NHCONHR6; n = 1-4 for R5 = CONHR6, C(:S)NHR6; R6 = (un)substituted tetrahydrobenzothiazolyl, Ph, pyridinyl, isoxazolyl, etc.], and their pharmaceutically acceptable salts, that are inhibitors of VEGFR-2 and methods of using them. Thus, reacting [4-[7-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]amine (preparation given) with 3-trifluoromethylphenyl isocyanate gave imidazopyridine II in 66% yield. III demonstrated in vitro inhibition of against cell-based KDR autophosphorylation (IC50 = 42 nM). III displayed antitumor activity in PC-3 prostate tumor xenografts. I are useful as angiogenesis inhibitors and antitumor agents.
- IT 908265-53-2P, 1-[4-[7-[6-(Morpholin-4-yl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
- RN 908265-53-2 CAPLUS
- CN Urea, N-[[4-[7-[6-(4-morpholinyl)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




- IT 908263-98-9P, 1-[4-[7-(2-Methyl-2H-[1,2,4]triazol-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 908264-21-1P, 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 908264-22-2P, 1-[4-[7-(Thien-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-23-3P,
 1-(4-Chloro-3-trifluoromethylphenyl)-3-[4-[7-(thien-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]urea 908264-27-7P,
 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(4-trifluoromethylphenyl)urea 908264-34-6P,
 1-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-trifluoromethylphenyl)urea 908264-45-9P,
 1-[4-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-46-0P,
 1-[4-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-trifluoromethylphenyl)urea 908264-47-1P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(4-trifluoromethylphenyl)urea 908264-51-7P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(2-

trifluoromethylphenyl)urea 908264-59-5P,
 1-[3-[7-(Pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-67-5P,
 1-[4-[7-(Thiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-68-6P,
 1-[4-[7-(Pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-69-7P,
 1-[4-[7-(Pyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-70-0P,
 1-[4-[7-[2-[(Diethylamino)methyl]pyridin-4-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-72-2P,
 1-[4-[7-[5-[(Diethylamino)methyl]pyridin-2-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908264-73-3P,
 1-(2-Fluoro-5-trifluoromethylphenyl)-3-[4-[7-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]urea 908264-74-4P,
 1-[4-[7-(1H-Pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-17-8P,
 1-[4-[7-(6-Methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-18-9P,
 1-[4-[7-[4-[(Dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-50-9P,
 1-[4-[7-[6-(4-Methylpiperazin-1-yl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-63-4P,
 1-[4-[7-(6-Methylaminopyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-66-7P,
 1-[4-[7-(6-Oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea 908265-68-9P,
 (3-Trifluoromethylphenyl)carbamic acid
 4-[7-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]benzyl ester 908266-19-3P, 3-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(3-trifluoromethylphenyl)propionamide 908266-22-8P, 3-[4-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(4-trifluoromethylphenyl)propionamide 908266-23-9P, 3-[3-[7-(4-Methylsulfonylphenyl)imidazo[1,2-a]pyridin-3-yl]phenyl]-N-(3-trifluoromethylphenyl)propionamide 908267-31-2P, 1-[4-[7-[4-[(4-Methylpiperazin-1-yl)carbonyl]phenyl]imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)


RN 908263-98-9 CAPLUS

CN Urea, N-[[4-[7-(1-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-21-1 CAPLUS

CN Urea, N-[[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-22-2 CAPLUS

CN Urea, N-[[4-[7-(3-thienyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-23-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-[7-(3-thienyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]- (CA INDEX NAME)




RN 908264-27-7 CAPLUS

CN Urea, N-[[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-34-6 CAPLUS

CN Urea, N-[[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-45-9 CAPLUS

CN Urea, N-[[4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-46-0 CAPLUS

CN Urea, N-[[4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-47-1 CAPLUS

CN Urea, N-[[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-51-7 CAPLUS

CN Urea, N-[[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-59-5 CAPLUS

CN Urea, N-[[3-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-67-5 CAPLUS

CN Urea, N-[[4-[7-(2-thiazolyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-68-6 CAPLUS

CN Urea, N-[[4-[7-(3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-69-7 CAPLUS

CN Urea, N-[[4-[7-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-70-0 CAPLUS

CN Urea, N-[[4-[7-[2-[(diethylamino)methyl]-4-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-72-2 CAPLUS

CN Urea, N-[[4-[7-[5-[(diethylamino)methyl]-2-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908264-73-3 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[[4-[7-(4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]- (CA INDEX NAME)




RN 908264-74-4 CAPLUS

CN Urea, N-[[4-[7-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-17-8 CAPLUS

CN Urea, N-[[4-[7-(6-methoxy-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-18-9 CAPLUS

CN Urea, N-[[4-[7-[4-[(dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-50-9 CAPLUS

CN Urea, N-[[4-[7-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-63-4 CAPLUS

CN Urea, N-[[4-[7-[6-(methylamino)-3-pyridinyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-66-7 CAPLUS

CN Urea, N-[[4-[7-(1,6-dihydro-6-oxo-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908265-68-9 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-,
[4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl
ester (9CI) (CA INDEX NAME)




RN 908266-19-3 CAPLUS

CN Benzenepropanamide, 4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908266-22-8 CAPLUS

CN Benzenepropanamide, 4-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 908266-23-9 CAPLUS

CN Benzenepropanamide, 3-[7-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 908267-31-2 CAPLUS
 CN Urea, N-[[4-[7-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



IT 908271-57-8P, 1-[4-(7-Chloroimidazo[1,2-a]pyridin-3-yl)benzyl]-3-(3-trifluoromethylphenyl)urea
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
 RN 908271-57-8 CAPLUS
 CN Urea, N-[[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 908271-67-0, 1-[4-[7-(6-Fluoropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]benzyl]-3-(3-trifluoromethylphenyl)urea
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of imidazo[1,2-a]pyridines as VEGFR-2 inhibitors for treating neoplasm)
 RN 908271-67-0 CAPLUS
 CN Urea, N-[[4-[7-(6-fluoro-3-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:634786 CAPLUS Full-text
DOCUMENT NUMBER: 145:103692
TITLE: Preparation of
4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives
and related compounds
INVENTOR(S): Barker, Emma; Jenmalm Jensen, Annika; Nordling, Erik;
Proud, Andrew; Slater, Martin; Weber, Mikael
PATENT ASSIGNEE(S): Biovitrum AB, Swed.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067224	A2	20060629	WO 2005-EP57132	20051222
WO 2006067224	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060217375	A1	20060928	US 2005-318126	20051222
PRIORITY APPLN. INFO.:			SE 2004-3160	A 20041223
			US 2005-653803P	P 20050217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:103692; MARPAT 145:103692
GI



AB The invention relates to compds. I [m, n are 0 or 1; A, Y are independently CH₂, O, NH or alkylimino; R₁ is Ph, naphthyl or aza analogs (with provisos)] for use in the prophylaxis or treatment of orexin-1 or orexin-2 receptor-related disorders such as obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders. Thus, I (m, n = 1, A = NH, Y = CH₂, R₁ = 5-quinolinyl), prepared by condensation of 5-bromo-2-hydroxybenzyl alc. with N-carboethoxy-4-piperidone, followed by deprotection and arylation reaction, showed K_i = 349 nM for inhibition of the orexin-1 receptor.


IT 895524-99-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spirobenzodioxinepiperidine derivs. and related compds. for inhibition of orexin receptor)

RN 895524-99-9 CAPLUS

CN Acetamide, 2-(3-spiro[4H-1,3-benzodioxin-2,4'-piperidin]-6-ylphenoxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 895525-93-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spirobenzodioxinepiperidine derivs. and related compds. for inhibition of orexin receptor)

RN 895525-93-6 CAPLUS

CN Spiro[4H-1,3-benzodioxin-2,4'-piperidine]-1'-carboxylic acid, 6-[3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:631117 CAPLUS Full-text

DOCUMENT NUMBER: 145:103737

TITLE: Sulfonamido-macrocycles as Tie2 inhibitors and their preparation, pharmaceutical compositions and use for treatment of dysregulated vascular growth diseases

INVENTOR(S): Kettschau, Georg; Briem, Hans; Hartung, Ingo; Luecking, Ulrich; Schaefer, Martin; Thierauch, Karl-Heinz; Schwede, Wolfgang; Husemann, Manfred

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: Eur. Pat. Appl., 34 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1674469	A1	20060628	EP 2004-90508	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
AU 2005318360	A1	20060629	AU 2005-318360	20051219
CA 2590522	A1	20060629	CA 2005-2590522	20051219
WO 2006066956	A2	20060629	WO 2005-EP13956	20051219
WO 2006066956	A3	20061012		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1828209	A2	20070905	EP 2005-826661	20051219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101087797	A	20071212	CN 2005-80044293	20051219
JP 2008524302	T	20080710	JP 2007-547385	20051219
BR 2005019210	A2	20090106	BR 2005-19210	20051219
US 20060194823	A1	20060831	US 2005-312648	20051221
IN 2007DN03345	A	20070831	IN 2007-DN3345	20070504
MX 2007007422	A	20080829	MX 2007-7422	20070619
KR 2007097525	A	20071004	KR 2007-716660	20070720
PRIORITY APPLN. INFO.:			EP 2004-90508	A 20041222
			US 2004-639803P	P 20041229
			WO 2005-EP13956	W 20051219

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:103737; MARPAT 145:103737

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to sulfonamido-macrocycles according to the general formula I and the salts thereof. The invention also related to pharmaceutical compns. comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compds. effectively interfere with angiopoietin and therefore influence Tie2 signaling. Compds. of formula I wherein A is phenylene or C6-heteroarylene; Z is O, S, NR₃, or CHR₃; R₁-R₃ are independently H or (un)substituted C₁-10 alkyl; R₄ is H, halo, NO₂, amino, CN, C₁-6 alkyl, C₁-6 alkoxy, NH(C₁-6 alkyl), N(C₁-6alkyl), etc.; X is a bond or methylene; Y is methylenedioxyphenyl, ethylenedioxyphenyl, (un)substituted phenylene, (un)substituted oxyalkyl, etc.; m is from 3 to 6; and their pharmaceutically acceptable salts, solvates, hydrates, N-oxides, isomers, diastereoisomers, and enantiomers are claimed. Example compound II was prepared by Suzuki coupling of compound III with 1-(4-fluorophenyl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)phenoxy]ethanone. All the invention compds. were evaluated for their Tie2 inhibitory activity. From the assay, it was determined that compound II inhibit Tie2 with an IC₅₀ value of about 1 μ M or less.


IT 1175149-78-6

RL: PRPH (Prophetic)

(Sulfonamido-macrocycles as Tie2 inhibitors and their preparation, pharmaceutical compositions and use for treatment of dysregulated vascular growth diseases)

RN 1175149-78-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:87930 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:246535

TITLE: Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution

AUTHOR(S): Yamazaki, Kazuto; Kusunose, Naoto; Fujita, Katsuya; Sato, Hideshi; Asano, Shigehiro; Dan, Akihito; Kanaoka, Masaharu

CORPORATE SOURCE: Sumitomo Pharmaceuticals Co., Ltd, Konohana-ku, Osaka, 554-0022, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
16(5), 1371-1379
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB We identified new lead candidates which showed potent dual inhibition against phosphodiesterase-1 and 5 by a ligand-based virtual screening optimized for lead evolution. This virtual screening method, consisting of classification and regression tree anal. using 168 2-center pharmacophore descriptors and 12 macroscopic descriptors, demonstrated a high predictive ability for bioactivity of new chemical compds. The obtained lead candidates were structurally diverse, although only the structure-activity relationship data of hydroxamic acid derivs. were used to configure the prediction model for the virtual screening.

IT 334497-92-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution)

RN 334497-92-6 CAPLUS

CN Acetamide, 2-[4-(2-amino-3-cyano-5,6,7,8-tetrahydro-5-oxo-4H-1-benzopyran-4-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 2005:1305459 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:205134

TITLE: Design, Synthesis, and Structure-Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A2B Adenosine Receptor


AUTHOR(S): Carotti, Angelo; Cadavid, Maria Isabel; Centeno, Nuria B.; Esteve, Cristina; Loza, Maria Isabel; Martinez, Ana; Nieto, Rosa; Ravina, Enrique; Sanz, Ferran;

Segarra, Victor; Sotelo, Eddy; Stefanachi, Angela;
 Vidal, Bernat
 CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Bari,
 Bari, I-70125, Italy
 SOURCE: Journal of Medicinal Chemistry (2006), 49(1), 282-299
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:205134
 GI



AB Substituted 9-deazaxanthines such as I (R = Me, EtCH₂; R₁ = H, MeO; R₂ = Br, Ph) are prepared and evaluated for their binding affinity at the recombinant human adenosine A₂B and A₂A receptors. I (R = Me, EtCH₂; R₁ = H, MeO; R₂ = Br, Ph) bind to the human adenosine A₂B receptor with pK_i values of 8.28-8.58 and with selectivities of 500-1400 fold and >1000-2300 fold for human adenosine A₂B receptors over human adenosine A₂A and A₃ receptors, resp.; I have low selectivities (3.4-11.7 fold) for binding to human adenosine A₂B receptors over human adenosine A₁ receptors. Structure-affinity relationships for substituted 9-deazaxanthines suggest that binding to the human adenosine A₂B receptor is mainly modulated by the steric bulk and lipophilicities of substituents at positions 1 and 3 of substituted 9-deazaxanthines and by the electronic properties and lipophilicities of the substituents at position 8. Comparisons between the affinity and selectivity profiles of 9-deazaxanthines with those of the corresponding xanthines suggest possible differences in their binding modes to human adenosine A₂ receptors.

IT 480991-24-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of substituted 9-deazaxanthines and the structure-activity relationships for their binding to human adenosine A₂B receptors and their selectivities towards binding to human adenosine A₁, A₂A, A₂B, and A₃ receptors)
 RN 480991-24-0 CAPLUS
 CN Acetamide, 2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)






OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1215905 CAPLUS Full-text
 DOCUMENT NUMBER: 143:465586
 TITLE: Hair preparations containing 2-oxy-acetamide derivatives for stimulating or inducing hair growth
 INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel; Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005107687	A1	20051117	WO 2005-FR926	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2869224	A1	20051028	FR 2004-4298	20040422
FR 2869224	B1	20060609		
EP 1763382	A1	20070321	EP 2005-757128	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007533708	T	20071122	JP 2007-508932	20050418
US 20070092467	A1	20070426	US 2006-583792	20061020
PRIORITY APPLN. INFO.:				
			FR 2004-4298	A 20040422
			US 2004-566599P	P 20040430
			WO 2005-FR926	W 20050418

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 143:465586; MARPAT 143:465586
 GI



AB The invention relates to the following 2-oxy-acetamide compds., the salts and/or solvates thereof as an inhibitor of 15-PGDH, II, III, IV, R₃OCH₂CONHCH₂SiMe₃, wherein: (i) R⁷ and R⁸ represent H, halogen, CF₃, CN, OR₄, SR₄, NHR₆, NR₆R'₆, OCOR₄, COR₄, CSR₄, COOR₄, SO₂R₄, SiR₄R'₄R''₄, OCF₃, and R₄, R'₄, R''₄, R₆, R'₆ represent H or an alkyl that is optionally substituted by Ph, an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring; (ii) Z represents q; (iii) X and Y represent H or A₂ or form a (hetero)cycle which is optionally substituted and/or fused to another ring; (iv) A represents m; (v) R₃ represents an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring, said rings being optionally substituted; and (vi) A₂ represents halogen, CF₃, CN, OR₄, SR₄, NR₄R'₄, OCOR₄, COR₄, CSR₄, COOR₄, SO₂R₄, SiR₄R'₄R''₄, NO₂, OCF₃, an optionally-substituted alkyl, a (hetero)cycle which is optionally fused to another ring, where rings C₁₁ and C₁₂ can be substituted. Thus, N-benzylcyclohexyloxyacetamide (I) was prepared by the reaction of cyclohexanol with N-benzyl-2-chloroacetamide. Efficacy of 2-oxy-acetamide derivs. as specific inhibitors of 15-PGDH is shown. A hair lotion contained I 0.10, latanoprost 0.10, propylene glycol 30.00, Et alc. 40.00, and water q.s. 100.00g.


IT 302551-11-7

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(hair preps. containing 2-oxy-acetamide compound for stimulating or inducing hair growth)

RN 302551-11-7 CAPLUS

CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 867257-98-5P 867258-00-2P


RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hair preps. containing 2-oxy-acetamide compound for stimulating or inducing

hair growth)


RN 867257-98-5 CAPLUS

CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 867258-00-2 CAPLUS

CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1152777 CAPLUS Full-text

DOCUMENT NUMBER: 143:410607

TITLE: Hair preparations containing 2-oxyacetamides for the
stimulation or induction of hair growth and/or
delaying hair loss

INVENTOR(S): Rozot, Roger; Breton, Philippe; Neuwels, Michel;
 Boulle, Christophe
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Fr. Demande, 80 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2869224	A1	20051028	FR 2004-4298	20040422
FR 2869224	B1	20060609		
WO 2005107687	A1	20051117	WO 2005-FR926	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1763382	A1	20070321	EP 2005-757128	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007533708	T	20071122	JP 2007-508932	20050418
US 20070092467	A1	20070426	US 2006-583792	20061020
PRIORITY APPLN. INFO.:				
			FR 2004-4298	A 20040422
			US 2004-566599P	P 20040430
			WO 2005-FR926	W 20050418

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:410607

AB Hair prepsns. containing 2-oxyacetamides are used as 15-PGDH specific inhibitors for the stimulation or induction of hair growth and/or delaying hair loss. Thus, N-(2,6-dimethyl-phenyl)-2-(quinolin-8-yloxy)-acetamide (I) was prepared by the reaction of 8-hydroxyquinoline with 2-chloro-2',6'-acetoxylylide. Efficacy of I as inhibitor of enzymic activity of 15-PGDH is shown. Formulations of hair growth stimulants containing 2-oxyacetamide derivs. are disclosed.


IT 302551-11-7

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)


(hair prepsns. containing 2-oxyacetamides for stimulation or induction of hair growth and/or to delay hair loss)

RN 302551-11-7 CAPLUS


CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 867257-98-5P 867258-00-2P
 RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (hair preps. containing 2-oxyacetamides for stimulation or induction of hair growth and/or to delay hair loss)
 RN 867257-98-5 CAPLUS
 CN Acetamide, 2-[4-(1H-pyrrol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 867258-00-2 CAPLUS
 CN Acetamide, 2-[4-(1H-imidazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1144491 CAPLUS Full-text
 DOCUMENT NUMBER: 143:432020

TITLE: Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists
 AUTHOR(S): Palani, Anandan; Shapiro, Sherry; McBriar, Mark D.; Clader, John W.; Greenlee, William J.; O'Neill, Kim; Hawes, Brian
 CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5234-5236
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:432020
 GI




I

AB Herein, we report the discovery of the potent and selective biaryl diamide derived MCH-R1 receptor antagonist I, which was identified upon modification of a previously disclosed biaryl urea series. This paper describes one of the strategies incorporated to remove the highly mutagenic biarylaniline present in an otherwise promising biaryl urea series.
 IT 868631-50-9P 868631-53-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists)
 RN 868631-50-9 CAPLUS
 CN Urea, N-[(3'-cyano[1,1'-biphenyl]-4-yl)methyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 868631-53-2 CAPLUS
 CN Urea, N-[(3'-cyano[1,1'-biphenyl]-4-yl)methyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1034703 CAPLUS Full-text
 DOCUMENT NUMBER: 144:205129
 TITLE: A structural study of new potent and selective antagonists to the A2B adenosine receptor
 AUTHOR(S): Ferretti, Valeria; Pretto, Loretta; Tabrizi, Mojgan Aghazadeh; Bertolasi, Valerio
 CORPORATE SOURCE: Dipartimento di Chimica, Centro di Strutturistica Diffraattometrica, University of Ferrara, Ferrara, I-44100, Italy
 SOURCE: Acta Crystallographica, Section B: Structural Science (2005), B61(5), 569-576
 CODEN: ASBSDK; ISSN: 0108-7681

PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Xanthines, including the natural derivs. theophylline and caffeine, are non-selective antagonists of adenosine. They are able to bind with good affinity to all four adenosine-receptor subtypes A1, A2A, A2B and A3. To develop new drugs with few side effects, over the last few years many efforts have been devoted to the discovery of new adenosine antagonists with enhanced selectivity properties. The present paper reports the crystal structures of five new xanthinic derivs., which display different affinities and selectivity properties towards the A2B receptor. Besides the crystallog. study, a structural comparison has been made with the calculated geometry of other xanthinic derivs. which are reported to have similar biol. characteristics to understand the structural features controlling their affinity capabilities and selectivity. This structural comparison has been interpreted in the light of a recently published study on the binding of N-benzo[1,3]-dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl- 2,3,6,9-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-iloxy]-acetamide to a model of the A2B receptor, which shows the most interesting affinity and selectivity properties.

IT 264622-60-8

RL: PAC (Pharmacological activity); BIOL (Biological study)
(structural study of A2B adenosine receptor antagonists)

RN 264622-60-8 CAPLUS

CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1004726 CAPLUS Full-text

DOCUMENT NUMBER: 143:305940

TITLE: Preparation of β -ketoamide derivatives as antagonists of MCH receptor

INVENTOR(S): Roth, Gerald-Juergen; Lustenberger, Philipp;
Schindler, Marcus; Thomas, Leo; Stenkamp, Dirk;
Mueller, Stephan Georg; Lehmann-Lintz, Thorsten;
Santagostino, Marco; Lotz, Ralf Richard Hermann

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005085221	A1	20050915	WO 2005-EP2132	20050301
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004010893	A1	20050922	DE 2004-102004010893	20040306
CA 2552907	A1	20050915	CA 2005-2552907	20050301
EP 1730130	A1	20061213	EP 2005-715624	20050301
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2007527424	T	20070927	JP 2007-501195	20050301
US 20050245500	A1	20051103	US 2005-71797	20050303
US 7605176	B2	20091020		

PRIORITY APPLN. INFO.:

DE 2004-102004010893A	20040306
US 2004-554229P	P 20040318
WO 2005-EP2132	W 20050301

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:305940
GI



AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form alkylene bridge in which one or two CH2 groups may be substituted by either O, S, CO, etc.; R3 = H, alkyl, phenylalkyl, etc.; X = alkylene bridge in which one or two non-neighboring CH2 groups may be substituted by either O, S, CO, etc.; Z = single bond or CR6R7CR8R9; A, B and Y independently = Ph, (un)saturated carbocycle, heterocycle, etc.; n = 0-1; R4 and R5 independently = H, CF3, F, etc.; R6 and R8 independently = H, Cl, alkyl, etc.; R7 and R9 independently = H, F, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared

and disclosed as antagonists of MCH receptors. Thus, e.g., II was prepared by subsequent couplings of 4-acetylbiphenyl with di-Et carbonate and 2-[4-(pyrrolidin-1-yl-methyl)-phenyl]-ethylamine. The antagonistic activity of II was evaluated in a MCH-1 receptor binding assay and it was revealed that this compound possesses an IC50 value of 63.7 nM. I as antagonist of MCH receptor should prove useful in the treatment of diseases such as but not limited to diabetes, obesity and bulimia. Pharmaceutical compns. comprising I are disclosed.

IT 864659-27-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of β -ketoamide derivs. as antagonists of MCH receptor)


RN 864659-27-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, β -oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:216619 CAPLUS Full-text

DOCUMENT NUMBER: 142:297864

TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020921	A2	20050310	WO 2004-US28001	20040827
WO 2005020921	A3	20051006		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004268621	A1	20050310	AU 2004-268621	20040827
CA 2536954	A1	20050310	CA 2004-2536954	20040827
EP 1663204	A2	20060607	EP 2004-782473	20040827
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007504160	T	20070301	JP 2006-524905	20040827
US 20080096892	A1	20080424	US 2007-569873	20070904
PRIORITY APPLN. INFO.:			US 2003-499224P	P 20030829
			WO 2004-US28001	W 20040827

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:297864; MARPAT 142:297864

GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)₃ and NaN₃ in AcOH followed by NaNO₂/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC₅₀ of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

IT

483337-40-2P	483337-41-3P	505052-18-6P
506433-09-6P	847606-67-1P	847606-71-7P
847606-73-9P	847606-74-0P	847606-76-2P
847606-77-3P	847606-78-4P	847606-81-9P
847606-84-2P	847606-87-5P	847606-88-6P
847606-90-0P	847606-92-2P	847606-93-3P
847607-05-0P	847607-13-0P	847607-17-4P
847607-18-5P	847607-19-6P	847607-20-9P
847607-22-1P	847607-25-4P	847607-26-5P
847607-27-6P	847607-28-7P	847607-29-8P
847607-37-8P	847607-38-9P	847607-51-6P
847607-56-1P	847607-57-2P	847607-58-3P
847607-61-8P	847607-63-0P	847607-66-3P
847607-68-5P	847607-69-6P	847607-70-9P
847607-71-0P	847607-74-3P	847607-76-5P
847607-77-6P	847607-78-7P	847607-79-8P
847607-80-1P	847607-81-2P	847607-82-3P
847607-86-7P	847607-87-8P	847607-88-9P
847607-89-0P	847607-90-3P	847607-91-4P
847607-92-5P	847607-93-6P	847607-94-7P
847607-95-8P	847607-96-9P	847607-97-0P
847607-98-1P	847607-99-2P	847608-00-8P
847608-01-9P	847608-02-0P	847608-03-1P
847608-04-2P	847608-05-3P	847608-06-4P
847608-07-5P	847608-08-6P	847608-09-7P
847608-10-0P	847608-11-1P	847608-12-2P
847608-13-3P	847608-14-4P	847608-15-5P
847608-16-6P	847608-17-7P	847608-18-8P
847608-19-9P	847608-20-2P	847608-21-3P
847608-23-5P	847608-24-6P	847608-25-7P
847608-31-5P	847608-32-6P	847608-42-8P
847608-44-0P	847608-46-2P	847608-48-4P
847608-50-8P	847608-51-9P	847608-53-1P
847608-55-3P	847608-58-6P	847608-59-7P
847608-60-0P	847608-61-1P	847608-62-2P
847608-63-3P	847608-64-4P	847608-67-7P
847608-68-8P	847608-69-9P	847608-70-2P
847608-71-3P	847608-73-5P	847608-74-6P
847608-75-7P	847608-77-9P	847608-79-1P
847608-80-4P	847608-81-5P	847608-82-6P
847608-83-7P	847608-84-8P	847608-85-9P
847608-86-0P	847608-87-1P	847608-88-2P


847608-89-3P	847608-90-6P	847608-91-7P
847608-93-9P	847608-94-0P	847608-95-1P
847608-96-2P	847608-98-4P	847609-00-1P
847609-04-5P	847609-06-7P	847609-08-9P
847609-10-3P	847609-12-5P	847609-14-7P
847609-16-9P	847609-18-1P	847609-20-5P
847609-30-7P	847609-35-2P	847609-36-3P
847609-39-6P	847609-41-0P	847609-43-2P
847609-46-5P	847609-48-7P	847609-50-1P
847609-52-3P	847609-54-5P	847609-56-7P
847609-57-8P	847609-58-9P	847609-59-0P
847609-60-3P	847609-63-6P	847609-65-8P
847609-67-0P	847609-73-8P	847609-75-0P
847609-79-4P	847609-81-8P	847609-86-3P
847609-93-2P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)


RN 483337-40-2 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 483337-41-3 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 505052-18-6 CAPLUS

CN Acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]-
(CA INDEX NAME)




RN 506433-09-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-67-1 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-71-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847606-73-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847606-74-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-76-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]thio]- (CA INDEX NAME)




RN 847606-77-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847606-78-4 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)




RN 847606-81-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847606-84-2 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-87-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-quinoxaliny)phenyl]methyl]- (CA INDEX NAME)




RN 847606-88-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)




RN 847606-90-0 CAPLUS

CN Benzamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847606-92-2 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847606-93-3 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-,
[3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847607-05-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4H-1,2,4-triazol-4-yl)phenoxy]- (CA INDEX NAME)




RN 847607-13-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-17-4 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-18-5 CAPLUS

CN Acetamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-19-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-20-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-methyl-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-22-1 CAPLUS

CN Acetamide, N-[4-chloro-2-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-25-4 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-26-5 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-methyl-2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-27-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,4-dichloro-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-28-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-29-8 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid,
1-[3-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-,
methyl ester (CA INDEX NAME)




RN 847607-37-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-
pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-38-9 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-
yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-51-6 CAPLUS

CN Acetamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-
yl)phenoxy]- (CA INDEX NAME)




RN 847607-56-1 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[3-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847607-57-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-pyrrol-2-yl)phenoxy]- (CA INDEX NAME)



RN 847607-58-3 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-61-8 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-

pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-63-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-furanyl)phenoxy]-
(CA INDEX NAME)




RN 847607-66-3 CAPLUS

CN Benzenepropanamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(1H-tetrazol-1-yl)-
(CA INDEX NAME)




RN 847607-68-5 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3,5-dimethyl-4-isoxazolyl)phenoxy]-
(CA INDEX NAME)




RN 847607-69-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(7-quinolinyl)phenoxy]- (CA INDEX NAME)




RN 847607-70-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-furanyl)phenoxy]- (CA INDEX NAME)




RN 847607-71-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-dibenzofuranyl)phenoxy]- (CA INDEX NAME)




RN 847607-74-3 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-76-5 CAPLUS

CN Hydrazinecarboxamide, N-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847607-77-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-78-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-79-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-80-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-81-2 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847607-82-3 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847607-86-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-methyl-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-87-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-88-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-89-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-90-3 CAPLUS

CN Benzenesulfonamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847607-91-4 CAPLUS

CN Benzenesulfonamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-N-methyl-3-(1H-tetrazol-1-yl)-
(CA INDEX NAME)




RN 847607-92-5 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-93-6 CAPLUS

CN Acetamide, 2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847607-94-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847607-95-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-96-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-methoxy-4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-97-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-98-1 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-99-2 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,3,5,6-tetrafluoro-4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-00-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-01-9 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-02-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-03-1 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-04-2 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-05-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-06-4 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-07-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-08-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-09-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-10-0 CAPLUS


CN 1H-Indole-1-carboxylic acid, 2-[4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847608-11-1 CAPLUS
 CN Benzenesulfonamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-4-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847608-12-2 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]- (CA INDEX NAME)



RN 847608-13-3 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,6-difluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-14-4 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-15-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-16-6 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-17-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847608-18-8 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-19-9 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-20-2 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-21-3 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-23-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-24-6 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-25-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-31-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(3-pyridinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-32-6 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, 1-[4-(5-pyrimidinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-42-8 CAPLUS

CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-44-0 CAPLUS

CN Urea, N-[[3-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-46-2 CAPLUS

CN Urea, N-[[4-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-48-4 CAPLUS

CN Urea, N-[[3-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-50-8 CAPLUS

CN Urea, N-[4-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-51-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(3-pyridinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 847608-53-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(5-pyrimidinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 847608-55-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-indol-2-yl)phenoxy]- (CA INDEX NAME)




RN 847608-58-6 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-59-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-60-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-61-1 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-, methyl ester (CA INDEX NAME)




RN 847608-62-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-quinoxalinylyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-63-3 CAPLUS

CN Urea, N-[[3-(2-amino-5-methyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-64-4 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-, methyl ester (CA INDEX NAME)




RN 847608-67-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-68-8 CAPLUS

CN Urea, N-[[3-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-69-9 CAPLUS

CN Urea, N-[[4-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-70-2 CAPLUS

CN Urea, N-[[3-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 847608-71-3 CAPLUS

CN Urea, N-[[4-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-73-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 847608-74-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-75-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-77-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-79-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-80-4 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-81-5 CAPLUS

CN Urea, N-[[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-82-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-83-7 CAPLUS

CN Urea, N-[[4-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-84-8 CAPLUS

CN Urea, N-[[3-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-85-9 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-86-0 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847608-87-1 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-88-2 CAPLUS
CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
(3-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 847608-89-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[6-(hydroxymethyl)-3-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847608-90-6 CAPLUS

CN Urea, N-[[3-(6-acetyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-91-7 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-cyano-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847608-93-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847608-94-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 847608-95-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

CF₃

RN 847608-96-2 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 847608-98-4 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847609-00-1 CAPLUS

CN Urea, N-[[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-04-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(1H-benzimidazol-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-06-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847609-08-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-3-
pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847609-10-3 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-12-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 847609-14-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-16-9 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
(4-pyrazinylphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 847609-18-1 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX
NAME)


PAGE 1-A




PAGE 2-A



RN 847609-20-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-30-7 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-35-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-36-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-39-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (CA INDEX NAME)




RN 847609-41-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-43-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-2-pyrazinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847609-46-5 CAPLUS

CN Urea, N-[[3-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-48-7 CAPLUS

CN Urea, N-[[4-[5-amino-6-(1-piperazinylcarbonyl)-2-pyrazinyl]phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-50-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-52-3 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-54-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [3-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-56-7 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-57-8 CAPLUS

CN Urea, N-[[3-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-58-9 CAPLUS

CN Urea, N-[[4-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-59-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-60-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-63-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-2-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847609-65-8 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(2,6-dimethyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-67-0 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(5-methoxy-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-73-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-isoquinolinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-75-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-isoquinoliny)phenyl]methyl]- (CA INDEX NAME)




RN 847609-79-4 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-81-8 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-86-3 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847609-93-2 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-(4-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



IT 847606-70-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of anilines and related compds. as C-kit modulators)
 RN 847606-70-6 CAPLUS
 CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-[4-(trimethylsilyl)-
 1H-1,2,3-triazol-1-yl]phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:136570 CAPLUS Full-text
 DOCUMENT NUMBER: 142:212386
 TITLE: Combination of mGluR2 antagonist and ache inhibitor
 for treatment of acute and/or chronic neurological
 disorders
 INVENTOR(S): Ballard, Theresa Maria; Gatti McArthur, Silvia;
 Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas
 Johannes
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014002	A1	20050217	WO 2004-EP8020	20040717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004262897	A1	20050217	AU 2004-262897	20040717
AU 2004262897	B2	20090820		
AU 2004262897	B9	20091217		
CA 2532347	A1	20050217	CA 2004-2532347	20040717
EP 1651234	A1	20060503	EP 2004-741126	20040717
EP 1651234	B1	20070926		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004012919	A	20060926	BR 2004-12919	20040717
CN 1856312	A	20061101	CN 2004-80027808	20040717
JP 2007504096	T	20070301	JP 2006-521458	20040717
AT 374030	T	20071015	AT 2004-741126	20040717
PT 1651234	E	20071228	PT 2004-741126	20040717
ES 2293287	T3	20080316	ES 2004-741126	20040717
NZ 544719	A	20090430	NZ 2004-544719	20040717
RU 2357734	C2	20090610	RU 2006-105721	20040717
US 20050049243	A1	20050303	US 2004-896494	20040722
US 7235547	B2	20070626		
MX 2006000705	A	20060411	MX 2006-705	20060118
NO 2006000328	A	20060217	NO 2006-328	20060120
ZA 2006000693	A	20070530	ZA 2006-693	20060124
IN 2006CN00303	A	20070817	IN 2006-CN303	20060124
IN 237281	A1	20091225		
KR 2006037404	A	20060503	KR 2006-701762	20060125
KR 764330	B1	20071005		

PRIORITY APPLN. INFO.:

EP 2003-16968	A	20030725
WO 2004-EP8020	W	20040717

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:212386

AB The present invention relates to a method of treatment or prevention of acute and/or chronic neurol. disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.
Dihydrobenzo[b][1,4]diazepin-2-one derivs. were prepared as mGluR2 antagonists.


IT 579476-79-2

RL: PRPH (Prophetic)

(Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders)

RN 579476-79-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:589417 CAPLUS Full-text

DOCUMENT NUMBER: 141:140320

TITLE: A preparation of insecticidal piperidine and pyridine derivatives

INVENTOR(S): Ding, Ping; Henrie, Robert H., II; Cohen, Daniel H.;
 Lyga, John W.; Rosen, David S.; Theodoridis, George;
 Zhang, Qun; Yeager, Walter H.; Donovan, Stephen F.;
 Zhang, Steven Shunxiang; Shulman, Inna; Yu, Seong Jae;
 Wang, Guozhi; Zhang, Y. Larry; Gopalsamy, Ariamala;
 Warkentin, Dennis L.; Rensner, Paul E.; Silverman, Ian
 R.; Cullen, Thomas G.

PATENT ASSIGNEE(S): FMC Corporation, USA

SOURCE: PCT Int. Appl., 182 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060371	A1	20040722	WO 2003-US38878	20031208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296308	A1	20040729	AU 2003-296308	20031208
EP 1572207	A1	20050914	EP 2003-814662	20031208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017324	A	20051116	BR 2003-17324	20031208
CN 1729178	A	20060201	CN 2003-80106750	20031208
CN 100400519	C	20080709		
CN 1744895	A	20060308	CN 2003-80109445	20031208
CN 100384421	C	20080430		
JP 2006516149	T	20060622	JP 2005-508561	20031208
CN 101139340	A	20080312	CN 2007-10153751	20031208
TW 287544	B	20071001	TW 2003-92135801	20031217
IN 2005DN02490	A	20061229	IN 2005-DN2490	20050609
IN 214118	A1	20080222		
ZA 2005004870	A	20060426	ZA 2005-4870	20050614
ZA 2005004871	A	20060426	ZA 2005-4871	20050614
MX 2005006427	A	20050908	MX 2005-6427	20050615
US 20060135504	A1	20060622	US 2005-538998	20051216
US 7300946	B2	20071127		
US 20080090828	A1	20080417	US 2007-874015	20071017
US 7683070	B2	20100323		
IN 2008DN00379	A	20080215	IN 2008-DN379	20080114
IN 2008DN00376	A	20080815	IN 2008-DN376	20080114
IN 2008DN00377	A	20080815	IN 2008-DN377	20080114
IN 2008DN00378	A	20080815	IN 2008-DN378	20080114
PRIORITY APPLN. INFO.:			US 2002-434718P	P 20021218
			US 2003-495059P	P 20030814
			CN 2003-80109445	A3 20031208
			WO 2003-US38878	W 20031208
			IN 2005-DN2490	A3 20050609
			US 2005-538998	A3 20051216

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:140320
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of insecticidal piperidine and pyridine derivs. of formula I [wherein: A is C or CH; B is substituted phenyl; C is O0-1; D is (CH2)0-3; E is a bridging group selected from (CR9R10)-(CR11R12)0-1, (CR9R10)-(CR11R12)0-10, C3H6, C(O), or C(S)NH, etc.; R1 is H, alkyl, alkoxyalkyl, or aryl; R2, R3, R4, R5, and R6 are independently selected from H, halogen, (halo/hydroxy)alkyl, alkylthio, CN, or NO2, etc.; R7 is (halo/hydroxy/alkoxy/dialkylamino)alkyl, sulfonatoalkyl, arylalkyl, or arylcarbonyl, etc.; R8 is H, (cyclo)alkyl, alkoxy, amino, morpholinyl, or indolyl, etc.; R9, R10, R11, and R12 are independently selected from H, alkyl, aryl, etc.]. Prepared compds. were evaluated for activity against tobacco budworm in a surface-treated diet test. For instance, piperidine derivative II (compound 101, insecticidal activity: 100% mortality, 100% growth inhibition) was prepared via elimination reaction of hydroxymethylpiperidine derivative III, N-benzoylation of the obtained methylenepiperidine derivative IV by 4-nitrophenylmethyl bromide, subsequent reduction of the nitro-group, N-carboxylation of the obtained amine V, and N-oxidation (example 1).


IT 726131-69-7F

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of insecticidal piperidine and pyridine derivs.)

RN 726131-69-7 CAPLUS

CN Carbamic acid, [4-(trifluoromethyl)phenyl]-, [1,1'-biphenyl]-4-yl[1-[[4-(2-ethyl-2H-tetrazol-5-yl)phenyl]methyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:566609 CAPLUS Full-text


DOCUMENT NUMBER: 141:123608

TITLE: Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds


INVENTOR(S): Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Wu, Kun K.; Buchler, Ingrid P.; Xie, Jin;

PATENT ASSIGNEE(S): Vernier, William F.
 SOURCE: Pharmacia Corporation, USA
 PCT Int. Appl., 573 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058762	A1	20040715	WO 2003-US40811	20031219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2509565	A1	20040715	CA 2003-2509565	20031219
WO 2004058762	A1	20040715	WO 2003-XA40811	20031219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003297431	A1	20040722	AU 2003-297431	20031219
US 20040152739	A1	20040805	US 2003-742494	20031219
US 20040209897	A1	20041021	US 2003-742072	20031219
EP 1572693	A1	20050914	EP 2003-814268	20031219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017430	A	20051025	BR 2003-17430	20031219
CN 1747949	A	20060315	CN 2003-80109626	20031219
JP 2006514043	T	20060427	JP 2004-563888	20031219
ZA 2005004898	A	20061129	ZA 2005-4898	20031219
MX 2005006569	A	20050922	MX 2005-6569	20050617
US 20080113971	A1	20080515	US 2007-958229	20071217
PRIORITY APPLN. INFO.:			US 2002-434962P	P 20021220
			US 2003-742494	A1 20031219
			WO 2003-US40811	W 20031219
OTHER SOURCE(S):	MARPAT 141:123608			
GI				



I



II

AB The title compds. [I; Z1, Z3, Z4 = C, N; Z2, Z5 = C, N, S, O, and join together with Z1, Z3 and Z4 to form a ring that is selected from a pyrrole, furan, thiophene, oxazole, thiazole, triazole, and imidazole; when either Z2, or Z5 = O or S, it has no substituent group; when Z1-Z5 form an imidazole ring, Z1 = C and if Z2 and Z5 = N, one is unsubstituted and Z3 and Z4 = C, if Z3 and Z5 = N, Z5 is unsubstituted and Z2 and Z4 = C, and if Z2 and Z4 = N, Z2 is unsubstituted and Z3 and Z5 = C; when Z1-Z5 form an oxazole or thiazole ring, Z1, Z3 and Z4 = C and one of Z2 and Z5 = N that is unsubstituted; when Z1-Z5 form a triazole ring, Z2 and Z5 = N that is unsubstituted; T = C, N; p = 0-3; X = C, S; Ra = (un)substituted 5-6 membered hetero(aryl) or partially unsatd. 5-6 membered ring; R2, R5, R50-R53, R56 = absent, H, alkyl, aryl, etc.; R54, R55 = oxo, absent] which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2), were prepared Thus, reacting 2-(2-chloropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (preparation given) with 3-thiopheneboronic acid in the presence of Cs2CO3, Pd(PPh3)4 in DMF afforded 57% II.TFA. The compds. I were tested for MK-2 inhibition activity (biol. data given for over 800 compds). Methods of using compds. I for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF α , are described, where the method involves administering to the subject an MK-2 inhibiting compound I. Therapeutic compns., pharmaceutical compns. and kits which contain the present MK-2 inhibiting compds. I are also described. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]


IT 724730-57-8P 724730-68-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compds. for preventing or treating a TNF α mediated diseases)


RN 724730-57-8 CAPLUS

CN Acetamide, 2-[2-methoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 724730-68-1 CAPLUS

CN Acetamide, 2-[2-ethoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:892800 CAPLUS Full-text

DOCUMENT NUMBER: 139:395950

TITLE: Preparation of substituted pyrazines as protein kinase modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2484209	A1	20031113	CA 2003-2484209	20030502
AU 2003234464	A1	20031117	AU 2003-234464	20030502
AU 2003234464	B2	20090604		
EP 1501514	A2	20050202	EP 2003-728690	20030502
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			


IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005530760 T 20051013 JP 2004-501436 20030502
 US 20060211709 A1 20060921 US 2005-513081 20050727
 US 7704995 B2 20100427
 PRIORITY APPLN. INFO.: US 2002-377933P P 20020503
 WO 2003-US13869 W 20030502
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 139:395950
 GI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(:NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 625468-71-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of protein kinase modulators)
 RN 625468-71-5 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)

L4 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:633697 CAPLUS Full-text
DOCUMENT NUMBER: 139:180090
TITLE: Preparation of dihydrobenzodiazepin-2-ones as
metabotropic glutamate receptor antagonists for the
treatment of neurological disorders
INVENTOR(S): Adam, Geo; Goetschi, Erwin; Wichmann, Juergen;
Woltering, Thomas Johannes
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 323 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066623	A1	20030814	WO 2003-EP859	20030128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
TW 296622	B	20080511	TW 2002-91105209	20020319
US 20030166639	A1	20030904	US 2003-350713	20030124
US 6949542	B2	20050927		
CA 2474219	A1	20030814	CA 2003-2474219	20030128
CA 2474219	C	20100413		
AU 2003205695	A1	20030902	AU 2003-205695	20030128
AU 2003205695	B2	20080403		
BR 2003007474	A	20041109	BR 2003-7474	20030128
EP 1474416	A1	20041110	EP 2003-702549	20030128
EP 1474416	B1	20070926		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1633430	A	20050629	CN 2003-806545	20030128
CN 100497333	C	20090610		

JP 2005522440	T	20050728	JP 2003-565996	20030128
JP 4077411	B2	20080416		
NZ 534122	A	20061222	NZ 2003-534122	20030128
AT 374196	T	20071015	AT 2003-702549	20030128
PT 1474416	E	20071227	PT 2003-702549	20030128
RU 2315764	C2	20080127	RU 2004-126945	20030128
ES 2294264	T3	20080401	ES 2003-702549	20030128
HR 2004000678	A2	20051031	HR 2004-678	20040723
ZA 2004006032	A	20051012	ZA 2004-6032	20040728
NO 2004003237	A	20040802	NO 2004-3237	20040802
NO 327697	B1	20090914		
MX 2004007516	A	20041110	MX 2004-7516	20040803
IN 2004CN01700	A	20060224	IN 2004-CN1700	20040803
IN 210045	A1	20071214		
HK 1078858	A1	20091204	HK 2005-110731	20051125
PRIORITY APPLN. INFO.:			EP 2002-2012	A 20020206
			WO 2003-EP859	W 20030128

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:180090

GI



AB This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compds., a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer's disease. Three examples of pharmaceutical compns. containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μ M for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preps. of I and many example preps. of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR'R'', pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R' is H, lower alkyl or C3-C6-cycloalkyl; R'' is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or

=N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH₂)_n-C(O)-OR'', -(CH₂)_n-C(O)-NR'R'', -(CH₂)_n-SO₂-NR'R'', -(CH₂)_n-C(NH₂):NR'', hydroxy, lower alkoxy, lower alkylthio, C₃-C₆-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR'R'', hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4.

IT 579476-79-2P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-80-5P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-81-6P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-85-0P, [2-[[3-[3-(6-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-86-1P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-89-4P, [5-Dimethylamino-2-[[3-[3-(2-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-90-7P, [2-[[3-[3-(6-Methylpyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-92-9P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-94-1P, [2-[[3-[3-(2-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579476-97-4P, [2-[[3-Oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-03-5P, [4-Methyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-05-7P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-08-0P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-11-5P, [2-[[3-Oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-13-7P, [5-Methoxy-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-14-8P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-15-9P, [2-[[3-Oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-18-2P, [5-Dimethylamino-2-[[3-[3-(6-methoxypyridazin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-20-6P, [5-Methoxy-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-21-7P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-23-9P, [2-[[3-Oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579477-25-1P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-26-2P, [5-Dimethylamino-2-[[3-[3-(2,6-dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-28-4P, [5-Methyl-2-[[3-oxo-3-[3-(pyridazin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-29-5P, [2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-40-0P, [5-Ethoxy-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-42-2P, [5-[(Cyclopropyl)(methyl)amino]-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-43-3P, [5-Isobutylamino-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-45-5P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-47-7P, [4-Methyl-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-53-5P, [5-Chloro-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-61-5P, [5-Methyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-62-6P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-64-8P, [4-Methyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-65-9P, [5-Dimethylamino-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-67-1P, [5-[(Methyl)(propyl)amino]-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-68-2P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-69-3P, [5-Chloro-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-73-9P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-75-1P, [5-Methyl-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-76-2P, [2-[[3-Oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-77-3P, [5-Dimethylamino-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-78-4P, [5-Chloro-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-80-8P, [4-Methyl-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-82-0P, [5-Chloro-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579477-84-2P, [5-Methyl-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-

trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-85-3P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-86-4P,
[4-Chloro-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-87-5P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-4-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-88-6P,
[5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-92-2P,
[4-Methyl-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-93-3P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-96-6P,
[4-Chloro-2-[[3-oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-97-7P, [4-Chloro-2-[[3-oxo-3-[3-(pyrimidin-5-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579477-98-8P,
[2-[[3-Oxo-3-[3-(pyrazin-2-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579477-99-9P, [4-Chloro-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-00-5P,
[2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-03-8P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-04-9P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-05-0P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-methyl-5-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-06-1P,
[5-Chloro-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-08-3P, [4-Chloro-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl
ester 579478-09-4P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-10-7P, [5-Ethoxy-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl
ester 579478-12-9P, [5-Methyl-2-[[3-[3-(6-methylpyrazin-2-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-13-0P,
[4-Methyl-2-[[3-[3-(6-methylpyrazin-2-yl)phenyl]-3-oxopropionyl]amino]-5-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-18-5P, [2-[[3-[3-(2,5-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579478-19-6P,
[5-Chloro-2-[[3-[3-(2,5-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-20-9P, [2-[[3-[3-(2,5-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579478-21-0P, [5-Ethoxy-2-[[3-[3-(2,5-dimethylpyridin-4-yl)phenyl]-

3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-23-2P, [2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-24-3P, [2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-25-4P, [5-Chloro-2-[[3-[3-(2,3-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-26-5P, [2-[[3-[3-(2,3-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-27-6P, [5-Ethoxy-2-[[3-[3-(2,3-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-29-8P, [2-[[3-[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-30-1P, [2-[[3-[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-31-2P, [2-[[3-[3-(5-Ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-32-3P, [5-Ethoxy-2-[[3-[3-(5-ethyl-2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-34-5P, [2-[[3-[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-35-6P, [2-[[3-[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-36-7P, [5-Chloro-2-[[3-[3-(2-ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-37-8P, [2-[[3-[3-(2-Ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-38-9P, [5-Ethoxy-2-[[3-[3-(2-ethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-39-0P, [5-Dimethylamino-2-[[3-[3-(6-methylpyridin-2-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-45-8P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-46-9P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-47-0P, [2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-49-2P, [2-[[3-[3-(6-Methoxypyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-50-5P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-51-6P, [5-Methyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-52-7P, [5-Methoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-58-3P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-59-4P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579478-61-8P, [2-[[3-[3-(6-Isopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-64-1P, [5-Chloro-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-65-2P, [5-Ethoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-68-5P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-69-6P, [5-(Morpholin-4-yl)-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-71-0P, [5-Ethoxy-2-[[3-[3-(6-ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-72-1P, [2-[[3-[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-73-2P, [2-[[3-[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-74-3P, [2-[[3-[3-(6-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-75-4P, [5-Cyclopropylmethoxy-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-76-5P, [5-Cyclopropylmethoxy-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-77-6P, [5-Cyclopropylmethoxy-2-[[3-[3-(6-cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-79-8P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-80-1P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-86-7P, [2-[[3-[3-(6-Cyanopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-88-9P, [2-[[3-Oxo-3-[3-(pyridazin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-94-7P, [5-(2-Methoxyethoxy)-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-96-9P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2-methoxyethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579478-98-1P, [2-[[3-[3-(2-Cyanopyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-00-3P, [5-Ethyl-2-[[3-oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-06-4P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid tert-butyl ester 579479-08-6P, [2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-10-0P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-12-2P, [2-[[3-[3-(6-Dimethylaminopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579479-14-4P, [2-[[3-[3-(6-Dimethylaminopyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-16-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-18-8P,
[2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-20-2P, [2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-22-4P,
[2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-24-6P, [5-Ethyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-26-8P, [2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-28-0P,
[2-[[3-[3-(6-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-30-4P, [2-[[3-[3-(4-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-32-6P, [2-[[3-[3-(2-Cyclopropylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-34-8P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-36-0P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-38-2P,
[2-[[3-Oxo-3-[3-(pyridin-3-yl)phenyl]propionyl]amino]-5-propyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-40-6P, [5-Ethoxy-2-[[3-[3-(4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-42-8P, [2-[[3-[3-(4-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-44-0P, [5-Methyl-2-[[3-[3-(4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-46-2P, [2-[[3-[3-(2-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-48-4P,
[5-Ethoxy-2-[[3-[3-(2-ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-50-8P, [2-[[3-[3-(2-Ethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-52-0P, [5-Methyl-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-54-2P, [5-Ethoxy-2-[[3-[3-(6-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-56-4P, [2-[[3-[3-(6-Methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-58-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-fluoro-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579479-60-0P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid tert-butyl ester
579479-62-2P, [5-(2-Methoxyethoxy)-2-[[3-[3-(2-methylpyridin-4-


yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-64-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2-
methoxyethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-67-7P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-4-trifluoromethyl-5-vinylphenyl]carbamic acid
tert-butyl ester 579479-69-9P,
[2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-
4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-71-3P, [2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-
yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic
acid tert-butyl ester 579479-73-5P,
[2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-75-7P,
[2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-
trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-76-8P, [2-[[3-[3-(2-Ethyl-6-methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-78-0P,
[5-Ethoxy-2-[[3-[3-(2-ethyl-6-methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-80-4P, [2-[[3-[3-(2-Ethyl-6-methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-
trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-81-5P, [2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-83-7P,
[2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-
trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-85-9P, [2-[[3-[3-(6-Ethyl-4-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-86-0P,
[5-Ethoxy-2-[[3-[3-(6-ethyl-4-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-88-2P, [2-[[3-[3-(6-Ethyl-4-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-
trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-90-6P, [2-[[3-[3-(2-Cyclopropyl-6-methylpyridin-4-
yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic
acid tert-butyl ester 579479-91-7P,
[2-[[3-[3-(2-Cyclopropyl-6-methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-92-8P,
[2-[[3-[3-(2-Cyclopropyl-6-methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-
trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-94-0P, [5-Methyl-2-[[3-[3-(2-methylpyridin-3-yl)phenyl]-3-
oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-96-2P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-[[3-(tetrahydropyran-2-yl)oxy]methyl]-4-
trifluoromethylphenyl]carbamic acid tert-butyl ester
579479-97-3P, [2-[[3-[3-(2-Isobutylpyridin-4-yl)phenyl]-3-
oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid
tert-butyl ester 579479-99-5P,
[2-[[3-[3-(2-Isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-
trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-03-8P, [5-Methyl-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-
yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid

tert-butyl ester 579480-04-9P,
 [5-Chloro-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid
 tert-butyl ester 579480-05-0P,
 [2-[[3-Oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-06-1P, [5-Ethoxy-2-[[3-oxo-3-[3-(2-trifluoromethylpyridin-4-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-10-7P, [2-[[3-[3-(2-Isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-12-9P, [2-[[3-[3-(2-Isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-13-0P, [5-Chloro-2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-15-2P, [2-[[3-[3-(2-Isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-17-4P, [5-Ethoxy-2-[[3-[3-(2-isopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-18-5P, [5-Chloro-2-[[3-[3-(2-isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-21-0P, [5-Ethoxy-2-[[3-[3-(2-isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-22-1P, [2-[[3-[3-(2-Isobutylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-26-5P, [5-Methyl-2-[[3-oxo-3-[3-[2-[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-28-7P, [5-Chloro-2-[[3-oxo-3-[3-[2-[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-29-8P, [2-[[3-Oxo-3-[3-[2-[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-31-2P, [5-Ethoxy-2-[[3-oxo-3-[3-[2-[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)


RN 579476-79-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-80-5 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-81-6 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-85-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-86-1 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-89-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-90-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methyl-3-pyridazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-92-9 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(6-methyl-3-pyridazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-94-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579476-97-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-03-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-05-7 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-08-0 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-11-5 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-13-7 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-14-8 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-15-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-18-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(6-methoxy-3-pyridazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-20-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-21-7 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-23-9 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-25-1 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-26-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[[3-[3-(2,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-28-4 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridazinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-29-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-40-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-42-2 CAPLUS

CN Carbamic acid, [5-(cyclopropylmethylamino)-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-43-3 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-45-5 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-47-7 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-53-5 CAPLUS

CN Carbamic acid, [5-chloro-2-[[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-61-5 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-62-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-64-8 CAPLUS

CN Carbamic acid, [4-methyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-65-9 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-67-1 CAPLUS

CN Carbamic acid, [5-(methylpropylamino)-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-68-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-69-3 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-73-9 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-75-1 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-76-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-77-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-78-4 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-80-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-82-0 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-84-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-85-3 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-86-4 CAPLUS

CN Carbamic acid, [4-chloro-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-87-5 CAPLUS

CN Carbamic acid, [4-chloro-2-[[1,3-dioxo-3-[3-(4-pyridinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-88-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-92-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-93-3 CAPLUS

CN Carbamic acid, [4-chloro-2-[[1,3-dioxo-3-[3-(2-pyridinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-96-6 CAPLUS

CN Carbamic acid, [4-chloro-2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-97-7 CAPLUS

CN Carbamic acid, [4-chloro-2-[[1,3-dioxo-3-[3-(5-pyrimidinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-98-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-(3-pyrazinylphenyl)propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579477-99-9 CAPLUS

CN Carbamic acid, [4-chloro-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-00-5 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-03-8 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ester (9CI) (CA INDEX NAME)




RN 579478-04-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-05-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-methyl-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-06-1 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-08-3 CAPLUS

CN Carbamic acid, [4-chloro-2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-09-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-10-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-12-9 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(6-methylpyrazinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-13-0 CAPLUS

CN Carbamic acid, [4-methyl-2-[[3-[3-(6-methylpyrazinyl)phenyl]-1,3-dioxopropyl]amino]-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-18-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-19-6 CAPLUS


CN Carbamic acid, [5-chloro-2-[[3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-20-9 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-21-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,5-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-23-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-24-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-25-4 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-26-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-27-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,3-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-29-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-30-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-31-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-32-3 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(5-ethyl-2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-34-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-35-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-36-7 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-37-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-38-9 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(2-ethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-39-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(6-methyl-2-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-45-8 CAPLUS


CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-46-9 CAPLUS


CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ester (9CI) (CA INDEX NAME)




RN 579478-47-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-49-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methoxy-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-50-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-51-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-52-7 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-58-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-[6-(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-59-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-[6-(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-61-8 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-[6-(1-methylethyl)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-64-1 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-65-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-68-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-69-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 579478-71-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-72-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-73-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-74-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-75-4 CAPLUS


CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579478-76-5 CAPLUS


CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[[1,3-dioxo-3-[3-(2-methyl-4-pyridinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-77-6 CAPLUS

CN Carbamic acid, [5-(cyclopropylmethoxy)-2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-79-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 579478-80-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)




RN 579478-86-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyano-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-88-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridazinyl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-94-7 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-96-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579478-98-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyano-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-00-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-06-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-ethenyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-08-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-10-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-12-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-[6-(dimethylamino)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-14-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-[6-(dimethylamino)-3-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-16-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-18-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-20-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-22-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-24-6 CAPLUS

CN Carbamic acid, [5-ethyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-26-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-28-0 CAPLUS


CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-30-4 CAPLUS


CN Carbamic acid, [2-[[3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 579479-32-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-34-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-36-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-38-2 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(3-pyridinyl)phenyl]propyl]amino]-5-propyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-40-6 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-42-8 CAPLUS


CN Carbamic acid, [2-[[3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-44-0 CAPLUS


CN Carbamic acid, [5-methyl-2-[[3-[3-(4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 579479-46-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-48-4 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-50-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-52-0 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-54-2 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-56-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-58-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-fluoro-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-60-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethenyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-62-2 CAPLUS

CN Carbamic acid, [5-(2-methoxyethoxy)-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-64-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2-methoxyethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-67-7 CAPLUS

CN Carbamic acid, [5-ethenyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-69-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-71-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-73-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-75-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-76-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-78-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-80-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-ethyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-81-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-83-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-85-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-86-0 CAPLUS


CN Carbamic acid, [5-ethoxy-2-[[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579479-88-2 CAPLUS


CN Carbamic acid, [2-[[3-[3-(6-ethyl-4-methyl-3-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-90-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-91-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-92-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-6-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-94-0 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(2-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-96-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-97-3 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579479-99-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-03-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-04-9 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-05-0 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-06-1 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-(trifluoromethyl)-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-10-7 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-12-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-13-0 CAPLUS


CN Carbamic acid, [5-chloro-2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-15-2 CAPLUS


CN Carbamic acid, [2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-17-4 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-(1-methylethyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-18-5 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-21-0 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-22-1 CAPLUS

CN Carbamic acid, [2-[[3-[3-[2-(2-methylpropyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-26-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-28-7 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-[2-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-29-8 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-31-2 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-[[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 579480-32-3P, [2-[[3-[3-(6-Cyclopropyl-4-methylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-34-5P, [2-[[3-[3-(4,6-Dimethylpyridin-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-36-7P, [2-[[3-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-38-9P, [2-[[3-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-40-3P, [2-[[3-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-42-5P, [2-[[3-[3-(2-Cyclopropylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-44-7P, [5-Cyclopropyl-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-45-8P, [2-[[3-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-methyl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-47-0P, [2-[[3-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-49-2P, [2-[[3-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-ethoxy-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-51-6P, [2-[[3-[3-(2-Cyclopentylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-53-8P, [5-[(Isobutyl)(methyl)amino]-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-55-0P, [5-[(Isopropyl)(methyl)amino]-2-[[3-[3-(2-methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-59-4P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic

acid tert-butyl ester 579480-61-8P,
[5-[(Isobutyl)(methyl)amino]-2-[[3-oxo-3-[3-[2-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-67-4P, [5-[(Methyl)(propyl)amino]-2-[[3-oxo-3-[3-[2-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-69-6P, [5-[(Isopropyl)(methyl)amino]-2-[[3-oxo-3-[3-[2-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-71-0P, [5-(Dimethylamino)-2-[[3-oxo-3-[3-[2-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-73-2P, [2-[[3-[3-(2-Methylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-75-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-77-6P, [5-Ethoxy-2-[[3-[3-[2-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-79-8P,
[2-[[3-[3-[2-(Morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-82-3P, [5-Methyl-2-[[3-[3-[2-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579480-84-5P, [2-[[3-Oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-86-7P,
[5-Methyl-2-[[3-oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-88-9P,
[5-Ethoxy-2-[[3-oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-90-3P,
[2-[[3-Oxo-3-[3-[2-(pyrrolidin-1-yl)pyridin-4-yl]phenyl]propionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579480-98-1P, [5-Methyl-2-[[3-[3-[2-methyl-6-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-00-8P, [5-Chloro-2-[[3-[3-[2-methyl-6-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-02-0P, [2-[[3-[3-[2-Methyl-6-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-5-(2,2,2-trifluoroethoxy)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-04-2P, [5-Ethoxy-2-[[3-[3-[2-methyl-6-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-06-4P, [2-[[3-[3-[2-Methyl-6-[[[(tetrahydropyran-2-yl)oxy]methyl]pyridin-4-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-08-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(isobutyl)(methyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
579481-10-0P, [5-Dimethylamino-2-[[3-[3-(2,6-dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 579481-14-4P,
[2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-pyrrolidin-1-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

579481-16-6P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(isopropyl)(methyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester


579481-17-7P, [2-[[3-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-3-oxopropionyl]amino]-5-[(methyl)(propyl)amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)


RN 579480-32-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(6-cyclopropyl-4-methyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-34-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(4,6-dimethyl-3-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-36-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-38-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-40-3 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-42-5 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-44-7 CAPLUS

CN Carbamic acid, [5-cyclopropyl-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-45-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopropyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-47-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-49-2 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579480-51-6 CAPLUS


CN Carbamic acid, [2-[[3-[3-(2-cyclopentyl-4-pyridinyl)phenyl]-1,3-

dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-53-8 CAPLUS

CN Carbamic acid, [5-[methyl(2-methylpropyl)amino]-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-55-0 CAPLUS

CN Carbamic acid, [5-[methyl(1-methylethyl)amino]-2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-59-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-61-8 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-[[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-67-4 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-[[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-69-6 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-[[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-71-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-73-2 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2-methyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-75-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-77-6 CAPLUS

CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-79-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-82-3 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-[2-(4-morpholinyl)-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-84-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-86-7 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-88-9 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-90-3 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[2-(1-pyrrolidinyl)-4-pyridinyl]phenyl]propyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579480-98-1 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-[2-methyl-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-00-8 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-[2-methyl-6-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-02-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-[2-methyl-6-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579481-04-2 CAPLUS


CN Carbamic acid, [5-ethoxy-2-[[3-[3-[2-methyl-6-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579481-06-4 CAPLUS


CN Carbamic acid, [2-[[3-[3-[2-methyl-6-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyridinyl]phenyl]-1,3-dioxopropyl]amino]-4-

(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-08-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-10-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-14-4 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 579481-16-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 579481-17-7 CAPLUS

CN Carbamic acid, [2-[[3-[3-(2,6-dimethyl-4-pyridinyl)phenyl]-1,3-dioxopropyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:221693 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:238197

TITLE: Preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against

hyperproliferative diseases

INVENTOR(S): Adams, Jerry Leroy; Bryan, Deborah Lynne; Feng, Yanhong; Matsunaga, Shinichiro; Maeda, Yutaka; Miyazaki, Yasushi; Nakano, Masato; Rocher, Jean-Philippe; Sato, Hideyuki; Semones, Marcus; Silva, Domingos J.; Tang, Jun

PATENT ASSIGNEE(S): Glaxosmithkline K.K., Japan; Smithkline Beecham Corporation

SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022852	A2	20030320	WO 2002-US28650	20020910
WO 2003022852	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333524	A1	20030324	AU 2002-333524	20020910
EP 1425284	A2	20040609	EP 2002-798181	20020910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK				
JP 2005508904	T	20050407	JP 2003-526926	20020910
US 20050004142	A1	20050106	US 2004-489052	20040309
US 7427623	B2	20080923		
US 20080287466	A1	20081120	US 2008-169800	20080709
PRIORITY APPLN. INFO.:				
			US 2001-318766P	P 20010911
			WO 2002-US28650	W 20020910
			US 2004-489052	A3 20040309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:238197


GI



AB Furo- and thienopyrimidine derivs. (shown as I; variables defined below; e.g. 4-Amino-3-(4-methoxyphenyl)-2-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine), which are useful as TIE-2 (tyrosine kinase containing immunoglobulin and EGF homol. domains) and/or VEGFR-2 kinase inhibitors against hyperproliferative diseases are described herein. Enzyme inhibitions by

.apprx.60 examples of I are included as ranges; also, 4-amino-3-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]phenyl]thieno[2,3-d]pyrimidine exhibited IC50 = 0.0018 μ M in the TIE-2 fluorescence polarization kinase activity assay. For I: X is O or S; A is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥ 1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, -C(O)R4; D is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥ 1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, or -C(O)R4. R is C1-C6 alkylene, C3-C7 cycloalkylene, C1-C6 alkenylene, or C1-C6 alkynylene; R1 is H, C1-C6 alkyl, C1-C6 alkoxy, -SR4, -S(O)2R4, -NR7R7, -NR'N R'''R''', -N(H)RR3, -C(O)OR7, or -C(O)NR7R7. R2 is H, -OH, -NR7R7 or :NH; R3 is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C7 cycloalkoxy, C1-C6 haloalkoxy, aryl, aralkyl, aryloxy, heteroaryl, heterocyclyl, -CN, -NHC(O)R4, -N(R8)HC(O)R4, -NHC(S)R4, -NR5R6, -RNR5R6, -SR4, -S(O)2R4, -RC(O)OR4, -C(O)OR4, -C(O)R4, -C(O)NR5R6, -NHS(O)2R4, -N(S(O)2R4)S(O)2R4, -S(O)2NR5R6, or -NHC(:NH)R4. R4 is H, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, -RR3, -NR'''R''', or -NR'NR'''R'''; R5 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -NHC(O)OR''', -R'NHC(O)OR''', -R'NHC(O)NR'''R''', or -R'C(O)OR'''. R6 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -C(O)OR''', or -R'C(O)NR'''R'''; R7 is H, C1-C6 alkyl, aryl, or -C(O)OR'''; R8 is C1-C3 alkyl; R' is C1-C3 alkylene; R'' is heteroalkyl or NRR'''R'''; R''' is H, C1-C6 alkyl, aryl, aralkyl, heteroaryl, or C3-C7 cycloalkyl; R'''' is H, C1-C6 alkyl, aryl, heteroaryl, or C3-C7 cycloalkyl. Although the methods of preparation are not claimed, several example preps. of I are included and characterization data is given for .apprx.480 examples of I.

IT 501695-83-6P, 4-Amino-5-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]methyl]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)
 RN 501695-83-6 CAPLUS
 CN Urea, N-[[4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl]methyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:196948 CAPLUS Full-text

DOCUMENT NUMBER: 138:221357
 TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers
 INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 675,674.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531495	B1	20030311	US 2000-698078	20001030
DE 19947457	A1	20010405	DE 1999-19947457	19991002
US 20030171351	A1	20030911	US 2002-252385	20020924
US 6686395	B2	20040203		
US 20040102513	A1	20040527	US 2003-691624	20031024
US 7514582	B2	20090407		
US 20090192096	A1	20090730	US 2009-419069	20090406


PRIORITY APPLN. INFO.:

DE 1999-19947457	A	19991002
US 2000-675674	A2	20000929
US 2000-698078	A3	20001030
US 2002-252385	A3	20020924
US 2003-691624	A1	20031024

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:221357

GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or Cph2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane

followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.2 μ M - 11.3 μ M. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).



IT 498578-07-7P 498578-08-8P 498578-12-4P
498578-13-5P 498578-16-8P 498578-18-0P
498578-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-08-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-12-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-18-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-21-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-
 [[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX
 NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:193044 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 138:187521
 TITLE: Preparation of 2'-aminomethylbiphenyl-2-carboxamides
 as Kv1.5 potassium channel blockers.
 INVENTOR(S): Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025189	A1	20010412	WO 2000-EP9151	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19947457	A1	20010405	DE 1999-19947457	19991002
CA 2385859	A1	20010412	CA 2000-2385859	20000919
CA 2385859	C	20091124		
BR 2000014465	A	20020611	BR 2000-14465	20000919
EP 1222163	A1	20020717	EP 2000-967703	20000919
EP 1222163	B1	20060712		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003511363	T	20030325	JP 2001-528137	20000919
HU 2002003505	A2	20030328	HU 2002-3505	20000919
HU 2002003505	A3	20040128		
EE 2002000160	A	20030415	EE 2002-160	20000919
EE 5000	B1	20080415		
AU 766365	B2	20031016	AU 2000-77778	20000919
NZ 518065	A	20040827	NZ 2000-518065	20000919
RU 2252214	C2	20050520	RU 2002-111561	20000919
IL 148870	A	20070515	IL 2000-148870	20000919
SK 286756	B6	20090507	SK 2002-438	20000919
MX 2002002691	A	20020730	MX 2002-2691	20020313
NO 2002001398	A	20020531	NO 2002-1398	20020320
NO 327709	B1	20090914		
HR 2002000264	A2	20040229	HR 2002-264	20020328
IN 223624	A1	20081121	IN 2002-CN463	20020401
HK 1048986	A1	20050729	HK 2003-101193	20030218

PRIORITY APPLN. INFO.:

DE 1999-19947457	A	19991002
WO 2000-EP9151	W	20000919

OTHER SOURCE(S): MARPAT 138:187521
 GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or Cph2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl,

or CF₃; or NR₃R₄ = heterocyclyl; R₅, R₆, R₇, R₈ = independently H, halo, CF₃, NO₂, cyano, etc.; R₃₀ and R₃₁ = independently H or alkyl; CR₃₀R₃₁ = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO₃ in dioxane and H₂O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC₅₀ = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).



IT 498578-07-7P 498578-08-8P 498578-12-4P
498578-13-5P 498578-16-8P 498578-18-0P
498578-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-08-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-12-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 498578-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)





RN 498578-18-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 498578-21-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:5963 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:73267

TITLE: Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors

INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:832787 CAPLUS Full-text
DOCUMENT NUMBER: 137:337786
TITLE: Preparation of chiral alkylaminochroman derivatives as β 3-adrenoreceptor agonists
INVENTOR(S): O'Connor, Stephen J.; Ladouceur, Gaetan H.; Bullock, William H.; Campbell, Ann-Marie; Dai, Miao; Dally, Robert; Dumas, Jacques; Hatoum-Mokdad, Holia N.; Khire, Uday; Lee, Wendy; Liu, Qingjie; Lowe, Derek B.; Magnuson, Steven R.; Qi, Ning; Shelekhin, Tatiana E.; Shen, Quanrong; Smith, Roger A.; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085891	A1	20021031	WO 2002-US12940	20020422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002254717	A1	20021105	AU 2002-254717	20020422
US 20030078260	A1	20030424	US 2002-131448	20020422
US 6660752	B2	20031209		
EP 1389202	A1	20040218	EP 2002-723958	20020422
EP 1389202	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532227	T	20041021	JP 2002-583418	20020422
ES 2230487	T3	20050501	ES 2002-723958	20020422
US 20040072828	A1	20040415	US 2003-666903	20030917
US 6919371	B2	20050719		
US 20050215594	A1	20050929	US 2005-117759	20050428



PRIORITY APPLN. INFO.:

US 2001-285719P	P	20010423
US 2001-324518P	P	20010926
US 2002-131448	A1	20020422
WO 2002-US12940	W	20020422
US 2003-666903	A3	20030917

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:337786

GI



AB This invention relates to novel 2,6-substituted chroman derivs. which are useful in the treatment of β 3-adrenoreceptor mediated conditions. Title compds. I [wherein R = independently OH, :O, halo, CN, NO₂, (halo)alkyl, CF₃, NR₁R₁, SR₁, OR₁, SO₂R₂, OCOR₂, NR₁COR₂, COR₂, NR₁SO₂R₂, or (un)substituted Ph or heterocyclyl; R₁ = independently H, (CH₂)_mO(CH₂)_mR₅, or (un)substituted (cyclo)alkyl, Ph, or naphthyl; or NR₁R₁ = heterocyclyl; R₂ = independently R₁, OR₁, NR₁R₁, or (un)substituted NHSO₀-2-Ph, NHSO₀-2-naphthyl, NHSO₀-2-alkyl, or heterocyclyl; R₃ = H, alkyl, or COR₃; R₄ = H, alkyl(phenyl), or alkylpyridyl; R₅ = H or CO₂H; R₆ = H or (un)substituted alkyl or alkyl-SO₀-2-alkyl; Ar = Ph or (fused) hetero(aryl); Y = halo, NO₂, R₆, SR₁, SO₀-2C₆H₄CO₂R₁, (CONR₄CR₄R₄)pCO₂R₁, or (un)substituted Ph or heterocyclyl; m = 1-3; n = 0-5; p = 1 or 2; and pharmaceutically acceptable salts and esters thereof] were prepared as β 3-adrenoceptor agonists. For example, coupling of (2R)-6-iodo-3,4-dihydro-2H-chromene-2-carboxylic acid and (1R)-2-amino-1-(3-pyridinyl)ethanol•2HCl with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl, and TEA in CH₂Cl₂ gave the amide (74%). Reduction using borane-dimethylsulfide complex in THF afforded the chromanmethaneamine II (84%). Over one hundred compds. of the invention demonstrated β 3-adrenergic receptor agonist activity with EC₅₀ values \leq 1 μ M. I are useful in the treatment of β 3-adrenergic receptor mediated conditions, including obesity, diabetes, gastrointestinal disorders, cardiovascular disorders, and urinary disorders (no data).

IT 474114-16-4P, 3-[(1R)-1-Hydroxy-2-[[[(2R)-6-[3-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]sulfonyl]phenyl]-3,4-dihydro-2H-chromen-2-yl]methyl]amino]ethyl]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(β 3-adrenoreceptor agonist; preparation of chiral alkylaminochroman derivs. as β 3-adrenoreceptor agonists)

RN 474114-16-4 CAPLUS


CN Benzenesulfonamide, 3-[(2R)-3,4-dihydro-2-[[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]methyl]-2H-1-benzopyran-6-yl]-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:814125 CAPLUS Full-text
DOCUMENT NUMBER: 137:325438
TITLE: Preparation of dihydro-benzo[b][1,4]diazepin-2-one
derivatives as metabotropic glutamate receptor 2
(mGluR2) antagonists
INVENTOR(S): Adam, Geo; Goetschi, Erwin; Mutel, Vincent; Wichmann,
Juergen; Woltering, Thomas Johannes
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083665	A1	20021024	WO 2002-EP3643	20020402
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2441771	A1	20021024	CA 2002-2441771	20020402
CA 2441771	C	20081230		

AU 2002310912	A1	20021028	AU 2002-310912	20020402
AU 2002310912	B2	20050616		
EP 1379522	A1	20040114	EP 2002-735209	20020402
EP 1379522	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008887	A	20040629	BR 2002-8887	20020402
CN 1522252	A	20040818	CN 2002-807821	20020402
CN 1268626	C	20060809		
JP 2004525965	T	20040826	JP 2002-581420	20020402
JP 4043953	B2	20080206		
HU 2004000991	A2	20040830	HU 2004-991	20020402
HU 2004000991	A3	20090629		
AT 287883	T	20050215	AT 2002-735209	20020402
NZ 528345	A	20050429	NZ 2002-528345	20020402
PT 1379522	E	20050531	PT 2002-735209	20020402
ES 2235044	T3	20050701	ES 2002-735209	20020402
RU 2270197	C2	20060220	RU 2003-130648	20020402
IL 158021	A	20100415	IL 2002-158021	20020402
US 20020198197	A1	20021226	US 2002-116597	20020403
US 6548495	B2	20030415		
ZA 2003007242	A	20041216	ZA 2003-7242	20030916
HR 2003000791	A2	20050630	HR 2003-791	20031001
HR 2003000791	B1	20060630		
NO 2003004496	A	20031008	NO 2003-4496	20031008
NO 325300	B1	20080325		
IN 2003CN01593	A	20051125	IN 2003-CN1593	20031008
IN 205655	A1	20070629		
MX 2003009317	A	20040212	MX 2003-9317	20031010
BG 108253	A	20050331	BG 2003-108253	20031010
HK 1068339	A1	20061020	HK 2005-100429	20050117
PRIORITY APPLN. INFO.:			EP 2001-109126	A 20010412
			WO 2002-EP3643	W 20020402
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 137:325438				
GI				



AB This invention is concerned with dihydro-benzo[b][1,4]diazepin-2-one derivs. of general formula [I; R1 = cyano, each (un)substituted fluoro-lower alkyl, lower alkoxy, fluoro-lower alkoxy, or is pyrrol-1-yl; R2 = H, if R1 is optionally substituted pyrrol-1-yl as defined above, or R2 = halogen, HO, lower alkyl, fluoro-lower alkyl, lower alkoxy, hydroxymethyl, hydroxyethoxy, lower alkoxy(ethoxy)n (n = 1-4), lower alkoxymethyl, cyanomethoxy, morpholin-4-yl, thiomorpholin-4-yl, 1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, 4-oxopiperidin-1-yl 4-alkoxypiperidin-1-yl, 4-hydroxypiperidin-1-yl, 4-hydroxyethoxypiperidin-1-yl, 4-lower alkylpiperazin-1-yl, alkoxy carbonyl, 2-

dialkylaminoethylsulfanyl, N,N-bis(lower alkyl)amino-lower alkyl, carbamoylmethyl, etc.; Y = CH, N; R₃ = halogen, lower alkyl, fluoro-lower alkyl, lower alkoxy, cyano, -(CH₂)_nCO-OR''-(CH₂)_n-CO-NR'R'', or (un)substituted five-membered aromatic heterocycle; R' = H, lower alkyl, C₃-6-cycloalkyl, fluoro-lower alkyl or 2-lower alkoxy-lower alkyl; R'' = H, lower alkyl, C₃-6-cycloalkyl, fluoro-lower alkyl, 2-lower alkoxy lower alkyl, -(CH₂)₂-4-di-lower alkylamino, -(CH₂)₂-4-morpholinyl, -(CH₂)₂-4-pyrrolidinyl, -(CH₂)₂-4-piperidinyl, 3-hydroxy-lower alkyl; n = 0-4] and their pharmaceutically acceptable addition salts. The invention further relates to medicaments containing these compds. and a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders including psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits. Thus, a mixture of (2-amino-5-thiomorpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-Bu ester and 3-(2-cyanopyridin-4-yl)-3-oxopropionic acid tert-Bu ester in toluene was heated to 80-120° to give [2-[3-(2-cyanopyridin-4-yl)-3-oxopropionylamino]-5-thiomorpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-Bu ester which was treated with CF₃CO₂H in CH₂Cl₂ to give 4-(4-Oxo-8-thiomorpholin-4-yl-7-trifluoromethyl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)pyridine-2-carbonitrile (II). II in vitro inhibited the [3H]-LY354740 binding on mGluR2 transfected CHO cell membranes with K_i of 0.0009 μM.

IT 473538-38-4P 473538-40-8P,
 [2-[3-[3-(3-Methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-5-morpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-59-9P, [2-[3-[3-(2-Methyl-2H-pyrazol-3-yl)phenyl]-3-oxopropionyl]amino]-5-(morpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-60-2P 473538-61-3P,
 [2-[3-[3-(5-((Dimethylamino)methyl)-[1,2,3]triazol-1-yl)phenyl]-3-oxopropionyl]amino]-5-(morpholin-4-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-62-4P,
 [2-[3-[3-(3-Methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-5-thiomorpholin-4-yl-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-64-6P 473538-66-8P,
 [5-Methoxy-2-[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-67-9P 473538-68-0P 473538-69-1P,
 [5-(Morpholin-4-yl)-2-[3-oxo-3-(3-(pyrazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-70-4P, [5-(Morpholin-4-yl)-2-[3-oxo-3-(3-(4H-[1,2,4]triazol-4-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-71-5P 473538-72-6P 473538-74-8P,
 [5-Ethoxy-2-[3-oxo-3-(3-([1,2,3]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-75-9P, [5-Methoxy-2-[3-oxo-3-(3-([1,2,3]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-80-6P 473538-81-7P,
 [5-Chloro-2-[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-83-9P 473538-84-0P,
 [5-Methyl-2-[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-85-1P, [5-Chloro-2-[3-oxo-3-(3-([1,2,4]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-86-2P,
 [5-Chloro-2-[3-(3-(imidazol-1-yl)phenyl)-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-87-3P, [5-Chloro-2-[3-oxo-3-(3-([1,2,3]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid


tert-butyl ester 473538-88-4P,
 [5-Methyl-2-[[3-oxo-3-(3-([1,2,4]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-89-5P, [5-Methyl-2-[[3-(3-(imidazol-1-yl)phenyl)-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-90-8P, [5-Methyl-2-[[3-oxo-3-(3-([1,2,3]triazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473538-91-9P,
 [5-Methyl-2-[[3-oxo-3-(3-(pyrazol-1-yl)phenyl)propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473538-92-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of dihydro-benzo[b][1,4]diazepin-2-one derivs.

as

metabotropic glutamate receptor 2 (mGluR2) antagonists for treatment and/or prevention of acute and/or chronic neurol. disorders)


RN 473538-38-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 473538-40-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-59-9 CAPLUS

CN Carbamic acid, [2-[[3-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-60-2 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[3-[[tetrahydro-2H-pyran-2-yl)oxy)methyl]-5-isoxazolyl]phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-61-3 CAPLUS

CN Carbamic acid, [2-[[[3-[3-[5-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]phenyl]-1,3-dioxopropyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-62-4 CAPLUS

CN Carbamic acid, [2-[[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-(4-thiomorpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-64-6 CAPLUS

CN Carbamic acid, [5-(1,1-dioxido-4-thiomorpholinyl)-2-[[1,3-dioxo-3-[3-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-66-8 CAPLUS

CN Carbamic acid, [5-methoxy-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-67-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-68-0 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[4-(trifluoromethyl)-2-methoxyphenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-69-1 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-70-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(4H-1,2,4-triazol-4-yl)phenyl]propyl]amino]-5-(4-morpholinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-71-5 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-fluoro-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-72-6 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-74-8 CAPLUS

CN Carbamic acid, N-[2-[[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-ethoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-75-9 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methoxy-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-80-6 CAPLUS

CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-81-7 CAPLUS

CN Carbamic acid, [5-chloro-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-83-9 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[5-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-84-0 CAPLUS

CN Carbamic acid, [5-methyl-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-85-1 CAPLUS

CN Carbamic acid, [5-chloro-2-[[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-86-2 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-87-3 CAPLUS

CN Carbamic acid, N-[5-chloro-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-88-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473538-89-5 CAPLUS


CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473538-90-8 CAPLUS
 CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473538-91-9 CAPLUS
 CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-5-methyl-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473538-92-0 CAPLUS
 CN Carbamic acid, [5-chloro-2-[[1,3-dioxo-3-[3-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,4-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:814112 CAPLUS Full-text
 DOCUMENT NUMBER: 137:325447
 TITLE: Preparation of dihydrobenzo[b][1,4]diazepin-2-ones as mGluR2 antagonists for treatment of neurological

INVENTOR(S): disorders
 Adam, Geo; Goetschi, Erwin; Mutel, Vincent; Wichmann,
 Juergen; Woltering, Thomas Johannes
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
 SOURCE: PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083652	A1	20021024	WO 2002-EP3644	20020402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442557	A1	20021024	CA 2002-2442557	20020402
CA 2442557	C	20081223		
AU 2002312788	A1	20021028	AU 2002-312788	20020402
AU 2002312788	B2	20051110		
EP 1379511	A1	20040114	EP 2002-737911	20020402
EP 1379511	B1	20050720		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008891	A	20040420	BR 2002-8891	20020402
HU 2004000851	A2	20040728	HU 2004-851	20020402
HU 2004000851	A3	20100329		
JP 2004529925	T	20040930	JP 2002-581408	20020402
JP 4071115	B2	20080402		
CN 1535266	A	20041006	CN 2002-808181	20020402
CN 1264825	C	20060719		
NZ 528315	A	20050429	NZ 2002-528315	20020402
AT 299868	T	20050815	AT 2002-737911	20020402
RU 2263112	C2	20051027	RU 2003-130637	20020402
PT 1379511	E	20051031	PT 2002-737911	20020402
ES 2246012	T3	20060201	ES 2002-737911	20020402
IL 157873	A	20081126	IL 2002-157873	20020402
US 20020193367	A1	20021219	US 2002-115826	20020403
US 6544985	B2	20030408		
ZA 2003007243	A	20041216	ZA 2003-7243	20030916
HR 2003000792	A2	20051031	HR 2003-792	20031001
NO 2003004576	A	20031112	NO 2003-4576	20031010
MX 2003009311	A	20040212	MX 2003-9311	20031010
BG 108254	A	20040930	BG 2003-108254	20031010
IN 2003CN01610	A	20051125	IN 2003-CN1610	20031010
IN 203568	A1	20070330		
HK 1068888	A1	20060929	HK 2005-101555	20050224
PRIORITY APPLN. INFO.:			EP 2001-109125	A 20010412
			WO 2002-EP3644	W 20020402

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:325447
 GI



- AB Title compds. I [wherein X = single bond or ethynediyl group; when X = single bond, R1 = CN, halo, (cyclo)alkyl, (fluoro)alkoxy, fluoroalkyl, or (un)substituted pyrrolyl or Ph; when X = ethynediyl, R1 = (un)substituted Ph; R2 = NR4R5, alkoxy, or R5-(un)substituted oxopiperazinyl, pyrrolidinyl, or piperidinyl; R3 = halo, (fluoro)alkyl, alkoxy, CN, (CH2)nCO2R5, (CH2)nCONR4R5, or (un)substituted 5-membered heteroaryl; R4 = H, (cyclo)alkyl, fluoroalkyl, or alkoxyalkyl; R5 = H, (cyclo)alkyl, fluoroalkyl, alkoxyalkyl, (CH2)m-dialkylamino, (CH2)m-morpholinyl, (CH2)m-pyrrolidinyl, (CH2)m-piperidinyl, or hydroxyalkyl; Y = CH, or N; m = 2-4; n = 0-4; or their pharmaceutically acceptable salts thereof] were prepared as metabotropic glutamate receptor 2 (mGluR2) antagonists. For example, coupling (5-amino-2-dimethylamino-2',3'-difluorobiphenyl-4-yl)carbamic acid tert-Bu ester with 3-oxo-3-(3-[1,2,3]triazol-1-ylphenyl)propionic acid Et ester (preparation of starting materials given) in toluene afforded the amide, which was cyclized using TFA to give the benzodiazepinone II (Ki = 0.070 μ M). Twenty-nine compds. of the invention displayed mGluR2 antagonist activity with Ki values ranging from 0.003 μ M to 0.48 μ M. Thus, I are useful for the treatment or prevention of acute and/or chronic neurol. disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, and memory deficits (no data).
- IT 473549-06-3P, [5-Dimethylamino-2-[[3-oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-07-4P, [5-Dimethylamino-2-[[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-20-1P, [5-Dimethylamino-2-[[3-[3-(2-methyl-2H-pyrazol-3-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-23-4P 473549-26-7P, [2-[[3-Oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-5-(pyrrolidin-1-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-30-3P, [5-Dimethylamino-2-[[3-oxo-3-[3-[3-(tetrahydropyran-2-yloxymethyl)isoxazol-5-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
 473549-33-6P, [5-Dimethylamino-2-[[3-oxo-3-[3-[5-(tetrahydropyran-

2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-39-2P, [2-[3-Oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-5-(pyrrolidin-1-yl)-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-41-6P, [5-(Azetidin-1-yl)-2-[3-[3-(3-methylisoxazol-5-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-43-8P,
[5-(Azetidin-1-yl)-2-[3-oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-44-9P,
[5-Dimethylamino-2-[3-oxo-3-[3-(pyrazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-45-0P, [5-Dimethylamino-2-[3-[3-(imidazol-1-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-47-2P, [5-Dimethylamino-2-[3-oxo-3-[3-[4-(tetrahydropyran-2-yloxymethyl)pyrazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-48-3P, [5-Dimethylamino-2-[3-[3-[3-methyl-4-(tetrahydropyran-2-yloxymethyl)isoxazol-5-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-49-4P, [5-Dimethylamino-2-[3-oxo-3-[3-[4-(tetrahydropyran-2-yloxymethyl)isoxazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-50-7P, [5-Dimethylamino-2-[3-[3-(2-methylsulfanylimidazol-1-yl)phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-51-8P,
[5-Dimethylamino-2-[3-[3-[2-methyl-4-(tetrahydropyran-2-yloxymethyl)-2H-pyrazol-3-yl]phenyl]-3-oxopropionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-53-0P, [5-Dimethylamino-2-[3-oxo-3-[3-(1,2,4-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-55-2P 473549-57-4P,
[5-Dimethylamino-2-[3-oxo-3-[3-[2-[2-(tetrahydropyran-2-yloxy)ethyl]-2H-pyrazol-3-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-60-9P,
[5-Dimethylamino-2-[3-oxo-3-[3-[5-[2-(tetrahydropyran-2-yloxy)ethyl]-1,2,3-triazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-61-0P, [5-Dimethylamino-2-[3-oxo-3-[3-[5-(tetrahydropyran-2-yloxymethyl)pyrazol-1-yl]phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester
473549-62-1P, [5-Dimethylamino-2-[3-oxo-3-[3-(1,2,3-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473549-90-5P 473549-91-6P
473549-92-7P 473549-93-8P 473549-94-9P
473549-95-0P 473550-05-9P 473550-06-0P
473550-07-1P 473550-10-6P 473550-12-8P
473550-13-9P, [2-[3-[3-(Imidazol-1-yl)phenyl]-3-oxopropionyl]amino]-5-isobutylamino-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473550-16-2P,
[5-(Isobutylamino)-2-[3-oxo-3-[3-(1,2,3-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473550-18-4P,
[5-(Isobutylamino)-2-[3-oxo-3-[3-(1,2,4-triazol-1-yl)phenyl]propionyl]amino]-4-trifluoromethylphenyl]carbamic acid tert-butyl ester 473553-34-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzodiazepinone mGluR2 antagonists by

coupling benzenediamines with dioxinones or oxopropanoates followed by cyclization)


RN 473549-06-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-07-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-20-1 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473549-23-4 CAPLUS


CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[5-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]phenyl]-1,3-dioxopropyl]amino]-4-

(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-26-7 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[5-[[[tetrahydro-2H-pyran-2-yl)oxy)methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-30-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[[1,3-dioxo-3-[3-[3-[[[tetrahydro-2H-pyran-2-yl)oxy)methyl]-5-isoxazolyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-33-6 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[[1,3-dioxo-3-[3-[5-[[[tetrahydro-2H-pyran-2-yl)oxy)methyl]-3-isoxazolyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-39-2 CAPLUS

CN Carbamic acid, [2-[[[1,3-dioxo-3-[3-[5-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-3-isoxazolyl]phenyl]propyl]amino]-5-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-41-6 CAPLUS

CN Carbamic acid, [5-(1-azetidiny1)-2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-43-8 CAPLUS

CN Carbamic acid, [5-(1-azetidiny1)-2-[[[1,3-dioxo-3-[3-[5-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-44-9 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-45-0 CAPLUS

CN Carbamic acid, N-[5-(dimethylamino)-2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-47-2 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[4-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-48-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[3-methyl-4-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-5-isoxazolyl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-49-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[4-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-3-isoxazolyl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-50-7 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[2-(methylthio)-1H-imidazol-1-yl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-51-8 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[3-[3-[1-methyl-4-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-5-yl]phenyl]-1,3-dioxopropyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-53-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-55-2 CAPLUS

CN Carbamic acid, [5-[(cyclopropylmethyl)methylamino]-2-[[1,3-dioxo-3-[3-[5-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-57-4 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-5-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-60-9 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-61-0 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-[5-[[1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1H-pyrazol-1-yl]phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-62-1 CAPLUS

CN Carbamic acid, N-[5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473549-90-5 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-91-6 CAPLUS

CN Carbamic acid, [2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-92-7 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-93-8 CAPLUS

CN Carbamic acid, [2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-94-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-[5-[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]phenyl]propyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473549-95-0 CAPLUS

CN Carbamic acid, [2-[[3-[3-(3-methyl-5-isoxazolyl)phenyl]-1,3-dioxopropyl]amino]-5-[methyl(1-methylethyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-05-9 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-06-0 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-(methylpropylamino)-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-07-1 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-pyrazol-1-yl)phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-10-6 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473550-12-8 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[methyl(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-13-9 CAPLUS

CN Carbamic acid, N-[2-[[3-[3-(1H-imidazol-1-yl)phenyl]-1,3-dioxopropyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-16-2 CAPLUS

CN Carbamic acid, N-[2-[[1,3-dioxo-3-[3-(1H-1,2,3-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473550-18-4 CAPLUS

CN Carbamic acid, [2-[[1,3-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)phenyl]propyl]amino]-5-[(2-methylpropyl)amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473553-34-3 CAPLUS

CN Carbamic acid, [5-(dimethylamino)-2-[[1,3-dioxo-3-[3-(4H-1,2,4-triazol-4-yl)phenyl]propyl]amino]-4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:555466 CAPLUS Full-text

DOCUMENT NUMBER: 137:125096

TITLE: Preparation of phenyl derivatives containing
inhibitors of coagulation factor for prophylaxis
and/or therapy of thromboembolic disorders

INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis,
Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes,
Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057236	A1	20020725	WO 2001-EP14296	20011205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10102322	A1	20020725	DE 2001-10102322	20010119
CA 2434937	A1	20020725	CA 2001-2434937	20011205
AU 2002227993	A1	20020730	AU 2002-227993	20011205
AU 2002227993	B2	20070809		
EP 1351938	A1	20031015	EP 2001-989580	20011205
EP 1351938	B1	20070411		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001016804	A	20040217	BR 2001-16804	20011205
CN 1518541	A	20040804	CN 2001-823061	20011205
JP 2004535362	T	20041125	JP 2002-557917	20011205
JP 4180375	B2	20081112		
HU 2005000110	A2	20050628	HU 2005-110	20011205
AT 359271	T	20070515	AT 2001-989580	20011205
ES 2284718	T3	20071116	ES 2001-989580	20011205
MX 2003006483	A	20030922	MX 2003-6483	20030718
IN 2003KN01033	A	20060602	IN 2003-KN1033	20030813
ZA 2003006419	A	20041118	ZA 2003-6419	20030818
US 20040087582	A1	20040506	US 2003-466680	20031218
US 7273867	B2	20070925		

PRIORITY APPLN. INFO.: DE 2001-10102322 A 20010119
WO 2001-EP14296 W 20011205

OTHER SOURCE(S): MARPAT 137:125096

AB Novel compds. of the formula R1R2C6H3-W-X-Y-T in which W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders. Thus, 3-(5-methyl-1,2,4-oxadiazol-3-yl)phenol wa reacted with Et 2-bromovalerate, sodium hydroxide, thionyl chloride, 4-morpholin-4-ylaniline, followed a hydrogenation in acetic acid to give 2-(3-amidinophenoxy)-N-(4-morpholin-4-ylphenyl)valeramide acetate, showing IC50=3x10⁻⁷ M and IC50=4.9x10⁻⁷ M.


IT 444002-21-5P

RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph derivs. containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders)

RN 444002-21-5 CAPLUS

CN Pentanamide, N-[4-(2,5-dioxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:539647 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:109128

TITLE: Preparation of biaryl compounds for treatment of hyperlipidemia and arteriosclerosis

INVENTOR(S): Kori, Masakuni; Ishikawa, Eiichiro; Nakata, Mikiyo; Kobayashi, Makoto

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 470 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055484	A1	20020718	WO 2002-JP73	20020110
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002226675	A1	20020724	AU 2002-226675	20020110


JP 2003055326
PRIORITY APPLN. INFO.:

A 20030226

JP 2002-4422
JP 2001-5823
JP 2001-174901
WO 2002-JP73

20020111
A 20010112
A 20010608
W 20020110

OTHER SOURCE(S): MARPAT 137:109128
GI



AB The title compds. I [rings A and B each represents an optionally substituted five- or six-membered aromatic ring; R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; X1, X2, X3, and X4 each represents a bond or an optionally substituted divalent hydrocarbon group; Y represents NR3CO, CONR3, NR3SO2, SO2NR3, NR3CH2 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group), etc.; Z represents CONH, CSNH, CO, or SO2; and Ar represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group] are prepared I increase the amount of low-d. lipoprotein (LDL) receptors. The LDL receptor gene transcription promoting activities of compds. of this invention were demonstrated. Processes for preparing I are disclosed.


IT 443340-76-9P 443340-77-0P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)


RN 443340-76-9 CAPLUS

CN Carbamic acid, [[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443340-77-0 CAPLUS

CN Urea, N-[[4'-(aminomethyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


IT	443340-78-1P	443340-79-2P	443340-80-5P
	443340-81-6P	443340-82-7P	443340-83-8P
	443340-84-9P	443340-85-0P	443340-86-1P
	443340-87-2P	443340-88-3P	443340-89-4P
	443340-90-7P	443340-91-8P	443340-97-4P
	443341-26-2P	443341-27-3P	443341-28-4P
	443341-29-5P	443341-30-8P	443341-31-9P
	443341-32-0P	443341-33-1P	443341-34-2P
	443341-35-3P	443341-36-4P	443341-40-0P
	443341-42-2P	443341-45-5P	443341-48-8P
	443341-49-9P	443341-51-3P	443341-53-5P
	443341-55-7P	443341-57-9P	443341-59-1P
	443341-61-5P	443341-63-7P	443341-65-9P
	443341-68-2P	443341-69-3P	443341-72-8P
	443341-73-9P	443341-78-4P	443341-79-5P
	443342-57-2P	443342-58-3P	443342-59-4P
	443342-60-7P	443342-63-0P	443342-64-1P
	443342-65-2P		

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)

RN 443340-78-1 CAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443340-79-2 CAPLUS

CN Urea, N-[[4'-[(cyclopentylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA


INDEX NAME)



●2 HCl

RN 443340-80-5 CAPLUS


CN Urea, N-[[4'-[(cycloheptylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-81-6 CAPLUS


CN Urea, N-[[4'-[(cyclooctylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-82-7 CAPLUS


CN Urea, N-[[4'-[[[(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2)
(CA INDEX NAME)



●2 HCl

RN 443340-83-8 CAPLUS


CN Urea, N-[[4'-[[[(1-methylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2)
(CA INDEX NAME)



●2 HCl

RN 443340-84-9 CAPLUS


CN Urea, N-[[4'-[[[(nonylamino)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-85-0 CAPLUS


CN Urea, N-[[4'-[[bis(3-phenylpropyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 443340-86-1 CAPLUS

CN Urea, N-[[4'-[[[(phenylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443340-87-2 CAPLUS


CN Urea, N-[[4'-[[[(4-fluorophenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443340-88-3 CAPLUS


CN Urea, N-(3-pyridinylmethyl)-N-[[4'-[[(3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 443340-89-4 CAPLUS

CN Urea, N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-N-[[4'-[[[4-(trifluoromethyl)phenyl]methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

PAGE 1-A

PAGE 1-B


—CF₃

RN 443340-90-7 CAPLUS

CN Urea, N-[[4'-[[[4-(methoxyphenyl)methyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-,

hydrochloride (1:2) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—OMe

RN 443340-91-8 CAPLUS
CN Urea, N-[[4'-[[bis(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




RN 443340-97-4 CAPLUS
CN Urea, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 443341-26-2 CAPLUS

CN Benzamide, N-[[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-27-3 CAPLUS

CN Cyclohexanecarboxamide, N-[[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-28-4 CAPLUS

CN Benzenesulfonamide, N-[[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 443341-29-5 CAPLUS

CN Benzamide, N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 443341-30-8 CAPLUS

CN Benzamide, 4-nitro-N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-31-9 CAPLUS

CN Benzamide, 4-fluoro-N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-32-0 CAPLUS

CN Benzamide, 4-methoxy-N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-33-1 CAPLUS

CN Benzamide, 4-methyl-N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-34-2 CAPLUS

CN Benzamide, 4-cyano-N-[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-35-3 CAPLUS

CN Hexanamide, N-[[4'-[[3-pyridinylmethyl][4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 443341-36-4 CAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(phenylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443341-40-0 CAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




RN 443341-42-2 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(4-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-45-5 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-2-pyridinyl-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-48-8 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(2-methyl-3-pyridinyl)methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 443341-49-9 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(6-methyl-3-pyridinyl)methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 443341-51-3 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-phenyl-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 443341-53-5 CAPLUS
 CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(4-methoxyphenyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-55-7 CAPLUS


CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-57-9 CAPLUS


CN Urea, N-cyclohexyl-N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-59-1 CAPLUS


CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(cyclohexylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-61-5 CAPLUS


CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-thienylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 443341-63-7 CAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-furanylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 443341-65-9 CAPLUS


CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(2-phenylethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443341-68-2 CAPLUS


CN Urea, N-[[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-69-3 CAPLUS


CN Urea, N-[[3'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-72-8 CAPLUS


CN Urea, N-[[3'-[(aminomethyl)[1,1'-biphenyl]-3-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 443341-73-9 CAPLUS


CN Urea, N-[[3'-[(cyclohexylamino)methyl][1,1'-biphenyl]-3-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 443341-78-4 CAPLUS


CN Urea, N-[[4'-(cyclohexylamino)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 443341-79-5 CAPLUS


CN Urea, N-[(4'-amino[1,1'-biphenyl]-4-yl)methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 443342-57-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'--[[[3-pyridinylmethyl][4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443342-58-3 CAPLUS

CN Urea, N-[[4'-(1-piperidinylcarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443342-59-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(4-fluorophenyl)methyl]-4'--[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443342-60-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-(4-methoxyphenyl)-4'--[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443342-63-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-4'--[[2-pyridinyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443342-64-1 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-cyclohexyl-4'--[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 443342-65-2 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-(4-methoxyphenyl)-4'--[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




IT	443343-94-0P	443343-95-1P	443344-03-4P
	443344-04-5P	443344-06-7P	443344-35-2P
	443344-36-3P	443344-37-4P	443344-38-5P
	443344-39-6P	443344-40-9P	443344-41-0P
	443344-42-1P	443344-43-2P	443344-44-3P
	443344-45-4P	443344-46-5P	443344-47-6P
	443344-48-7P	443344-49-8P	443344-50-1P
	443344-51-2P	443344-52-3P	443344-62-5P
	443344-63-6P	443344-76-1P	443344-97-6P
	443344-99-8P	443345-01-5P	443345-04-8P
	443345-07-1P	443345-08-2P	443345-10-6P
	443345-12-8P	443345-14-0P	443345-16-2P
	443345-18-4P	443345-20-8P	443345-22-0P
	443345-24-2P	443345-27-5P	443345-29-7P
	443345-30-0P	443345-33-3P	443345-34-4P
	443345-39-9P	443345-40-2P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biaryl compds. for treatment of hyperlipidemia and arteriosclerosis)


RN 443343-94-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'--[[(3-pyridinylmethyl) [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 443343-95-1 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'--[[(3-pyridinylmethyl) [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443344-03-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'--[[2-pyridinyl] [[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 443344-04-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid,
4'--[[2-pyridinyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-
(CA INDEX NAME)




RN 443344-06-7 CAPLUS

CN [1,1'-Biphenyl]-4-acetic acid, 4'--[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 443344-35-2 CAPLUS

CN Urea, N-[[4'--[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-36-3 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-37-4 CAPLUS

CN Urea, N-[[4'-[(cyclohexylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-38-5 CAPLUS

CN Urea, N-[[4'-[(cyclopentylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-39-6 CAPLUS

CN Carbamic acid, cycloheptyl[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-40-9 CAPLUS

CN Carbamic acid, cyclooctyl[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-41-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-42-1 CAPLUS

CN Carbamic acid, (1-methylethyl)[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-43-2 CAPLUS

CN Carbamic acid, nonyl[[4'-[[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-44-3 CAPLUS

CN Urea, N-[[4'-[[bis(3-phenylpropyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-N-(3-pyridinylmethyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-45-4 CAPLUS

CN Carbamic acid, [(4-fluorophenyl)methyl][[4'-[[[3-pyridinylmethyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-46-5 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-47-6 CAPLUS

CN Carbamic acid, [[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-48-7 CAPLUS


CN Carbamic acid, [(4-methoxyphenyl)methyl][[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443344-49-8 CAPLUS


CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl)[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-

yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-50-1 CAPLUS

CN Urea, N-[[4'-[[bis(cyclohexylmethyl)amino]methyl][1,1'-biphenyl]-4-yl)methyl]-N-(3-pyridinylmethyl)-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 443344-51-2 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)[[4'-[[[(3-pyridinylmethyl)[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-52-3 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl)[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-62-5 CAPLUS

CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-63-6 CAPLUS

CN Carbamic acid, [[4'-[[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl](3-pyridinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-76-1 CAPLUS

CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 443344-97-6 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(phenylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443344-99-8 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(2-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-01-5 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(4-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-04-8 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[2-pyridinyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-07-1 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(2-methyl-3-pyridinyl)methyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-08-2 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(6-methyl-3-pyridinyl)methyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-10-6 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[phenyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-12-8 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[4-methoxyphenyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-14-0 CAPLUS

CN Carbamic acid, [[4'-[[butyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-16-2 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[cyclohexyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-18-4 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[cyclohexyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-20-8 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[cyclohexyl][[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 443345-22-0 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(2-furanylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-24-2 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(2-phenylethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-27-5 CAPLUS

CN Carbamic acid, cyclohexyl[[[3'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-29-7 CAPLUS

CN Carbamic acid, [[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-30-0 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-33-3 CAPLUS

CN Carbamic acid, [[3'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-34-4 CAPLUS

CN Carbamic acid, cyclohexyl[[3'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 443345-39-9 CAPLUS

CN Carbamic acid, cyclohexyl[[4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 443345-40-2 CAPLUS


CN Carbamic acid, [4'-[[[(3-pyridinylmethyl)[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:10426 CAPLUS Full-text
DOCUMENT NUMBER: 136:85822
TITLE: Preparation of biphenylcarboxamide compounds as GPR14
antagonists or somatostatin receptor regulators
INVENTOR(S): Tarui, Naoki; Santo, Takashi; Watanabe, Hiroyuki; Aso,
Kazuyoshi; Miwa, Tetsuo; Takekawa, Shiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000606	A1	20020103	WO 2001-JP5541	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001066346	A	20020108	AU 2001-66346	20010628
JP 2002080439	A	20020319	JP 2001-196645	20010628
EP 1295867	A1	20030326	EP 2001-943851	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040106792	A1	20040603	US 2002-312015	20021220
US 7091247	B2	20060815		
PRIORITY APPLN. INFO.:			JP 2000-200118	A 20000628
			WO 2001-JP5541	W 20010628
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):			MARPAT 136:85822	
GI				



AB The title compds. (I) or salts thereof [wherein R1 represents hydrogen or (un)substituted hydrocarbyl; X represents a spacer having a 1 to 12 atom linear chain moiety; A represents (un)substituted amino or N-heterocyclyl; R2 represents (un)substituted hydrocarbyl or amino; and R3 represents (un)substituted hydrocarbyl; ring B and C represent an optionally further substituted benzene ring], which have an antagonism against urotensin II receptor GPR14 (orphan receptor), are prepared These compds. are also somatostatin, in particular somatostatin 5 receptor-function regulators such as somatostatin receptor agonists and antagonists and are useful for the prevention and treatment of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, diabetes, obesity, diabetes complications, central diseases, digestive tract diseases, glaucoma, acromegaly, or tumor. Thus, 3'-[[2-[4- (aminosulfonyl)phenyl]ethyl]aminomethyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'- biphenyl-3-carboxamide was condensed with trans-cinnamic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in CH₂Cl₂ and DMF at room temperature for 18 h to give 3'-[[N-[2-[4-(aminosulfonyl)phenyl]ethyl]-N-[(E)-3-phenyl-2-propenoyl]amino]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-1,1'-biphenyl-3-carboxamide (II). N-(2-aminoethyl)-3'-[[N-[4-(aminosulfonyl)benzoyl]-N-(1-naphthylmethyl)amino]methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate and N-(2-aminoethyl)-3'-[[N-[4-[[[amino(imino)methyl]amino]methyl]benzoyl]- N-(1-naphthylmethyl)amino]methyl]-1,1'-biphenyl-2-carboxamide trifluoroacetate showed IC₅₀ of 3 and 6 nM for inhibiting the binding of [125I]-somatostatin to CHO cell line expressing human somatostatin 5 receptor. A capsule and a tablet formulation containing II were prepared

IT 386296-53-3P 386296-57-7P 386296-61-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylcarboxamide compds. as GPR14 antagonists or somatostatin receptor regulators for therapeutic agents)


RN 386296-53-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-aminoethyl)-3'-[[[2-(4-hydroxyphenyl)ethyl] [[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 386296-52-2


CMF C32 H31 F3 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 386296-57-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(6-aminoethyl)-3'-[[[2-(4-hydroxyphenyl)ethyl][[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 386296-56-6

CMF C36 H39 F3 N4 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 386296-61-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[[4-(aminomethyl)cyclohexyl]methyl]-3'-
[[[2-(4-hydroxyphenyl)ethyl][[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 386296-60-2
CMF C38 H41 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:631913 CAPLUS Full-text
 DOCUMENT NUMBER: 135:195556
 TITLE: Preparation of azolyphenyl oxamides as inosine
 monophosphate dehydrogenase (IMPDH) inhibitors
 INVENTOR(S): Broadhurst, Michael John; Hill, Christopher Huw;
 Hurst, David Nigel; Jones, Philip Stephen; Kay, Paul
 Brittain; Kilford, Ian Reginald; Mckinnell, Robert
 Murray
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 256 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1127883	A2	20010829	EP 2001-103521	20010216
EP 1127883	A3	20020807		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 20020052513	A1	20020502	US 2001-779116	20010208
US 6867299	B2	20050315		
CA 2337588	A1	20010824	CA 2001-2337588	20010220
HU 2001000836	A2	20011028	HU 2001-836	20010221
HR 2001000127	A2	20011231	HR 2001-127	20010221
NO 2001000900	A	20010827	NO 2001-900	20010222
CN 1310179	A	20010829	CN 2001-104906	20010223
BR 2001000790	A	20010925	BR 2001-790	20010223
IN 2001MA00167	A	20050304	IN 2001-MA167	20010223
JP 2001261663	A	20010926	JP 2001-51064	20010226
PRIORITY APPLN. INFO.:			GB 2000-4392	A 20000224
			GB 2000-15877	A 20000628
			GB 2000-20322	A 20000817
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 135:195556				
GI				



AB Title compds. (I; R1 = heterocyclyl; R2 = H, alkyl, alkoxy, halo, OH, cyano;
 R3 = H, alkyl, alkoxy, halo, cyano; R4 = H, alkyl, cycloalkyl, aryl,
 heterocyclyl; R5 = H, alkyl, alkoxy, halo, cyano; R6 = H, alkyl, alkoxy, halo,

cyano; R7, R8 = H, alkyl; R4R8N = heterocyclyl), were prepared Thus, 1,1-dimethyl-3-(4-nitrophenoxy)propylamine (preparation given) was coupled with N-[3-methoxy-4-(5-oxazolyl)phenyl]oxamic acid in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxy-7-azabenzotriazole to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide. Tested I inhibited IMPDH with IC50 = 0.010-0.277 μ M. I can be used for treating immune mediated conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative vascular diseases, tumors, and cancer.

IT 357184-32-8P 357184-60-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of azolylphenyl oxamides as inosine monophosphate

dehydrogenase

(IMPDH) inhibitors)


RN 357184-32-8 CAPLUS

CN Ethanediameide, N1-[3-methoxy-4-(5-oxazolyl)phenyl]-N2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 357184-60-2 CAPLUS

CN Ethanediameide, N1-[3-methoxy-4-(5-oxazolyl)phenyl]-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:526050 CAPLUS Full-text
DOCUMENT NUMBER: 135:107149
TITLE: Synthesis, antibacterial activity and RNA polymerase
inhibition of phenylamidine derivs.
INVENTOR(S): Li, Leping; Chen, Xiaoqui; Fan, Pingchen; Mihalic,
Jeffrey Thomas; Cutler, Serena
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051456	A2	20010719	WO 2001-US1219	20010112
WO 2001051456	A3	20011220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397575	A1	20010719	CA 2001-2397575	20010112
US 20020045749	A1	20020418	US 2001-759633	20010112
US 6780858	B2	20040824		
EP 1246795	A2	20021009	EP 2001-914329	20010112
EP 1246795	B1	20071031		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2003519676	T	20030624	JP 2001-551838	20010112
AT 376996	T	20071115	AT 2001-914329	20010112
ES 2293980	T3	20080401	ES 2001-914329	20010112
US 20040235911	A1	20041125	US 2004-877408	20040625
US 7053234	B2	20060530		
US 20060270651	A1	20061130	US 2006-344111	20060201
US 7148259	B1	20061212		

PRIORITY APPLN. INFO.:

US 2000-175892P	P	20000113
US 2001-759633	A1	20010112
WO 2001-US1219	W	20010112
US 2004-877408	A3	20040625

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 135:107149
 GI




AB Synthesis of hydroxyamidines, e.g. (I) and related compds. are disclosed which are suitable as antibacterial agents by their inhibition of RNA polymerase. Antibacterial activity against *S. aureus* and *E. coli* are given.

IT 350488-22-1F 350488-23-2F
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis, antibacterial activity and RNA polymerase inhibition of phenyl- and heterocyclylhydroxyamidine derivs.)


RN 350488-22-1 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 350488-23-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:861682 CAPLUS Full-text
 DOCUMENT NUMBER: 134:29253
 TITLE: Preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors
 INVENTOR(S): Linden, Joel M.; Jacobson, Kenneth A.; Kim, Yong-Chul
 PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073307	A2	20001207	WO 2000-US15233	20000601
WO 2000073307	A3	20010531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6545002	B1	20030408	US 2000-505504	20000217
CA 2370598	A1	20001207	CA 2000-2370598	20000601
EP 1192158	A2	20020403	EP 2000-938072	20000601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1999-136898P	P 19990601
			US 1999-136900P	P 19990601
			US 1999-505504	A 19990601
			US 1999-151875P	P 19990831
			US 2000-505504	A 20000217
			WO 2000-US15233	W 20000601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:29253

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; R, R1 = H, alkyl, alkenyl, etc.; Z = phenylene, cyclohexylene, cyclopentylene; X = alkylene, alkenylene, alkynylene, etc.; R2 = H, alkyl, alkenyl, etc.; R8 = H, cycloalkyl, aralkyl, etc.; R9 = cycloalkyl, aryl, alkyl, etc.] which are selective antagonists of A2B adenosine receptors (ARs), were prepared (general procedures for their preparation were given). Thus, hydrolysis of the ester II with 1N NaOH afforded the title compound III which showed Ki of 3.34 ± 0.51 nM against hA2B receptor binding.

IT 264622-60-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors)

RN 264622-60-8 CAPLUS

CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:384159 CAPLUS Full-text

DOCUMENT NUMBER: 133:30670

TITLE: Preparation of substituted benzo[de]isoquinoline-1,3-diones as glycoprotein IbIX antagonists

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Melzer, Guido; Raddatz, Peter; Wu, Zhengdong; Dhanoa, Daljit; Soll, Richard; Rinker, James; Graybill, Todd

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000032577	A2	20000608	WO 1999-EP8561	19991109
WO 2000032577	A3	20000921		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2352045	A1	20000608	CA 1999-2352045	19991109
BR 9915648	A	20010814	BR 1999-15648	19991109
EP 1144381	A2	20011017	EP 1999-968783	19991109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO



HU 2001004520	A2	20020429	HU 2001-4520	19991109
HU 2001004520	A3	20021028		
JP 2002537225	T	20021105	JP 2000-585219	19991109
AU 760136	B2	20030508	AU 2000-26603	19991109
TW 473474	B	20020121	TW 1999-88120540	19991124
NO 2001002544	A	20010523	NO 2001-2544	20010523
MX 2001005227	A	20011203	MX 2001-5227	20010524
ZA 2001005191	A	20021213	ZA 2001-5191	20010622
IN 2001KN00647	A	20050311	IN 2001-KN647	20010626

PRIORITY APPLN. INFO.:

US 1998-199413	A	19981125
US 1999-398783	A	19990920
WO 1999-EP8561	W	19991109

OTHER SOURCE(S): MARPAT 133:30670

GI



AB The title compds. [I; R = H, NO₂; R₁ = Het, -HetSO₂Ar, NO₂, etc.; R₂ = Ar, Het₁, -Het₁Ar, etc.; Ar = Ph, biphenyl, pyridyl, etc.; Het, Het₁ = (un)substituted (un)saturated mono-, bi- or tricyclic 5-13 membered heterocycl[yl], useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders, were prepared and formulated. E.g., preparation of II was given. Compds. I are effective at 0.02-10 mg/kg/day.

IT 1098870-39-3 1098871-39-6 1098871-40-9
1098871-94-3 1098872-08-2 1098872-09-3
1098872-14-0 1098872-73-1 1098872-90-2
1098873-23-4 1098873-24-5 1098873-33-6
1098873-68-7 1098873-74-5 1098873-75-6
1098873-66-0


RL: PRPH (Prophetic)

(Preparation of substituted benzo[de]isoquinoline-1,3-diones as
glycoprotein IbIX antagonists)


RN 1098870-39-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098871-39-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A





PAGE 2-A




RN 1098871-40-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A







RN 1098871-94-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1098872-08-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1098872-09-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1098872-14-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1098872-73-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-90-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-23-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-24-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-33-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-68-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-74-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A




PAGE 2-A



RN 1098873-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1098878-66-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:286882 CAPLUS Full-text
DOCUMENT NUMBER: 132:308340
TITLE: Preparation of aryltriazolones as agrochemical
fungicides.
INVENTOR(S): Brown, Richard James; Frasier, Deborah Ann; Howard,
Michael Henry, Jr.; Koether, Gerard Michael
PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA
SOURCE: U.S., 46 pp., Cont.-in-part of U.S. Ser. No. 442,433,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6057352	A	20000502	US 1997-952380	19971113
WO 9636616	A1	19961121	WO 1996-US6534	19960508
W: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RW: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
AU 9657350	A	19961129	AU 1996-57350	19960508
EP 825988	A1	19980304	EP 1996-915613	19960508
R: DE, ES, FR, GB, IT				
BR 9608756	A	19990706	BR 1996-8756	19960508
JP 2002515014	T	20020521	JP 1996-534897	19960508
PRIORITY APPLN. INFO.:				
			US 1995-442433	B2 19950517
			US 1995-443295	A 19950517
			US 1995-4183P	P 19950922
			WO 1996-US6534	W 19960508

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 132:308340
 GI



AB Title compds. [I; E = (substituted) 1,2-phenylene; A = O, S, N, NR₅, CR₁₄; G = C, N; when G = C, then A = O, S or NR₅ and the floating double bond is attached to G; when G = N, then A = N or CR₁₄ and the floating double bond is attached to A; W = O, S, NH, NA, NOA; A = alkyl; X = OR₁, SOR₁, halo; R₁ = alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl; R₂ = H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkenyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl, OH, alkoxy, AcO; R₅ = H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, alkylcarbonyl, alkoxy carbonyl; R₁₄ = H, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl; Y = NR₁₅, CO, CHR₁₅OC(S)NR₁₅, etc.; R₁₅ = H, alkyl, cycloalkyl, (substituted) Ph, PhCH₂, etc.; Z = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, heterocyclyl, etc.], were prepared. Thus, 4-[2-(bromomethyl)phenyl]-2,4-dihydro-5-methoxy-2-methyl-3H-1,2,4-triazol-3-one (preparation given) was treated with 4'-chlorothiopropananilide and KOCMe₃ followed by stirring overnight and brief reflux to give [[2-(1,5-dihydro-3-methoxy-1-methyl-5-oxo-4H-1,2,4-triazol-4-yl)phenyl]methyl]-N-(4-chlorophenyl)propanimidothioate. Several I at 200 ppm gave complete control of Puccinia recondita on wheat seedlings.


IT 1100545-83-2 1100547-52-1 1100552-05-3
 1100552-58-6

RL: PRPH (Prophetic)

(Preparation of aryltriazolones as agrochemical fungicides.)


RN 1100545-83-2 CAPLUS

CN Benzenepropanamide, 2-(1,5-dihydro-3-methoxy-1-methyl-5-oxo-4H-1,2,4-triazol-4-yl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1100547-52-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1100552-05-3 CAPLUS
 CN Benzenepropanamide, 2-(2,3-dihydro-5-methoxy-2-methyl-3-oxo-4-isoxazolyl)-
 N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1100552-58-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:135995 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 132:293729
 TITLE: Anilide derivatives of an 8-phenylxanthine carboxylic
 congener are highly potent and selective antagonists
 at human A2B adenosine receptors
 AUTHOR(S): Kim, Yong-Chul; Ji, Xiao-duo; Melman, Neli; Linden,
 Joel; Jacobson, Kenneth A.
 CORPORATE SOURCE: Molecular Recognition Section Laboratory of Bioorganic
 Chemistry National Institute of Diabetes Digestive and

SOURCE: Kidney Diseases, National Institutes of Health,
 Bethesda, MD, 20892-0810, USA
 Journal of Medicinal Chemistry (2000), 43(6),
 1165-1172
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB No highly selective antagonists of the A2B adenosine receptor (AR) have been reported; however such antagonists have therapeutic potential as antiasthmatic agents. Here the synthesis of potent and selective A2B receptor Antagonists is reported. The structure-activity relationships (SAR) of 8-phenyl-1,3-di-(n-propyl)xanthine derivs. in binding to recombinant human A2B ARs in HEK-293 cells (HEK-A2B) and at other AR subtypes were explored. Various amide derivs. of 8-[4-[[carboxymethyl]oxy]phenyl]-1,3-di(n-propyl)xanthine, I (R1 = n-Pr, X = OCH2, R2 = OH) (II), were synthesized. A comparison of aryl, alkyl, and aralkyl amides demonstrated that simple anilides, particularly those substituted in the para-position with electron-withdrawing groups, such as nitro, cyano, and acetyl, bind selectively to human A2B receptors in the range of 1-3 nM. The unsubstituted anilide I (R1 = n-Pr, X = OCH2, R2 = NHPh) had a Ki value at A2B receptors of 1.48 nM but was only moderately selective vs. human A1/A2A receptors and nonselective vs. rat A1 receptors. Highly potent and selective A2B antagonists were a p-aminoacetophenone derivative I (R1 = n-Pr, X = OCH2, R2 = 4-MeOC6H4NH) (Ki value 1.39 nM) and a p-cyanoanilide I (R1 = n-Pr, X = OCH2, R2 = NHC6H4CN-4) (III) (Ki value 1.97 nM). Compound III was 400-, 245-, and 123-fold selective for human A2B receptors vs. human A1/A2A/A3 receptors, resp., and 8.5- and 310-fold selective vs. rat A1/A2A receptors, resp. Substitution of the 1,3-di-Pr groups with 1,3-di-Et offered no disadvantage for selectivity, and high affinities at A2B receptors were maintained. Substitution of the p-carboxymethyloxy group of II and its amides with acrylic acid decreased affinity at A2B receptors while increasing affinity at A1 receptors. 1,3-Di(cyclohexylmethyl) groups greatly reduced affinity at ARs, although the p-carboxymethyloxy derivative I (R1 = cyclohexylmethyl, X = CH:CH, R2 = OH) was moderately selective for A2B receptors. Several selective A2B antagonists inhibited NECA-stimulated calcium mobilization in HEK-A2B cells.

IT 264622-60-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, human A2B adenosine receptor antagonist activity, and structure-activity relationship of phenylxanthine anilide derivs.)

RN 264622-60-8 CAPLUS

CN Acetamide, 2-[4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 112 THERE ARE 112 CAPLUS RECORDS THAT CITE THIS RECORD (113 CITINGS)
 REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:659233 CAPLUS Full-text
 DOCUMENT NUMBER: 131:286505
 TITLE: Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors
 INVENTOR(S): Gruber, Joseph Michael; Kroin, Julian Stanley; Norman, Bryan Hurst
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951228	A1	19991014	WO 1999-US7613	19990407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327617	A1	19991014	CA 1999-2327617	19990407
AU 9934769	A	19991025	AU 1999-34769	19990407
TR 2000002851	T2	20001221	TR 2000-2851	19990407
BR 9910112	A	20001226	BR 1999-10112	19990407
EP 1067928	A1	20010117	EP 1999-916456	19990407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
HU 2001001508	A2	20011028	HU 2001-1508	19990407
HU 2001001508	A3	20020429		
US 6369070	B1	20020409	US 2000-646062	20000913
MX 2000009655	A	20010316	MX 2000-9655	20001002
HR 2000000646	A2	20010630	HR 2000-646	20001003
NO 2000005023	A	20001205	NO 2000-5023	20001005
PRIORITY APPLN. INFO.:			US 1998-81080P	P 19980408
			WO 1999-US7613	W 19990407

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 131:286505
 GI



AB The title compds. (I) [where R = (un)substituted amino(alkyl) or aminoethoxy, or (CH₂)^mR₃; m and m' = independently 0, 1, or 2; R₃ = H, OH, alkoxy, amino ester, amino acid, or (un)substituted amino; R' = H, OH, or (un)substituted alkoxy] were prepared as inhibitors of 190 kDa multidrug resistance protein (MRP1) for inhibiting resistant neoplasms (14 specific neoplasm types claimed). Selected invention compds. were prepared via solution and solid phase combinatorial synthetic methods. For example, 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazoyl chloride was coupled with N-(5-methylisoxaz-3-oyl)-3-aminobenzylamine to form the amide followed by treatment with NaOH to yield the cyclized title compound (II). Several general procedures using substituted polystyrene resins for combinatorial preparation of title compds. were given. Representative compds. demonstrated significant reversal of MRP1 multiple drug resistance, and many compds. gave significant enhancement of oncolytic agent activities (no data). A large majority of the compds. tested were also said to have displayed a significant degree of selective inhibition of the HL60/ADR cell line over the HL60/VCR cell line in an assay for reversal of MRP1-mediated doxorubicin and vincristine resistance (no data).


IT 1101885-24-8

RL: PRPH (Prophetic)

(Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors)

RN 1101885-24-8 CAPLUS

CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (10 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:346786 CAPLUS Full-text

DOCUMENT NUMBER: 122:133193

ORIGINAL REFERENCE NO.: 122:24843a,24846a

TITLE: Preparation of
N-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-
yl]methyl]urea derivatives as angiotensin II
antagonists

INVENTOR(S): Mori, Tetsuya; Matsui, Toshiaki; Kawamura, Masanori

PATENT ASSIGNEE(S): Ono Pharmaceutical Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06211814	A	19940802	JP 1993-22099	19930114
JP 3116256	B2	20001211		

PRIORITY APPLN. INFO.: JP 1993-22099 19930114

OTHER SOURCE(S): MARPAT 122:133193

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; T = O, S; ring A = benzene ring, 4- to 7-membered ring monocyclic unsatd. heterocycle containing 1 S or 1 N atom.; R1 = C1-8 alkyl; R2 = H, C1-4 alkyl,alkoxy, alkylthio, or hydroxyalkyl, halo, trihalomethyl, trihalomethyloxy, NO2, Ph, OCH2Ph, DR4, etc. (wherein D = single bond, C1-4 alkylene or alkyleneoxy, R4 = CO2R5, CH(OH)CO2R5, C(O)CO2R5, COCH2OH; R5 = H, C1-4 alkyl, CH2CONR6R7; R6, R7 = H, C1-4 alkyl); R3 = H, C1-4 alkyl, C2-6 alkenyl, CO2H, C1-4 alkoxy carbonyl, CONR12R13 (wherein R12, R13 = H, C1-3 alkyl or N R12R13 = 4- to 7-membered ring saturated monocyclic heterocyclyl containing 1 or 2 N atoms or 1 N and 1 O atom); Z = 1H-tetrazol-5-yl; m = 1-3; provided that when m = 3, all 3 R2 = DR4 and all 3 R4 = CO2R5], useful for the treatment of hypertension, are prepared Thus, 77 µL Et3N and 105 mg Et 2-isocyanatobenzoate were added to a suspension of N-butyl-N-[[2'-(1-(2-cyanoethyl)tetrazol-5-yl)-1,1'- biphenyl-4-yl]methyl]amine hydrochloride in THF and the resulting mixture was stirred at room temperature for 1 h to give intermediate (II; R = CH2CH2CN). The latter compound was stirred with DBU in THF at room temperature for 5 h to give title compound II (R = H) which (109 mg) was dissolved in 1,4-dioxane-H2O (2:1), treated with 0.22 mL 1 N aqueous NaOH, and lyophilized to give 260 mg title compound Na salt II (R = Na) (III). A tablet formulation containing III was described.


IT 160838-05-1F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[[[(1H-tetrazolyl)biphenyl]methyl]-N-(Ph or heterocyclyl)urea derivs. as angiotensin II antagonists)

RN 160838-05-1 CAPLUS

CN Urea, N-butyl-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-N'-[2-(trifluoromethyl)phenyl]-, sodium salt (1:1) (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:22235 CAPLUS Full-text

DOCUMENT NUMBER: 118:22235

ORIGINAL REFERENCE NO.: 118:4185a,4188a

TITLE: Preparation of
N-[(carbamoylamino sulfonyl)biphenylmethyl]imidazoles
as angiotensin II receptor antagonists

INVENTOR(S): Wagner, Adalbert; Englert, Heinrich; Kleemann, Heinz
Werner; Gerhards, Hermann; Schoelkens, Berward;
Becker, Reinhard; Liz, Wolfgang

PATENT ASSIGNEE(S): Hoechst A.-G., Georgia

SOURCE: Eur. Pat. Appl., 88 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 503162	A1	19920916	EP 1991-122406	19920101
EP 503162	B1	19980422		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
CA 2058198	A1	19920705	CA 1991-2058198	19911220
AU 9190110	A	19920709	AU 1991-90110	19911231
AU 653760	B2	19941013		
IL 100568	A	19961114	IL 1991-100568	19911231
AT 165351	T	19980515	AT 1991-122406	19920101
ES 2114874	T3	19980616	ES 1991-122406	19920101
FI 9200017	A	19920705	FI 1992-17	19920102
NO 9200048	A	19920706	NO 1992-48	19920103
NO 301881	B1	19971222		
HU 60249	A2	19920828	HU 1992-21	19920103
BR 9200011	A	19920908	BR 1992-11	19920103
CN 1066844	A	19921209	CN 1992-100036	19920103
CN 1028755	C	19950607		
ZA 9200036	A	19931004	ZA 1992-36	19920103

PL 168887	B1	19960430	PL 1992-293064	19920103
RU 2104272	C1	19980210	RU 1992-5010754	19920103
JP 04308587	A	19921030	JP 1992-17423	19920104
JP 07110854	B	19951129		
LV 10435	B	19950820	LV 1993-286	19930504
LT 3373	B	19950825	LT 1993-716	19930625
US 5482957	A	19960109	US 1994-234591	19940428
PRIORITY APPLN. INFO.:			DE 1991-4100109	A 19910104
			DE 1991-4109949	A 19910326
			DE 1991-4121229	A 19910627
			US 1991-806634	B1 19911213
OTHER SOURCE(S):	MARPAT 118:22235			
GI				




AB Title compds. I [X, Y, Z = N, CR₂; R₁ = C₂-10 alkyl, C₃-8 cycloalkyl, benzyl, etc.; R₂ = H, halo, NO₂, cyano, Ph, etc.; A = substituted biphenyl; L = C₁-3 alkylene; q = 0,1] were prepared as angiotensin II receptor antagonists useful as antihypertensives. Thus, Et 2-n-butyl-4-methylthioimidazole-5-carboxylate (preparation given) was N-alkylated by 2-(4-BrCH₂C₆H₄)C₆H₄SO₂NHCONMe₂ (preparation given) followed by deaminoformylation, treatment with CH₂:CHCH₂N:C:O and hydrolysis to give title compound II, which had IC₅₀ of 4.6 nM in an angiotensin II receptor binding assay.

IT 144627-61-2P 144627-62-3P 144627-73-6P
144627-74-7P 144628-00-2P 144628-01-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II receptor antagonist)


RN 144627-61-2 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144627-62-3 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]amino]carbonyl- (CA INDEX NAME)




RN 144627-73-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[2-(trifluoromethyl)phenyl]amino]carbonyl- (CA INDEX NAME)




RN 144627-74-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 144628-00-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 144628-01-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-N-[[2-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:514704 CAPLUS Full-text

DOCUMENT NUMBER: 113:114704

ORIGINAL REFERENCE NO.: 113:19426h,19427a

TITLE: The conversion of phenols to primary and secondary aromatic amines via a Smiles rearrangement

AUTHOR(S): Coutts, Ian G. C.; Southcott, Mark R.

CORPORATE SOURCE: Dep. Chem. Phys., Nottingham Polytech., Nottingham, NG11 8NS, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1990), (3), 767-71
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:114704


AB The conversion of phenols to 2-(aryloxy)-2-methylpropanamides (I) and the Smiles rearrangement of these to N-aryl-2-hydroxy-2-methylpropanamides are described. Hydrolysis of the latter compds. yields anilines. The scope and limitations of reaction are discussed. Routes, some involving α -lactams, from phenols to N-substituted derivs. of I have been developed. Under the conditions of the Smiles rearrangement, these secondary 2-methylpropanamides can form anilides, N-alkylanilines, or benzoxazinones directly.

IT 128965-90-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Smiles rearrangement of)

RN 128965-90-2 CAPLUS

CN Propanamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[3,5-bis(trifluoromethyl)phenyl]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS
RECORD (25 CITINGS)

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 10:09:16 ON 13 JUL 2010